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This thesis has investigated and compared the short term
effect of treatment with 750 micrograms and 1500 micrograms twice
daily of inhaled beclomethasone dipropionate (BDP), and oral
prednisolone 40 mg per day, on lung function and quality of life in
105 patients with non asthmatic chronic airflow obstruction. The role
of physiological and clinical features in determining the response to
treatment in individuals has been investigated, and the systemic and
local side effects of therapy have been studied. The effect of
treatment on peripheral neutrophil function has been investigated in
a subgroup of patients, and observations on decline in FEV1 in a
separate cohort of patients are presented.
After three weeks treatment both doses of BDP produced
equivalent, small but statistically significant improvements in FEV1,
FVC, and mean PEF, compared to that seen with placebo. Individual
patients demonstrated a response, defined on the changes seen in
physiological variables, to active treatment more commonly than
with placebo. Bronchial responsiveness to inhaled histamine was
unaltered by treatment for three weeks with inhaled BDP. Quality of
life and subjective measures of dyspnea showed marked baseline
variability, but treatment with BDP significantly improved dyspnea
and patient's 'mastery' over the disease. Oral prednisolone did not
improve lung function or subjective measures further. A response to
active treatment in individual patients was more common in those
with more severe physiological impairment. Formal discriminant
analysis was unsuccessful in predicting response to treatment in
individual patients.
No significant deleterious effect of treatment with inhaled
BDP or oral prednisolone on global respiratory muscle strength was
detected. Treatment with BDP caused detectable adrenal
suppression, which was dose related, for 750 micrograms twice daily,
approximately one tenth that seen with oral prednisolone 40 mg per
day, and for 1500 micrograms twice daily, one quarter. Local side
effects were more common after inhaled therapy compared with
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placebo, but affected only a minority of patients.
Peripheral neutrophil activation was suppressed by treatment
with inhaled BDP, and a fall sputum albumin concentrationA
suggested a reduction in bronchial tree inflammation with
treatment.
The uncontrolled observational study failed to confirm
previously reported associations between decline in FEV1, and
bronchial hyperresponsiveness, and reversibility of FEV1 to
bronchodilators. The short term response to corticosteroids did not
correlate with subsequent decline in FEV1. In 32 patients who
started regular inhaled BDP midway through the observation period
the decline in FEY1 fell significantly, by over one half, over the
remaining period of observation. These observations question the
role of short term steroid trials, and suggest a disease retarding
effect of inhaled BDP in these patients with non asthmatic chronic
airflow obstruction.
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This thesis has been composed and written by myself.
The studies reported herein have for the most part been
carried out by myself. The work reported in chapters 11 to 13 was
carried out in collaboration with others, although the design of these
studies and the analysis was performed by myself. Cortisol assays
were performed by the Department of Clinical Chemistry at East
Birmingham Hospital. The assays of neutrophil function were
carried out by scientific officers, that for sputum and serum albumin
concentrations by myself. The data for the final chapter were
collected with the considerable help ofMr GA Wieland, who shared
the task of assessing patients with myself.
The data included in this thesis have not been submitted
elsewhere for any degree, diploma or professional qualification, and
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95%CI - The 95 percent confidence interval for
the mean.
BDP - Beclomethasone dipropionate.
COPD - Chronic obstructive pulmonary disease.
Used interchangeably with chronic airflow
obstruction,
cpm - Counts per minute
FEV1 - Forced expiratory volume in one second.
FRC - Functional residual capacity.
FVC - Forced vital capacity.
g/1 - Grammes per litre
IgE - Immunoglobulin E
kPa - Kilo Pascals
meg or mg - Micrograms.
mis or ml - Millilitre(s)
mmol - Millimole
nmol/1 - Nanomole per litre
PD20 - Provocative dose of histamine causing a
20% fall from baseline in FEV1.
PD20 USDW - Provocative dose of nebulised distilled
water causing a 20% fall from baseline in
FEV1.
PEF - Peak expiratory flow rate.
Pemax - Maximal expiratory mouth pressure.
Pimax - Maximal inspiratory mouth pressure.
PMN - Polymorphonuclear leucocytes. Used
interchangeably with neutrophils.
RV - Residual volume.
SEM - Standard error of the mean.
TLC - Total lung capacity,
ul - Microlitres
umol - Micromoles.




The effect of airflow obstruction on health appears to have
been described initially by Plato . He wrote
" When the lung whose office is to dispense the breath
to the body, is blocked by rheums, and affords no clear
passages, the breath fails to reach some parts, and
causes them to putrefy for lack of refreshment..."(1).
Plato obviously realised the deleterious effects that
respiratory failure can have on the function of other organs such as
the heart and kidney.
Badham was the first to introduce the word "bronchitis", and
he gave a more detailed description of the clinical condition(2). It
was Laennec who seems to have realised, over 150 years ago, that
chronic airflow obstruction could be the result of more than one
pathological process(3). He determined that airflow obstruction
could occur because of narrowing of the bronchi, or because of loss of
surrounding tissue support, or perhaps more commonly because of a
combination of both.
He wrote
" In emphysema the air makes its escape from the air
cells much slower than in a healthy state of the organ.
This seems to indicate either more difficult
communication between air contained in the air cells
and fnat of the bronchi, or else diminished elasticity of
the air cells themselves. Perhaps both causes conspire
to produce the effect in question."
However interest in chronic airflow obstruction was poor until
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late in the twentieth century. In 1923 Collis highlighted the
importance of chronic bronchitis as a cause of morbidity and
mortality, and the lack of interest in the condition by physicians
generally(4).
"The trite observation that familiarity breeds contempt
is essentially true with regard to the outlook on chronic
bronchitis: those afflicted are inclined to accept the
complaint as inevitable, as something troublesome but
not serious. Those called upon to treat it do not find it
sufficiently interesting to study it closely. At a hospital
it tends to be disregarded with an out-patient mixture
yet....records in England and Wales show that when
mortality and morbidity are taken together, bronchitis
is the most important of all diseases and further.... it is
at the same time a most preventable disease"
It was not until the Medical Research Council created a
committee to coordinate research into chronic bronchitis in 1953,
following the excess deaths associated with the December 1952
London fog, that our understanding of the epidemiology,
pathophysiology and treatment of the condition improved.
1.2 EPIDEMIOLOGY.
Studies have convincingly shown that cigarette smoking is the
most important cause of chronic airflow obstruction and
emphysema. A dose response relationship was seen between
mortality from chronic bronchitis (or chronic airflow obstruction)
and the amount of cigarettes smoked in a longitudinal study of
40,000 British doctors(5). However there is an individual
susceptibility to these agents, as only a minority of smokers develop
airflow obstruction and or emphysema. Outdoor air pollution, at
least that seen in the 1960's, has been causally associated with
morbidity and mortality from chronic airflow obstruction, and
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recently occupational exposure to dusts has been recognised as an
important causative factor(6). Indoor air pollution is a major cause
of chronic bronchitis in countries where open fires indoor are
common(7), and evidence suggests that childhood respiratory illness
predisposes to problems in adult life(8). Such causes explain the
occurrence of chronic airflow obstruction in non smokers, a fact
obvious in times when cigarette smoking was much less common(4).
Although clinically the impression is that the morbidity and
mortality from chronic airflow obstruction and emphysema are
falling, figures from the U.S.A show that in the age group 55-85
years, morbidity as measured by office visits has increased slowly
over the period 1979-1985(9). The increase is probably due to the
aging of the birth cohort born 1910-1949, who have had the greatest
cohort cigarette exposure, and who are only now presenting with
symptomatic smoking related chronic airflow obstruction.
In the late 1970's a population based study in Tecumseh,
U.S.A. showed a fairly high prevalence of airways obstruction,
defined as an FEV1 less than 65% of the predicted value. Ten to
fifteen percent of males aged 45-64 years, and approximately 5% of
females fulfilled these criteria(lO). It might be expected that only a
proportion of subjects with airflow obstruction would have symptoms
attributable to the physiological abnormality, but in the U.K. two
recent general practice based studies have shown symptoms of
cough, and dyspnoea on performing activities of daily living in 5-20%
of the population studied(l 1,12), suggesting the prevalence of
respiratory symptoms and airways obstruction in a community may
be similar, and confirming the significant morbidity from this cause.
Mortality from chronic bronchitis, emphysema and asthma
on the other hand, has halved over the period 1969 to 1985 in all age
groups, and in both sexes(13). A further decrease in mortality would
be expected in the future if the recent downward trend in smoking is
continued. The proportion of men smoking fell from 52% to 36%
from 1970 to 1984, and from 41% to 32% in females over the same
period. However the number of women smoking in the 20 to 34 year
age group has increased by 10% in the years 1980 to 1984, a statistic
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which suggests that chronic bronchitis and emphysema will continue
to cause significant amounts of illness in the population. Indeed in
1977/78 10% of all working days lost due to sickness were attributed
to these diseases(14), and in 1985 Williams and Nicholl suggested
sixty thousand patients in England and Wales should be receiving
long term treatment with oxygen because of the effects of severe
chronic airflow obstruction/15). Their figures suggest this subgroup
of patients with hypoxic disease probably represents about 3 % of
individuals with an FEV1 less than 70% of the predicted value, so the
potential demand on health service resources from this condition is
considerable.
1.3 DEFINITIONS.
Chronic airflow obstruction is a term which literally describes
the physical effects of a number of disease processes on the flow
volume characteristics of the lung. Because different disease
processes may have varying prognostic implications there has been
much semantic discussion about exact definitions of the disease
entities which make up the syndrome of chronic airflow obstruction.
Two Ciba symposia(16,17), and articles in learned journals reflect
this(18,19,20).
The three major disease processes which cause chronic
airflow obstruction are asthma, emphysema and chronic
(obstructive) bronchitis. Chronic bronchitis has been defined as a
cough productive of sputum on most days for at least three
consecutive months for two consecutive years(21). The condition is
not invariably associated with chronic airflow obstruction, and
epidemiological evidence suggests that chronic bronchitis and
chronic airflow obstruction should be considered as separate entities
rather than as different manifestations of the same disease(22).
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Pathologically chronic bronchitis is characterised by hyperplasia of
the mucous glands in the larger ( >2mm diameter) airways(23), and
an accompanying inflammatory cell infiltrate(24). In those patients
with chronic bronchitis and chronic airflow obstruction the site of
the obstruction to airflow is in the small airways, less than 2 mm in
diameter(25). These smaller airways show evidence of progressive
inflammatory cell infiltration, leading to fibrosis and thickening of
the airway walls(26).
Strictly emphysema is defined in pathological terms,
although it may be detected with reasonable accuracy in life by
indirect means, such as measurement of single breath carbon
monoxide gas transfer (TLCO), or the volume corrected diffusing
capacity (KCO)(27) or by CT scanning of the lungs(28).
Pathologically it has been defined as
"a condition of the lung characterised by abnormal
permanent enlargement of the airspaces distal to the
terminal bronchiole, accompanied by destruction of
their walls, and without obvious fibrosis"(29).
Emphysema is usually accompanied by chronic airflow
obstruction although the exact cause of this is still unclear(30). The
relative importance of loss of elastic recoil and reduction in
peribronchiolar support due to the emphysematous process, and the
thickening and narrowing of the peripheral airway lumen by the
chronic inflammation seen to the reduction in airflow is still debated.
The precise definition of asthma has been elusive, but
Scadding's attempt seems as good as any,
"a disease characterised by wide variations over short
periods of time in resistance to flow in intrapulmonary
airways(31)".
Difficulties arise however in deciding what degree of
variation constitutes asthma, and whether variation should be
expressed in absolute or percentage terms. Only recently has the
pathological changes in the airways of patients with asthma been
investigated. Epithelial denudation, and infiltration of the mucosa
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and lamina propria of large airways by eosinophils and lymphocytes
have been described(32,33).
In any one patient the contribution of each disease process to
symptoms and the abnormal physiology seen will vary and may be of
only academic significance. However it appears that prognosis, and
by implication response to treatment, depends upon the underlying
cause of the airflow obstruction. In Tucson a longitudinal population
based study has shown that patients with asthma, for whom effective
treatment in the form of inhaled corticosteroids is available(34,35),
have a more benign disease(36). In practical terms therefore it
appears important to identify those patients with asthma.
In 1986 The American Thoracic Society issued a definition
of asthma, and chronic obstructive pulmonary disease (chronic
airflow obstruction) which included symptoms, response to
treatment and histology(37). The major differences between asthma
and chronic airflow obstruction from other causes was the
paroxysmal and variable nature of both the symptoms and the
physiological abnormalities. Such a definition is not of major clinical
use as some patients labelled as asthmatic have persisting airflow
obstruction, with little spontaneous or drug induced related
reversibility in airflow obstruction(38), whereas many patients with
chronic airflow obstruction who smoke and have physiological
evidence of emphysema show varying but clinically relevant
reversibility in response to drugs. The similarity between asthma and
chronic airflow obstruction has led some workers to postulate that
they are but two manifestations of the same disease process(39).
Because of difficulties in definition of each disease, for the
purposes of this study a practical, clinically relevant definition of
asthma was adopted. Only patients with chronic airflow obstruction
who the physician felt were not obviously clinically asthmatic, and
therefore in whom the benefits of treatment with oral or inhaled
corticosteroids could not be assumed, were recruited. Asthma as the
underlying cause of the disease was favoured if there was a history of
childhood respiratory problems, or if the patient reported wheezing
and breathlessness on exposure to specific allergens, or marked
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variability in their symptoms except with exercise and infections. A
lack of a fixed element to the airflow obstruction also suggested
asthma as the underlying diagnosis. Conversely a history of heavy
cigarette consumption, persistent and constant symptoms, and a
classical history of chronic winter bronchitis implied a non
asthmatic cause to the disease.
Although firm physiological criteria to try to define
asthmatics were not used, and physicians will differ slightly in their
definition of asthma, the patients recruited were intended to reflect
clinical practice, and to be representative of those patients in whom
a therapeutic trial of corticosteroids has been recommended(40,41).
Such a definition of chronic airflow obstruction will include patients
whose physiological abnormality is the result of a number of
different causes, but it is simple and obviates the need for more
complex investigations, such as CT scanning or histological
examination of biopsy material, which would be necessary if more
precise accurate definition was required.
1.4. TREATMENT OF CHRONIC AIRFLOW OBSTRUCTION.
Patients with chronic airflow obstruction generally complain
of dyspnoea, cough and sputum production as their major
symptoms. Physiologically, abnormalities of expiratory flow, ie
reduced FEV1\FVC ratio, and reduced carbon monoxide gas
transfer are apparent. The aim of treatment is to relieve symptoms,
improve measures of airflow and if possible prevent progression of
disease. In smokers the cornerstone of management is smoking
cessation, although the success of physicians achieving this is poor,
varying from 5-10% with simple advice in outpatients attending chest
clinics, to only 25% at twelve months following intervention in well
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motivated smokers, recruited from the community, receiving
pharmacological and psychological help(42,43). Quitting smoking will
remove the cause of the disease and will result in a reduction in the
rate of loss of lung function, as measured by FEV1, to normal
levels(44,45). This probably occurs within 5 years , and in younger
patients an improvement in lung function may occur as a
consequence of stopping smoking alone(45).
Optimal use of both oral and inhaled bronchodilators will
maximise airflow, and will to a varying extent relieve symptoms of
dyspnoea. Both beta adrenergic and anti-cholinergic drugs are
effective in producing bronchodilation in most patients with chronic
airflow obstruction. In some patients subjective benefit may be
obtained from these drugs with little change in objective measures of
airflow obstruction, reflecting the complex relationship between
symptoms and objective measures of lung function in this group of
patients.
Oral methylxanthines are commonly used as second line
drugs, and are effective, but require monitoring of serum
concentrations to prevent toxicity problems, and to optimise
effect(46). The use of oral corticosteroids will be considered in greater
detail later.
Antibiotics are certainly effective during infective
exacerbations of the condition(47), but there is no evidence that
continuous long term antibiotic therapy has any beneficial effect on
disease progression(48). The role of mucolytics is controversial in the
UK, although recent evidence suggests that they produce
symptomatic benefit in the majority of patients(49). Formal exercise
programs are believed to be effective in some patients(50), and
inspiratory muscle training appears to improve exercise tolerance in
patients with fairly severe airflow obstruction^ 1).
Relief of breathlessness may be achieved by drugs acting
entirely on the neural mechanisms responsible for this sensation, eg
diazepam, dihydrocodeine. These drugs have no detectable effect
upon objective measures of airflow obstruction but may improve
exercise tolerance and breathlessness in 'pink puffers'(52), although
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anecdotally such treatment is rarely clinically useful. Available
treatments are not always successful, especially in the relief of
breathlessness, and this has led some to perform dubious surgery in
an attempt to obtain relief. Carotid body resection has been reported
to dramatically relieve dyspnoea, but at the expense of decreased
minute ventilation and worsening of arterial blood gases(53).
During infective exacerbations of the condition controlled
oxygen therapy, and diuretics are used for worsening cor pulmonale,
and antibiotics for infection. Oral corticosteroids are commonly used
during acute exacerbations, although the evidence that they are
effective is based on one study only. This showed small differences
between treated and placebo groups in lung function during the first
72 hours of admission. The clinical significance of these changes was
not clear, there were no differences in mortality, and the study did
not consider if treatment actually shortened hospital admission(54).
In terms of improving survival in patients with chronic
airflow obstruction, very few treatments have been shown to have any
effect. Long term oxygen therapy will prolong survival in the
subgroup of patients with severe airflow obstruction who are
hypoxaemic at rest(55,56). In addition two retrospective studies from
Dutch workers in Groningen have suggested that moderate doses of
oral prednisolone may slow down disease progression and improve
survival(57,58). If these findings are confirmed in prospective studies
the advice that corticosteroids should only be prescribed to patients
with chronic airflow obstruction who show objective improvement in
a short term 'trial of steroids' may turn out to be misguided(40,41).
9
1.5. CORTICOSTEROIDS IN THE TREATMENT OF CHRONIC
AIRFLOW OBSTRUCTION.
The efficacy of corticosteroids in the treatment of chronic
airflow obstruction has usually been assessed in short term studies
over two to four weeks. Many papers purporting to assess this short
term effect of corticosteroids in chronic airflow obstruction have
been published, and have been reviewed by other authors(59,60,61).
The majority are concerned with the use of oral corticosteroids(62-
92), very few studies have investigated the role of inhaled
corticosteroids in chronic airflow obstruction. Only two published
reports adequately address the longer term effect of corticosteroids
in chronic airflow obstruction, and these will be reviewed later(57,58).
1.5.1. Short term treatment with oral corticosteroids in chronic
airflow obstruction.
Comparison of the results reached by the various authors is
extremely difficult because of differences between studies in
fundamental areas such as trial design, patients studied, and often
in the method chosen to analyse the data collected. When assessing
the conclusions reached by different authors it is therefore
important to assess all the factors inherent in the trial which may
influence the results obtained. As Stoller et al have indicated
although the majority of published trials seem to show little benefit
from treatment with oral corticosteroids, the studies with positive
results are better designed and statistically the most precise of the
trials published(60).
The design of the trial and the use of appropriate controls
will have a strong influence upon the ability of the therapeutic trail
to detect a treatment effect. From 1951 to 1990 twelve studies used
an essentially flawed trial design, in that no placebo control was
used(62-73) (listed overleaf in table 1.1.). This makes the conclusions
reached by the authors almost impossible to evaluate as no
allowance has been made in their analysis of the short term
variability in the outcome measures used.
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Table 1.1. Published uncontrolled studies of the effect of oral
corticosteroids on chronic airflow obstruction
Author and Year No of
Pts






Lukas 62 1951 13 acth
cort
var 7 ? fvc
mbc
descriptive
Bickerman''3 1955 50 pred var var 7 SVC
mbc
categ 86% ?









































Fuleihan 7^ 1967 10 beta 4mg 21 clin fevl
fee
group pos ?







Lightbody 721978 10 pred 30mg 3 clin fevl
cycle erg
group neg 1.28





Drugs- pred=prednisolone, beta=betamethasone, cort=cortisone, meprd=methylprednisolone
Time- duration of trial. Entry criteria-clin= clinical criteria only
Outcome measures- parameters used in assessment of response,
mbc-maximal breathing capacity, cycle erg-cycle ergometry.
Analysis- see text for definitions. Second line refers to categorical analysis criteria.
Results- pos= steroids beneficial or neg= no effect of steroids for group analysis,
or numbers (%) responding for categorical analysis.
Mean FEV1 refers to all patients. ? Unclear from paper or data not given.
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The remaining studies have all used placebo controls in
either a single or double blind trial design. Four studies have used a
single blind design(74-77) (table 1.2.), with the placebo treatment
period preceding active treatment in all patients. This risks
introducing bias in the assessment of drug effect, as the observer is
aware of the treatment order but this can be controlled for by using
Table 1.2. Published single blind placebo controlled studies of the
effect of oral corticosteroids on chronic airflow obstruction
Author and Year No of
Pts














Williams 75 1980 20 pred 30mg 14 clin fevl.fvc
12mwd
group pos 0.98









Swinburn 77 1988 20 pred 30mg 14 clin fevl,fvc
Sa02
group pos 0.86
Drugs- pred=prednisolone, beta=betamethasone, cort=cortisone, meprd=methylprednisolone
Time- duration of trial. Entry criteria-clin=clinical criteria only
Outcome measures- parameters used in assessment of response
sGaw-specific airways conductance, 12mwd-12 minute walking distance, Sa02-capillary oxygen saturation.
Analysis- see text for definitions. Second line refers to categorical analysis criteria.
Results- pos= steroids beneficial or neg= no effect of steroids for group analysis,
or numbers (%) responding for categorical analysis.
Mean FEV1 refers to all patients. ? Unclear from paper or data not given.
rigorous predetermined criteria for acceptance of objective
measurements. In addition, as little information is available on the
time course of response to corticosteroids, such a design avoids the
possibility of a carry over effect from the active treatment into the
placebo, dummy period.
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The remaining fourteen studies have used a double blind
placebo controlled format, in twelve papers in a crossover
design(79-85,88-90,92,93) in the final two in a parallel group
design(87,91) (table 1.3. & 1.4.). Parallel group studies may be
confounded by the introduction of bias into the treatment groups
recruited. By chance they may not be balanced in terms of factors
likely to influence response to treatment which are not specifically
controlled for in the entry criteria for the study. This is especially
true in smaller studies.
As mentioned above a crossover design suffers from possible
carry over effects of active treatment into a subsequent placebo
treatment period. As patients are randomly allocated to the order in
which treatments are received, this effect may bias results by
increasing the number of apparent placebo responses and
diminishing the actual difference between placebo and active
treatments. This effect can be minimised by appropriate washout
periods between treatments. However there is a dearth of data on the
duration of effect of treatment after it has been withdrawn. Our own
analysis in a similar patient group suggests that treatment effects
may been seen up to six weeks after treatment is withdrawn(78). A
similar duration of effect of corticosteroids occurs in asthmatic
patients(79). At the very least therefore a washout period of three
weeks would appear advisable to ensure carry over effects will be
negligible.
In the studies in tables 1.3. and 1.4. washout periods varied
from zero(79,83,93), seven days(89), or 14 days(84,85,90,91), to 42
days(80). Hence in all but one of these studies a possible carry over
effect of active corticosteroid treatment may have occurred. Only one
of these studies specifically commented on a possible carry over
effect, but the ability of the study to detect such an effect was low
because of the small number of patients studied(92).
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Table 1.3. Published double blind placebo controlled studies of the
effect of oral corticosteroids on chronic airflow obstruction showing
no effect of corticosteroids
Author and Year No of
Pts






Beerel 80 1963 10 pred 30to
60mg







Morgan 8^ 1964 7 beta 3.6mg 28 clin fevl ,fvc
rv,tlc
group neg 1.22


































Drugs- pred=prednisolone, beta=betamethasone, cort=cortisone, meprd =methylprednisolone
Time- duration of trial. Entry criteria-clin=clinical criteria only
Outcome measures- parameters used in assessment of response
mbc-maximal breathing capacity, abg-arterial blood gases, sGaw-specific airways conductance, 12mwd-12 minute walking
distance, cycle erg-cycle ergometry.
Analysis- see text for definitions. Second line refers to categorical analysis criteria.
Results- pos= steroids beneficial or neg= no effect of steroids for group analysis,
or numbers (%) responding for categorical analysis.
Mean FEV1 refers to all patients. ? Unclear from paper or data not given.
t
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Table 1.4. Published double blind placebo controlled studies of the
effect of oral corticosteroids on chronic airflow obstruction showing a
positive effect of corticosteroids
Author and Year No of
Pts






Hurford 8^963 39 pred 30mg 7 clin fevl,mbc categ
> 150mls
4/19 0.86


















































Drugs- pred=prednisolone, beta betamethasone, cort=cortisone, meprd =methylprednisolone
Time- duration of trial. Entry criteria- clin=clinical criteria only
Outcome measures- parameters used in assessment of response,
mbc-maximal breathing capacity, 12mwd-12 minute walking distance.
Analysis- see text for definitions. Second line refers to categorical analysis criteria.
Results- pos= steroids beneficial or neg= no effect of steroids for group analysis,
or numbers (%) responding for categorical analysis.
Mean FEV1 refers to all patients. ? Unclear from paper or data not given.
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The method of analysis chosen will also affect the conclusions
of the study. Two main methods of analysis have been employed in
published papers. Group analysis investigates if treatment produces
a statistically significant change in the mean value of the outcome
variable studied. Statistically this method of analysis is valid but it
may mask responses to treatment in individual patients. Not all
patients with a particular disease would be expected to respond to all
therapy available to treat that disease, hence concentrating
exclusively on such analysis may lead to effective therapy for some
patients being discarded. In addition although statistically
significant changes may be shown after treatment their magnitude
may be such that clinically the improvement gained is trivial.
An alternative approach is to assess the efficacy of treatment
by determining the number of patients in whom a particular outcome
variable improves by a predetermined clinically relevant amount
(categorical analysis). Such an approach has been used in some
studies of corticosteroids in chronic airflow obstruction, but is only
valid if adequate precautions are taken to allow for natural
variability in the outcome measure used, both in the design of the
trial and in choosing the degree of change in the variable which will
be considered significant in an individual patient. Lack of data on
the natural short term variability of many of the outcome variables
used until recently(94) made the definition of significant
improvement an arbitrary choice, as is reflected in the wide variation
quoted in the published papers.
Ideally both methods of analysis should be used, so that
valuable information is not lost. Interestingly 4 out of the seven
negative double blind studies used a group analysis only(80-82,84),
whereas all but two(87,88) of the positive studies used both methods
of analysis. Subsequent group analysis of both these negative trials
also shows significant effects of corticosteroid^). Categorical
analysis of the positive trials indicates that between 17% and 33% of
patients will respond to corticosteroids with an increase in at least
one outcome variable by over 20%. Even in the negative trials where
categorical analysis has been undertaken between 12.5% to 30% of
patients appear to respond to corticosteroids.
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The number of patients studied is another factor which
determines the sensitivity of a study. If too few patients are studied a
statistically non significant result may occur even though a real
difference exists. Conversely a large study may detect small absolute
differences which are statistically significant, but which clinically are
meaningless. Stoller et al(60) show that in studies where a group
analysis was used, the three positive studies with the greatest
statistical precision(87,88,90) are the three studies with the greatest
number of patients recruited, 16, 24 and 39 patients compared to
7,10, and 10 patients in the three negative, less precise
studies(80,82,83). The choice of outcome measures will also have an
important bearing on the conclusions reached by a study. The
parameters chosen may be dictated by the question asked, but the
use of at least one objective measure has been advocated, because of
the supposed euphoriant effect of oral steroids(41), as Freedman
wrote
"the euphoriant effect of prednisolone led to a number
of greatly inaccurate subjective statements in patients
in whom the FEV1 remained the same or
diminished "(69).
The majority of trials since 1963 have placed little weight on
subjective improvement, and made scant attempt to quantify this.
Indeed only five published studies have related subjective change
after treatment with that seen in objective measures
used(75,77,83,90,92), most studies making vague comments about
symptomatic improvement. Whilst it is clear that potentially
dangerous drugs should not be prescribed for purely symptomatic
reasons, the patients assessment should arguably play a large part
in guiding treatment.
A wide variety of outcome measures have been used in the
published literature, as can be seen from the tables. This reflects the
fact that the most clinically relevant objective tests are not clear. The
results of the five studies which correlated change in objective
measures of lung function with formally measured symptomatic
change should provide data which could answer this question.
However their results are not in agreement. Williams and McGavin
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found changes in FVC correlated most strongly with subjective
change, measured by a visual analogue scale(75), but Swinburn et
al(77), O'Reilly et al(83) and Lam et al(90) found no correlation
between changes in FVC and changes in their subjective measures.
Mitchell et al found the strongest correlation between changes in 12
minute walking distance and a general well being scale, although
again changes in FVC correlated reasonably well with changes in
subjective measures(92). In a study specifically designed to detect
euphoric effects of steroids Swinburn et al did find an improvement
in a number of psychological measures which preceded any change in
the objective parameters, suggesting a euphoriant effect of the drug
and emphasising both types of assessment need to be an integral
part of such trials(77).
Most studies have used at least one of the spirometric
variables, FEV1 or FVC, as an outcome measure. Mitchell et al
comment however that serial peak expiratory flow(PEF)
measurements are a more sensitive test(93). Of 13 patients showing
an improvement in serial PEF of at least 20%, less than half showed
an associated improvement in FEV1. The increased number of
measurements made with serial PEF recordings was thought to
decrease the signal to noise ratio and hence increase the sensitivity
of the measurement. Their results are borne out by our own earlier
study(95). When changes in FEV1 and/or FVC and/or domiciliary
serial PEF measurements were used to define response to treatment,
a response occurred in all three variables in only 11% of responses,
to two variables in 26% of responses and in one variable only in
nearly two thirds of all the responses seen. Multiple outcome
variables therefore appear to increase the likelihood of detecting a
treatment effect.
A case can also be made for including functional measures in
the assessment of corticosteroid therapy. Measurement of exercise
capacity appears to provide extra, slightly different information, as
improvement in exercise performance has been shown to occur
without changes in spirometry(96). The extra information gained
requires a large investment in time terms, and others have shown
that change in 12 minute walking distance correlates with change in
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serial PEF(92), FVC(75), and carbon monoxide gas transfer(83). A
simpler objective measure may therefore suffice, but the ideal
objective measure or measures is far from clear.
Differences in the drug used in the assessment of response to
corticosteroids may alter the conclusions reached, but it is more
likely that differences in the dose used explain some of the
differences in response rate. In acute asthma Webb suggests that a
dose of prednisolone of 0.6mg/kg/day, equivalent to approximately
40mg per day, is optimal for producing physiological
improvement(97). Whether stable patients with non asthmatic
chronic airflow obstruction require similar doses to ensure
maximum response is unclear. Only nine of the studies tabulated
above however, used a daily dose of 40mg per day of prednisolone or
equivalent, although many more used 30 mg prednisolone per day.
Studies which employed lower doses of corticosteroid have always
produced negative results.
The duration of treatment given will also influence the
response to treatment. Hurford et al noted that response to
prednisolone may be delayed, with the maximum response not
appearing until after 14 days treatment in 2 of 6j)atients studied(87).
Blair and Light found significant improvements in lung function at
10 days but not after 5 days treatment with methylprednisolone(91).
Webb et al showed response to oral prednisolone in a group of
predominantly asthmatic patients occurred by the eleventh day of
treatment(98), and our own analysis suggests that maximum
response will not be reached in up to 20% of patients by fourteen
days(78). Hence of the trials listed in tables 2-4, five gave treatment
for inadequate periods(74,81,87,88,91) and only two gave treatment for
long enough periods to ensure all responders to treatment were
identified(80,81).
Finally differences in patient selection will also explain
differing conclusions. Response to corticosteroids appears to be
related to reversibility to bronchodilators(88,89,91), serum
eosinophilia(88) and skin test reactivity(71). Hence differing entry
criteria will inevitably lead to differences in the population studied,
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and partially explain response rates. Eliasson and colleagues(85)
comment that steroid response appears to be inversely related to
initial level of airflow obstruction is borne out by comparing the
mean baseline FEV1 of the trials in table 3 (negative) with table 4
(positive). Negative trials have an average baseline FEV1 of 1.07
litres, compared to 0.75 litres in trials with positive conclusions.
In summary the evidence suggests oral corticosteroids are
effective treatment in stable chronic airflow obstruction. The better
designed, statistically more precise trials reach positive conclusions.
Nevertheless the studies still have methodological flaws and the
conclusion may be more applicable to patients with severe airflow
obstruction.
1.5.2. Short term treatment with inhaled corticosteroids in chronic
airflow obstruction.
A number of studies have shown the benefit of inhaled
corticosteroids in patients with asthma(34,35,99). It would be expected
that patients with non asthmatic chronic airflow obstruction, a
proportion of whom show benefit from treatment with oral
corticosteroids, would respond to the inhaled form of the drug. Only
four studies have investigated this however(95,100-102).
The earliest published paper compared oral prednisolone
with inhaled betamethasone valerate and placebo(lOO). Patients were
defined on clinical and physiological grounds, with symptoms of
chronic bronchitis, and spirometric evidence of airways obstruction.
Two groups of 18 patients were studied, one group as inpatients, the
other in an outpatient setting. Outpatients received 10 days
treatment with placebo, followed by a modest dose of betamethasone
valerate (800ug per day) for a further 10 days, and finally oral
prednisolone 30 mg per day. This part of the trial was a single blind,
sequential, double dummy design. Two patients did not receive the
full dose of oral prednisolone.
The inpatients received 7-10 days of a placebo inhaler,
followed by inhaled betamethasone valerate 800 ug per day for 7-10
20
days, and finally oral prednisolone 30mg per day for one week. Half
of this group received the final treatment as an outpatient, and two
patients were withdrawn because of dyspepsia.
Only six of the 36 patients showed a response to oral
prednisolone, although response was not formally defined. Of these
six, the 4 inpatients showed a similar response to the inhaled drug,
whereas the outpatients showed little improvement after
betamethasone valerate. This was attributed to drug delivery
problems. The authors felt that supervision of aerosol inhalation
technique improved drug delivery and explained the differences in
the results. Although this study suggested inhaled corticosteroids
would be effective in this group of patients, the poor adherence to a
fixed trial design in the inpatients, the low dose of inhaled drug used,
and the short time for which it was given make firm conclusions
impossible.
Shim and Williams studied twelve patients with chronic
airflow obstruction who had previously shown a response to oral
prednisolone(lOl). Whilst continuing a maintainence dose of 5mg per
day of oral prednisolone, patients received either prednisolone 30mg
per day, or a low dose of inhaled beclomethasone dipropionate
160mcg per day. A double blind crossover design was used, with a 14
day washout period which would not reliably exclude a carry over
effect(78). Delivery of the drug was optimised by the improvised use
of a Ziploc freezer bag as a reservoir spacing device. In a group
analysis both oral prednisolone and inhaled beclomethasone
dipropionate improved FEV1 significantly. Five of the 12 patients
showed an increase in FEV1 of over 20% after inhaled
beclomethasone dipropionate, all showed a similar increase after
oral prednisolone. The magnitude of the increase after inhaled
beclomethasone dipropionate in FEV1 was approximately 50% of
that seen after oral prednisolone. The results suggest that inhaled
beclomethasone dipropionate is an effective treatment in a
proportion of patients with chronic airflow obstruction who respond
to oral prednisolone. However the results are not generally
applicable to all patients with chronic airflow obstruction, and must
be interpreted with caution as some patients had been taking inhaled
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beclomethasone dipropionate in unspecified doses for up to 2 weeks
prior to the study, and the effect of maintainence low dose oral
prednisolone is not clear.
In a small study of subjects with clinically defined chronic
airflow obstruction 22 patients received inhaled and oral
corticosteroids in a single blind sequential study which did not
appear to use a double dummy technique(102). Patients were treated
with placebo inhalers and tablets for two weeks , followed by placebo
tablets and inhaled beclomethasone dipropionate 1500ug per day for
a further two weeks, and finally oral prednisolone 30 mg per day
alone for two weeks. A group analysis did not show any significant
effect of either active drug in this small group of patients, but five
patients showed an increase of at least 20% over placebo in serial
PEF measurements and FEV1, or FVC after inhaled beclomethasone
dipropionate. A further mean improvement of 15% occurred in these
patients after oral prednisolone. Again the conclusion that inhaled
beclomethasone dipropionate is at least partially effective in patients
showing a response to oral corticosteroids must be tentative in view
of the inadequacies of trial design, and the loose entry criteria
adopted.
Our own study comparing oral prednisolone 40mg per day,
inhaled beclomethasone dipropionate 1500ug per day, and placebo is
the largest such study in the literature(95). One hundred and twenty
seven adults entered the study, 107 completed the protocol. The trial
was a double blind, crossover study using a double dummy
technique. Patients received an inhaler and tablets for each 2 week
treatment phase, which was followed by a two week washout period
before the next randomised treatment was started. Tablets and
inhalers contained active drug or placebo as appropriate. Only a
categorical analysis was undertaken, using criteria similar to those
used in previous studies to determine response. An improvement in
absolute values of FEV1, and/or FVC recorded on the final day of
treatment, and/or the mean PEF over the final seven days of the
treatment period of at least 20% over baseline values was considered
a response to treatment.
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Despite the two week washout period the analysis detected a
statistically significant order effect in the response to placebo. That
is responses to placebo were detected more frequently if placebo had
been preceded by an active treatment phase. This suggested a carry
over effect of active treatment of at least 14 days, and our subsequent
analysis showed an effect of active treatment 28 days after the
treatment had been withdrawn in some patients(78). This
complicated the analysis of the study, but we were able to show a
statistically significant effect of both oral prednisolone, and inhaled
beclomethasone over placebo. Approximately 20% of patients showed
a response to inhaled beclomethasone, and nearly twice this number
to oral prednisolone.
The use of three outcome measures to define response
probably explains the apparent increase in the response rate to oral
prednisolone compared to previous trials. The response rate to
inhaled beclomethasone may have been further increased if a
spacing device had been used to deliver the drug. Such devices
increase delivery of aerosolised drug by up to 100% (103), and even
with repeated instruction the correct use of metered dose inhalers
alone by patients is poor(104). The study lacked formal subjective
assessment in all patients. However the first 83 patients completed
visual analogue scales for five symptoms, and had 12 minute walking
distance measured. These showed a statistically significant
improvement in 12 minute walking distance in the responders to
active treatment, and an improvement in visual analogue scores
which was not statistically significant, possibly due to the large
variance of these measures(105).
The conclusion was that inhaled beclomethasone is about half
as effective in producing physiological response in patients with
chronic airflow obstruction compared to oral prednisolone. This
reduced effectiveness of inhaled corticosteroids may be explained by
a reduced dose of corticosteroid delivered to the airways and it is
possible that a higher dose of inhaled beclomethasone would be more
effective. This hypothesis was the underlying rationale for the
majority of the current study.
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1.5.3. Long term studies of corticosteroids in chronic airflow
obstruction.
There are no studies of adequate design which have
addressed the long term effect of oral or inhaled corticosteroids in
chronic airflow obstruction. Three uncontrolled studies have been
published, and the results from these suggest that moderate doses of
oral prednisolone may slow down disease progression and improve
mortality (57,58,106).
The earliest report was of an open study of the effects of
injections of 40mg methylprednisolone given every 8 to 14 days for
up to a year(106). Only 20% of patients with chronic airflow
obstruction showed an improvement in peak expiratory flow after
treatment, although the clinical result was thought to be acceptable
in 7 of 11 patients.
The initial report from the Groningen group concerned the
effect of treatment with oral prednisolone on decline in FEV1 and
mortality in 79 patients with severe chronic airflow obstruction, that
is an FEV1 at the start of the 18 year study of less than 1.0 litre(57).
This analysis identified three patterns of decline in FEV1 over the
follow up period. One pattern was a linear decrease in FEV1, a
second a significant increase followed by a decrease, and a third
showed no change in FEV1 with time. Survival in the three groups
was significantly different, the five year survival being 75%, 100%
and 86% respectively in the three groups, and at 14 years 20%, 58%
and 40%. In the group showing a linear decline in FEV1
prednisolone in a dose of at least 7.5 mg per day was taken on
average for 20% of the observation period, for 56% of the follow up
period in those showing an increase followed by a decrease in FEV1
and 90% of the time in patients showing no change in the FEV1 over
the observation period, strongly suggesting a disease slowing effect of
oral prednisolone. This group also demonstrated a strong
correlation between the time of reduction in dose of prednisolone to
less than 7.5mg per day, and subsequent decline in FEV1. When the
dose of oral prednisolone was reduced below this level, the FEV1
always began to fall, but often only after a time interval of between 6
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to 32 months.
This retrospective study provides good evidence, as survival
data over a long follow up period that oral prednisolone can
influence the course of the disease in patients with chronic airflow
obstruction. The data on decline in FEV1 need to be interpreted with
caution because of the uncontrolled nature of the study, although
each of the three groups was comparable in terms of possible
confounding factors, eg; age, initial FEV1 level, reversibility to
bronchodilators.
In a second report a similar analysis was conducted on
patients with less severe chronic airflow obstruction, that is with an
initial FEV1 greater than 1.2 litres(58). This study identified four
patterns of decline in FEV1 over 14 to 20 years. Again a correlation
between the time the daily dose of prednisolone was reduced below
lOmg, and the beginning of a decline in FEV1 was noted. Treatment
with at least 10 mg per day oral prednisolone was followed by an
increase in FEV1 over time, but often not until 6 to 24 months of
continuous treatment. The authors comment that in patients with
chronic airflow obstruction the effect of oral corticosteroids appears
to take a longer time to become apparent than in patients with
asthma. This suggestion implies that most published studies on the
use of corticosteroids in chronic airflow obstruction have failed to
identify all patients in whom this treatment would be beneficial.
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1.6. BRONCHIAL HYPERRESPONSIVENESS IN CHRONIC
AIRFLOW OBSTRUCTION.
Bronchial hyperresponsiveness is defined as an increase in
the magnitude and ease of airway narrowing to a variety of non
allergic stimuli(107). In the long term studies from the Groningen
group bronchial hyperresponsiveness to inhaled histamine was
shown to be an independent predictor of decline in FEV1(108). This
supported the hypothesis from the Dutch workers of the 1960's who
suggested that bronchial hyperresponsiveness was, in addition to an
allergic constitution the major pathogenetic mechanism involved in
the development of both asthma and chronic airflow obstruction, and
that these two diseases could be regarded as two aspects of the same
basic process(39).
A diagnosis of asthma is often taken as being synonymous
with bronchial hyperresponsiveness. Bronchial hyperresponsiveness
in asthma can be demonstrated to variety of inhaled agents, some of
which act directly on bronchial smooth muscle, eg metacholine,
histamine, and others that act indirectly, eg hyperventilation of cold
air, exercise, hypotonic or hypertonic aerosols. The presence and
severity of bronchial hyperresponsiveness in asthma correlates
reasonably well with disease activity, as measured by diurnal
variation in PEF(109), and treatment requirements(llO), suggesting it
is part of the underlying abnormality in asthma. The degree of
bronchial hyperresponsiveness also correlates with the number and
activation of inflammatory cells in bronchoalveolar lavage fluid
recovered from asthmatics(lll,112). Treatment with corticosteroids
improves bronchial responsiveness and asthmatic symptoms, and
also decreases inflammatory infiltration of the airway epithelium in
asthma(113,114,115), strongly supporting the contention that
bronchial hyperresponsiveness is a cardinal feature of asthma.
In patients with chronic airflow obstruction bronchial
hyperresponsiveness can also be demonstrated but it shows different
characteristics to that seen in asthma. The dose response curve in
non asthmatics shows a plateau not present in asthmatics(107), the
degree of bronchial hyperresponsiveness seen for a given reduction
in FEV1 is less(l 16), and there is a correlation between the degree of
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airflow obstruction and the bronchial hyperresponsiveness
seen(117,118). It would also appear that patients with chronic airflow
obstruction show a different pattern of sensitivity to inhaled agents
than patients with asthma. Asthmatics have a higher incidence of
bronchial hyperresponsiveness to metacholine, histamine,
propranolol, sulphur dioxide and cold air(l 19), and it has been
suggested that bronchoconstriction to the inhalation of a hypotonic
aerosol (fog) is specific to asthma(120).
These differences from bronchial hyperresponsiveness seen in
asthmatics have led to debate about whether the mechanisms
underlying bronchial hyperresponsiveness are the same in each
disease group, and to the relevance of the 'Dutch' hypothesis in the
pathogenesis of smoking related airflow obstruction(121).
In asthma bronchial hyperresponsiveness develops before the
development of a late asthmatic response in patients challenged with
various occupational agents(122). This change in bronchial
hyperresponsiveness occurred before any change in airway calibre,
and the degree of bronchial hyperresponsiveness seen at 3 hours
post challenge correlated with the severity of the late fall in FEV1.
These findings suggest that bronchial hyperresponsiveness in
asthma primarily reflects events in the bronchial wall which lead to
bronchoconstriction, and is independent of airway narrowing.
Airway hyperresponsiveness in patients with non asthmatic
chronic airflow obstruction however may reflect other causes.
Narrowing and distortion of airways may alter the smooth muscle
mechanics in the bronchial wall, so that a given stimulus to muscle
contraction causes a greater degree of airway narrowing. Such
changes in muscle mechanics could be due to hypertrophy of muscle
or secondary to a decrease in the force resisting contraction because
of loss of peribronchiolar attachments. There is evidence for both in
some patients with chronic bronchitis(123,124). Additionally any
thickening of the airway wall would result in exaggerated narrowing
of the airway lumen for a given degree of smooth muscle contraction.
Both mucosal inflammation and fibrosis would have this effect(26).
Finally the deposition and retention of the inhaled agent may change
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with increasing airway obstruction, and this may amplify the effect of
the agent.
These three putative mechanisms may explain bronchial
hyperresponsiveness in non asthmatic chronic airflow obstruction to
a large degree. Certainly the relationship between FEV1 and
bronchial responsiveness seen in most studies is likely to be due to
such causes. In Yan et al's study overall a correlation between
bronchial hyperresponsiveness (PC20) and FEV1:FVC ratio was
seen(125). However when patients with relatively normal FEV1
values were considered the relationship between PC20 histamine and
FEV1:FVC ratio disappeared. It is clear however that smokers with
chronic bronchitis and 'normal' FEV1 values do show bronchial
hyperresponsiveness of a minor degree, but certainly less than that
seen in asthmatics(126), suggesting other factors aside from
morphological changes to the airway contribute to bronchial
hyperresponsiveness in these patients. In a physiopathological study
workers from Vancouver showed significant independent influences
of airway calibre, airway inflammation, and cigarette smoking on
PC20 to histamine or metacholine(127). It would seem therefore that
bronchial hyperresponsiveness in non asthmatic chronic airflow
obstruction may reflect to a certain degree inflammatory processes
in the airway wall, as in asthma, but primarily the geometric effects
of the disease process.
Some studies have shown a relationship between accelerated
decline in FEV1 and bronchial hyperresponsiveness(108,128,129),
suggesting bronchial hyperresponsiveness is important in
pathogenesis. However in two of these studies bronchial
responsiveness was measured at the end of the period of observation,
and as a reduction in FEV1 can itself lead to bronchial
hyperresponsiveness due to geometric factors alone, separating
cause and effect and the relevance of bronchial hyperresponsiveness
in these studies is difficult.
As inflammation seems inextricably linked to bronchial
hyperresponsiveness in asthma, one possible way of studying the
importance of this phenomenon in chronic airflow obstruction is to
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look at the effects of interventions designed to reduce airway
inflammation on bronchial responsiveness and decline in lung
function.
Stopping smoking decreases bronchial inflammation(130),
and slows the rate of decline in FEV1 to normal(44). Hence if
bronchial hyperresponsiveness reflects active inflammation this
should improve. No studies have measured bronchial
hyperresponsiveness before and after stopping smoking. However in
a study of changes in bronchial responsiveness to inhaled histamine
and FEV1 over 4 years, the authors concluded that the lack of
change in bronchial hyperresponsiveness to histamine despite a
reduction in decline in FEV1 in ex smokers supported the
importance of geometric factors rather than active inflammation as
the major determinant of bronchial responsiveness(131).
Corticosteroids also reduce inflammation and bronchial
hyperresponsiveness in asthma(113,115). One study has examined the
effect of corticosteroids on bronchial hyperresponsiveness in patients
with chronic bronchitis(132). The patients selected for this study were
smokers with moderate to severe bronchial hyperresponsiveness to
inhaled histamine, but with no evidence of airway obstruction (FEV1
greater than 70% predicted). Over a twelve week period inhaled
budesonide at a dose of 800ug per day produced no significant
change in bronchial hyperresponsiveness or in lung function
parameters in the 8 patients receiving treatment compared to the ten
receiving placebo. Whether a higher dose of inhaled steroid or a
longer period of treatment would produce any change is still unclear.
Three other studies used higher doses of inhaled budesonide and
also failed to show any effect on bronchial hyperresponsiveness.
Pride et al studied 14 middle-aged smokers, known to have an
accelerated decline in FEV1, treated with inhaled budesonide at a
dose of 1200mcg per day over 12 weeks(133). No change in various
lung function parameters, or bronchial responsiveness to histamine
was noted. A recently published study showed no effect of 1600mcg
per day of inhaled budesonide for eight weeks on bronchial
hyperresponsiveness, spirometry or citric acid cough threshold in
smokers with chronic airflow obstruction(134). Oral prednisolone at
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a dose of 40 mg per day actually worsened bronchial
hyperresponsiveness in smokers with mild chronic airflow
obstruction, although the change was measured after only 4
days(135). These small studies, not all fully published, tend to suggest
that bronchial hyperresponsiveness in patients with non asthmatic
chronic airflow obstruction does not improve after measures which
improve bronchial hyperresponsiveness in asthmatic patients. This
would cast doubt on the 'Dutch' hypothesis and tend to relegate
bronchial hyperresponsiveness in these patients to a
paraphenomenon. As Postma has suggested however the beneficial
effect of corticosteroids on lung function in this group of patients
may not become apparent for up to six months, and hence the
studies so far reported may be misleading(58).
The differences in the characteristics of bronchial
hyperresponsiveness in asthma and chronic airflow obstruction,
especially the apparent specificity of a response to cold air
hyperpnea(119) and 'fog' inhalation(120) in asthma, have led to the
suggestion that bronchial hyperresponsiveness to indirect non
sensitising stimuli may identify a group of patients with chronic
airflow obstruction who will benefit from corticosteroid
treatment 136). No previous study has specifically addressed this
question, although from Ramsdale et al's data cold air
responsiveness did not seem to correlate with steroid response(118).
In a similar study there was a lack of correlation between cold air
responsiveness, and the response to a beta agonist or oral
prednisolone in 26 patients with clinical chronic obstructive
pulmonary disease(137). At the moment the role of bronchial
hyperresponsiveness to inhaled agents in predicting response to
corticosteroids in patients with chronic airflow obstruction is
unclear.
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1.7. THE ROLE OF THE NEUTROPHIL IN THE PATHOGENESIS
OF CHRONIC AIRFLOW OBSTRUCTION AND EMPHYSEMA.
Although the cellular events which eventually lead to the
development of chronic airflow obstruction and emphysema are still
unclear, there is a body of evidence that implicates the neutrophil in
the pathophysiology of these disease states. Indeed it is generally
accepted that the development of emphysema is at least in part due
to an elastase imbalance within the lung, the protease-antiprotease
theory(138). The major burden of elastase in the lung is thought to
derive from the neutrophil, although why only 15% or so of smokers
appear to be susceptible to the damaging effects of cigarette smoke is
unclear.
Pathological studies have lent support to such suggestions by
demonstrating neutrophils in the inflammatory infiltrate of
bronchial wall biopsies in patients with chronic airflow
obstruction 139). In addition polymorphonuclear leucocytes (PMN)
appear to accumulate in the alveolar septa of smokers, the
presumptive site of action of their elastase load, although in this
small study no correlation was seen between the accumulation of
polymorphonuclear leucocytes and the degree of emphysema(140).
Animal studies also implicate the neutrophil in the
development of both emphysema, and bronchial
hyperresponsiveness. The intratracheal instillation of human
neutrophil elastase can induce emphysema in experimental
animals(141,142), and neutrophils appear to be essential for the
development of bronchial hyperresponsiveness after ozone exposure
or allergen challenge in dogs(143,144).
In humans it has been known for a long time that persons
with a genetic deficiency of alpha-1-antitrpsin, the major serum
inhibitor of neutrophil elastase, are particularly susceptible to the
development of emphysema(145). This observation would lend weight
to the suggestion that it is this cell type which has the major role in
the pathogenesis of this disease.
Normal individuals who smoke also show increased numbers
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of neutrophils in bronchoalveolar lavage fluid(146), and in smokers
the elastase content of bronchoalveolar lavage fluid correlates with
the presence of emphysema defined both radiologically by CT
scanning and on physiological criteria(147). In this study a negative
correlation between the antielastase activity of bronchoalveolar
lavage fluid and emphysema was also seen, as was a positive
correlation between the number of neutrophils in bronchoalveolar
lavage fluid and the degree of emphysema, adding to the weight of
evidence for the protease-antiprotease theory. This group have also
shown higher neutrophil counts in the bronchial lavage fluid of
patients with chronic bronchitis compared to asymptomatic smokers
and normals, and a correlation between bronchial lavage fluid
neutrophilia and the degree of airway obstruction(148), suggesting in
addition an important role for the neutrophil in the chronic airflow
obstruction associated with emphysema.
The mechanism by which neutrophils are attracted to the
lung parenchyma from the peripheral circulation is not clear.
Cigarette smoke is not chemotactic to neutrophils(149), but cigarette
smoke will stimulate the release of potent neutrophil chemotactic
factors from alveolar macrophages(150). Similar chemotactic factors
can also be found in bronchoalveolar lavage fluid from patients with
chronic airflow obstruction(151), and it is likely these are involved in
recruitment of neutrophils to the lung. It is possible that the release
of such factors also explains the observation of increased
polymorphonuclear leucocyte activation in the peripheral blood of
cigarette smokers(152), and patients with chronic bronchitis and
emphysema(153). Indeed the production of the superoxide anion by
neutrophils isolated from the peripheral blood of patients with
chronic airflow obstruction correlates with the degree of bronchial
hyperresponsiveness in the patients. This suggests a role for these
cells in the pathogenesis of both conditions(154).
Although there is strong evidence supporting a pivotal role of
the neutrophil in the pathogenesis of chronic airflow obstruction and
emphysema, there is little information on the effects of treatment on
neutrophil function. Oral corticosteroids can reduce neutrophil
activation both in vivo and in vitro(155,156) in normal subjects, and
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inhaled budesonide has been shown to reduce some functions of
alveolar macrophages in smokers(157), but there is no data on the
effect of inhaled corticosteroids on neutrophil function in patients.
As inhaled corticosteroid improves lung function in patients with
chronic airflow obstruction(95), and low doses of oral prednisolone
slow disease progression in this disease(57), it would be interesting to
determine the effect of treatment with such drugs on peripheral
neutrophil function in patients with chronic airflow obstruction.
Especially as the peripheral white cell count is a predictor of decline
in lung function in subjects with chronic airflow obstruction(158).
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2. GENERAL AIMS.
The aims of the studies which form this thesis were to further
investigate the role of oral and inhaled corticosteroids in chronic
airflow obstruction, and to investigate cellular mechanisms which
may underlie response to such treatment. In addition one part of the
thesis documented the change in lung function in a group of patients
with chronic airflow obstruction and related the decline in lung
function to a number of factors, including treatment with
corticosteroids.
The specific aims of the main study were:
1. To compare treatment with placebo, and inhaled
beclomethasone at doses of 1500mcg and 3000mcg per day in
producing subjective and objective improvement in patients with
chronic airflow obstruction not due to asthma.
2. To assess the additional effect of adding oral prednisolone
40mg daily to the above treatment in producing subjective and
objective improvement in patients with chronic airflow obstruction
not due to asthma.
3. To assess the safety of the above treatment regimes,
determined by local oropharyngeal effects, and adrenal suppression.
4. To determine the effects of treatment as outlined above
with inhaled beclomethasone and oral prednisolone on bronchial
hyperresponsiveness to inhaled histamine in patients with chronic
airflow obstruction, and to relate in individual patients changes in
bronchial hyperresponsiveness and response to treatment.
5. To determine the effects of treatment as outlined above
with inhaled beclomethasone and oral prednisolone on global
respiratory muscle strength, measured as maximal inspiratory and
expiratory mouth pressures.
6. To examine the role of bronchial responsiveness to
ultrasonically nebulised distilled water in predicting response to
corticosteroids in these patients.
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7. To investigate the relationship between subjective response
measured by a quality of life instrument and physiological response
defined objectively.
8. To investigate the effect of inhaled beclomethasone and
oral prednisolone on peripheral neutrophil activation and
chemotaxis, and lung inflammation in a subgroup of patients.
In a second study the change in lung function in a cohort of
patients who completed a trial assessing steroid responsiveness
between 1983 to 1986 has been documented, and changes seen in
individual patients related to smoking, bronchial
hyperresponsiveness, the starting FEV1, response to treatment in
the original trial, and treatment with oral and inhaled





One hundred and five patients were recruited from NHS
Chest Clinics at Solihull Hospital, the Birmingham Chest Clinic,
and the East Birmingham Hospital. All six consultant chest
physicians working in these hospitals were circulated with details of
the trial, its aims and the patient selection criteria. All were
requested to refer new patients who fulfilled the criteria to myself for
assessment and possible inclusion in the trial. As the trial was
designed to reflect a clinical problem patients were recruited on the
basis of relevant clinical criteria.
The inclusion criteria were:
1. Male or female patients aged 18 years or over.
2. Chronic airflow obstruction defined as an FEV1/FVC ratio less
than 65% and an FEV1 of less than 70% of the predicted value.
3. Symptoms for at least 5 years, beginning during adult life.
Exclusion criteria adopted were;
1. A past or present diagnosis of asthma, made by a consultant
physician.
2. Treatment with inhaled or oral corticosteroids in the previous
3 months.
3. An infective exacerbation of their disease (acute on chronic
bronchitis) resolving within the 4 weeks prior to recruitment.
4. A history of poorly controlled concomitant disease eg; diabetes
mellitus, active peptic ulcer disease, uncontrolled congestive
heart failure and untreated pulmonary tuberculosis.
5. Pregnancy or lactation
6. Anybody unable to comply with the protocol due to physical or
mental disability (eg; blindness, illiteracy, language difficulties).
Reversibility of the airflow obstruction to bronchodilators was
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not included in the criteria because of the relationship between
reversibility and the starting FEV1(159), which makes the
interpretation of apparent reversibility to FEV1 in patients with low
starting FEVl's extremely difficult. A diagnosis of asthma was made
at the time of the initial assessment, and patients excluded from the
study, if they had a history of variability in symptoms except in
association with infections, and if they reported acute attacks of
wheezing and breathlessness, a history of chronic respiratory
symptoms in childhood, or a deterioration in symptoms following
exposure to a specific allergen.
3.2. TRIAL DESIGN.
Because of work showing a carry over effect of corticosteroids
of up to 6 weeks(78), the design of the trial was single blind with
three, 3 week sequential treatment periods. The treatment periods
were preceded by a baseline period of 14 to 21 days during which
time bronchodilator therapy was rationalised and optimised, on the
results of reversibility tests, and the various baseline investigations
performed. For the final week of the baseline period, and throughout
the remainder of the trial bronchodilator treatment was continued
unchanged.
At the end of the baseline period the patients were randomly
allocated one of four possible treatment regimes over the ensuing
nine weeks, that is a parallel group design was used. The
randomization was blind to both the investigator and the patients.
In all groups the first treatment period consisted of placebo inhalers
and tablets.
For the second treatment period the patients received either
inhaled beclomethasone dipropionate 750 meg b.d. plus placebo
tablets, or inhaled beclomethasone 1500 meg b.d. plus placebo
tablets. The inhaled drug was delivered by two identical inhalers and
patients were instructed to take 3 puffs from each inhaler twice daily.
Each puff of active treatment delivered 250 meg per puff of
beclomethasone. Eight placebo tablets were prescribed per day, to be
taken in the morning after breakfast.
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For the final treatment phase, the inhaled therapy allocated
during the second treatment phase was continued unchanged, but
two thirds of the patients in each BDP dosage group received 40 mg
per day oral prednisolone in addition. The remaining 1/3 of each
BDP dosage group continued treatment with inhaled beclomethasone
and placebo tablets for the final treatment phase.
The patients attended the laboratory on three occasions
during the baseline period for pretreatment assessments to be made,
ie day -21 (start of baseline), day -7 (mid-way through baseline
period) and day 0 (start of the placebo treatment). They were then
assessed on the final day of each treatment period, ie; day 21 (end of
placebo treatment), day 42 (end of inhaled BDP treatment), and day
63 (end of third treatment phase). Finally they were seen 4 weeks
after the end of treatment during which time they continued their
usual bronchodilator therapy.
The design employed a double dummy technique. All placebo
inhalers and active inhalers were identical and placebo and
prednisolone tablets appeared identical. Inhalers were taken via a
volumatic spacing device (Allen & Hanburys Ltd, Greenford
Middlesex). Patients were instructed at each attendance on how to
take inhalers via this device. In addition both written and verbal
instructions were given to each patient at each attendance on the
dose of each medication to be taken. They were instructed to take 3
puffs twice daily from each inhaler via the volumatic spacing device,
and 8 study tablets in the morning after breakfast.
The first three patients followed an identical protocol in a
pilot study, but are included in the final analysis.










Figure 3.1. Schematic representation of the trial design. Each phase
of the trial was 3 weeks long, with assessments on the final day of each
treatment phase. The proportion of patients following each pathway is
shown in bold type.
39
3.3. WITHDRAWAL CRITERIA.
Patients were withdrawn from the study for the following
reasons.
1. At the patients request because of unwillingness to continue
with the trial.
2. Development of significant side effects attributed to treatment
3. Inability to follow protocol
4. Any patient requiring treatment with oral corticosteroids
because of an exacerbation of their disease, that is an increase in
breathlessness, with or without purulent sputum, accompanied
by a fall in PEF or spirometric indices.




All lung function measurements were performed after 20
minutes rest and patients were instructed to refrain from inhaled
bronchodilators for 6 hours before the measurements and not to
take any oral bronchodilators in the previous 24 hours. All lung
function and biochemical tests were performed at the same time of
the day, with a tolerance of +/- 1 hour, at all visits.
Spirometry.
Forced expiratory volume in 1 second (FEV1) and forced vital
capacity (FVC) were measured on a dry wedge spirometer. This
measurement was performed at every visit. The highest value of at
least 3 attempts was recorded and used for future analysis, providing
the highest two readings of FEV1 were within 50 ml or 5 % of each
other. Baseline FEV1 and FVC were taken as the mean of the three
measurements on the three baseline visits before any treatment.
Patients were seen in three geographically distinct locations
(Birmingham Chest Clinic, Solihull Hospital and East Birmingham
Hospital) and a different dry wedge spirometer (Vitalograph) was
used at each site. However measurements in individual patients were
performed on the same dry wedge spirometer throughout the trial.
Each spirometer was regularly checked and calibrated, and
measurement of FEV1 and FVC of the author were within 5% on
each of the three machines used.
Carbon Monoxide Gas Transfer.
The diffusing capacity of carbon monoxide for the lung
(DLCO) was measured by the standardized single breath
technique(160). At each site a Morgan Transfer Test module was
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used. The best of three measurements made over a 20 minute period
was recorded, providing the top two measurements of the DLCO
were within 10%. The diffusion coefficient (KCO), ie the diffusing
capacity per unit lung volume, and the single breath alveolar volume
(VA) were also calculated. The analyzers were calibrated routinely
prior to any testing using a test gas and room air. The breath hold
time utilized was the maximum the patient could tolerate up to 9
seconds, and the vital capacity employed was at least 70% of that
obtained from a slow vital capacity maneuver on a dry wedge
spirometer.
This measurement was performed twice during the baseline
period, and at each of the three post treatment visits.
Static Lung Volumes.
Static lung volumes were measured by a closed circuit helium
dilution technique on one occasion during the baseline period. Re-
breathing was continued for a maximum of 20 minutes or until the
helium concentration changed by less than 0.03% over 1 minute. The
test was repeated if for any reason it was felt that the result was
technically unsatisfactory. Total lung capacity, vital capacity,
functional residual capacity, residual volume were all calculated
from the readings obtained and the result of slow vital capacity
maneuver following the test.
Reversibility ofFEV1 and FVC.
The reversibility of FEV1 and FVC to bronchodilators was
measured during the baseline period and also at the end of each
treatment period. During the baseline period all patients had
reversibility to 200 meg of Salbutamol and 72 meg of Ipratroprium
Bromide measured on different days. The drug was administered via
a Volumatic spacing device (Allen & Hanburys Ltd, Greenford, UK)
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by the investigator and the response measured 20 minutes later.
In patients with an FEV1 greater than 0.75 litres the
reversibility test was performed after the measurement of bronchial
responsiveness to inhaled histamine. To eliminate any possible effect
of prior bronchoconstriction upon the response to inhaled
bronchodilator, the drug was only administered after the FEV1 had
returned to the pre-histamine test level or after 30 minutes had
elapsed since the end of the test of bronchial responsiveness. The
reversibility of FEV1 and FVC was calculated with respect to the pre-
histamine FEV1 and FVC.
At the post treatment visits patients were randomised to have
reversibility to either Salbutamol or Ipratropium Bromide
measured.
Reversibility to FEV1 was expressed in four ways;
(a) as absolute change (ml) from prebronchodilator value
(absolute),
postbronchodilator FEV1 - prebronchodilator FEV1
(b) as a percentage of the initial prebronchodilator value (%
initial),
postbronchodilator FEY1-prebronchodilator FEV1 xl00%
prebronchodilator FEV1
(c) as a percentage of the predicted FEV1 (% predicted),
postbronchodilator FEY1-prebronchodilator FEV1 x 100%
predicted FEV1
(d) as a percentage of the 'possible' reversibility (% possible),ie
postbronchodilator FEV 1-prebronchodilator FEV1 x 100%
predicted FEV1- prebronchodilator FEV1
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3.4.2. Bronchial responsiveness to inhaled histamine.
Bronchial responsiveness to inhaled histamine was measured
by two different methods during the baseline period on separate
days. The method of Cockroft et al(161) was used to determine
bronchial hyperresponsiveness on one occasion during the baseline
period. On the other occasion, and after each treatment the method
of Yan et al(162) was employed.
All patients with an FEV1 greater than 0.75 1 had bronchial
responsiveness to histamine measured. All tests were performed with
the subject seated. After the baseline pre-test FEV1 had been
measured the patient inhaled the diluent, either phosphate buffered
saline (for the Cockroft method) or normal saline (for the Yan
method), as a control. Providing the FEV1 measured after the
control inhalation did not fall by more than 10%, increasing
concentrations of histamine were then inhaled until the protocol was
complete or the subjects FEV1 had fallen to below 80% of the lower
of the pre-test or post diluent value. The patient was then supervised
until the FEV1 had returned to within 10% of the pre-test value, or
until 30 minutes had elapsed from the end of the bronchial
responsiveness test, at which stage a reversibility test was performed.
For both methods the concentration (Cockroft method), or
cumulative dose (Yan method) of histamine which produced a 20%
fall in the FEV1 (PC20 & PD20 respectively) was estimated by linear
interpolation of a plot of percentage fall in FEV1 against the log dose
of histamine, with extrapolation to one doubling dose above the
maximum administered. The lower of the pre-test FEV1 and that
measured after the control inhalation was used to calculate the
percentage fall after each dose of histamine.
Cockroft Method.
A Wright nebuliser driven by air at a pre-determined flow
rate to produce an output from the nebuliser of 0.14 mg/'min of
nebulised solution was used. The nebuliser was primed with three
millilitres of solution and aerosol delivered to the subject by a loose
fitting face mask without intervening tubing. The subject wore a nose
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clip and inhaled the aerosol by tidal breathing for two minutes. The
FEV1 and FVC were recorded prior to any inhalation as described
above. After each inhalation, including the control inhalation of the
diluent, phosphate buffered saline, the FEV1 was recorded once,
unless technically unsatisfactory, at 30 and 90 seconds and at
subsequent 90 second intervals until the value showed no further fall.
Inhalations of histamine were given by successive doubling
concentrations from 0.03 mg/ml to a maximum of 16 mg/ml.
Yan Method.
The output of several hand held Devilbis number 40
nebulisers were measured to select five with an output within the
range 0.0018 to 0.0042 ml/puff. These were primed with 1 to 1.5 ml of
either saline or histamine dissolved in saline in concentrations 0.3,
0.6, 2.5 or 5 g/ml. The FEV1 was measured prior to any inhalations
as above, and subsequently four puffs of saline were given as the
control inhalation. The FEV1 was measured 60 seconds after the last
inhalation, and providing the FEV1 had not fallen by more than 10%
of the pre-test value histamine was administered.
One or more puffs were delivered from the nebuliser directly
in front of the subjects open mouth> at the beginning of a near
maximal inspiration from function residual capacity. The patients
were coached in the technique of coordinating inspiration. After each
dose from the nebuliser the patient held his breath for 3 seconds.
Histamine was administered according to a fixed regime to
achieve accumulative doses of 0.03 to 7.8 mmol.
3.4.3. Bronchial responsiveness to ultrasonically nebulised distilled
water.
Bronchial responsiveness to the inhalation of increasing
amounts of ultrasonically nebulised distilled water was determined
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on one occasion during the baseline period by a modification of the
method of Anderson et al(163). A Mistogen EH147C ultrasonic
nebuliser with an air mist module was used to generate the aerosol.
The output of this module without the breathing circuit was 3
ml/min with a particle size 3 to 5 microns (manufacturers data). The
aerosol generated by the nebuliser was delivered to a 2 way valve
(Hans Rudolph, Inc., Kansas City, NO. 1500) via short lengths of 1.25
inch diameter corrugated tubing. The expired limb of the two way
valve was connected by a further corrugated tubing to a Wrights
respirometer, from which the volume of aerosol inhaled by the
patient was calculated.
The FEV1 was measured prior to the challenge as described
above. As a control the patient breathed 40 1 of room air through the
circuit without any aerosol being generated. The FEV1 was
determined 30 seconds after this procedure. If the FEV1 had fallen
by less than 15% of the initial value the challenge continued. The
variable output control of the nebuliser was set to its maximum and
the patient initially inhaled 10 litres of the nebulised aerosol. Thirty
seconds after the end of the inhalation the FEV1 was once again
determined. If the FEV1 had fallen by more than 20% the test was
terminated. If the FEV1 had fallen by between 10% and 20% a
further two aliquots of 10 litres of aerosol were inhaled sequentially
and the FEV1 determined 30 seconds after each inhalation, the test
terminating if the fall in FEV1 after either aliquot was greater than
20% of the pre challenge value. If the fall in FEV1 after the initial 10
litre aliquot of mist was less than 10% the volumes of aerosol used in
subsequent inhalations were 20 litres, 40 litres, 80 litres, 80 litres
and 80 litres, until a fall in FEV1 of at least 20% of the higher of the
pre-challenge or post-air value had been recorded. The test was
stopped after a maximum of 310 litres of aerosol had been inhaled.
After each inhalation the weight of the canister containing the
distilled water and the tubing connecting the canister to the two way
valve was measured using an electronic scale accurate to 0.1 gram.
From the change in the weight of this after each inhalation, the
volume of water delivered to the mouth of the patient could be
calculated. The dose of water in millilitres delivered to the mouth
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which caused a 20% fall in the FEV1 was calculated by linear
interpolation of a plot of the percentage fall in FEV1 against the
change in weight of the canister and tubing.
Following the challenge the patients received 200 meg
Salbutamol via a volumatic spacing device to reverse the
bronchoconstriction induced.
Bronchial responsiveness to ultrasonically nebulised distilled
water was not measured in all patients. The equipment required for
the test was only available after the trial had commenced. Hence only
75 patients were considered for the test and the test performed in 49
patients in whom the FEV1 was greater than 0.75 litres.
3.4.4. Static Mouth Pressures.
Maximum inspiratory and expiratory mouth pressures were
measured on two occasions during the baseline period and on the
final day of each treatment phase. A modification of the method of
Black and Hyatt was used(164).
A commercially available mouth piece of a semi-rigid plastic
flange type (PK Morgan, Chatham, Kent), was used. This was fitted
to a rigid stem incorporating a 3 way tap. The stem was of 20 mm
internal diameter and 12 cm in length. A leak hole of diameter 2.5
mm was situated 10 cm from the site of the mouth piece attachment.
The stem was connected by a 75 cm length of polythene tubing to an
anaeroid pressure transducer (Wika Ltd, Coulsdon, Surrey, UK).
The manometer was calibrated regularly using a U tube water filled
manometer.
Mouth pressures were measured with the subject in the
seated position wearing a nose clip. The flange mouth piece was held
in the mouth behind the lips and gripped firmly by the teeth, the
operator holding the stem. If necessary the subjects used their hands
to hold their lips firmly onto the mouth piece. For a maximum
expiratory pressure measurement the subject inspired to total lung
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capacity, the operator closed the three way tap and the subject was
asked to blow maximally down the tube. All subjects were given
verbal encouragement and were able to see the manometer reading.
A period of familiarization and learning preceded the definitive
measurements on each day mouth pressures were determined. At
least one minute rest was allowed between efforts. Only pressures
maintained for more than 1 second, judged from a stop watch, were
recorded. The measurement was repeated at least 3 times, or until
the two highest measurements were within 10% of each other. The
highest of the measurements was recorded for further analysis.
For maximal inspiratory pressure measurements, the subject
expired to residual volume, the operator closed the three way tap and
the subject was asked to inspire maximally. Any measurements
where there was a visual or audible leak around the mouth piece
were ignored.
3.4.5. Blood tests and smoking status.
All patients underwent venepuncture on one of the three
baseline visits for estimation of haemoglobin concentration, total
white cell count, differential white cell count including eosinophil
count, serum IgE level, serum alpha 1 antitrypsin level, and serum
thiocyanate. Serum IgE and alpha 1 antitrypsin levels were
measured in the Regional Immunology Laboratory at East
Birmingham Health by a standard nephelometric method.
Exhaled carbon monoxide concentration was measured using
a portable analyser (Ecocheck EC50, PK Morgan, Chatham, Kent).
Professed smoking status was confirmed using the results of this test
and the serum thiocyanate concentration. An exhaled carbon
monoxide concentration above 8 ppm, or a serum thiocyanate
greater than 70 micromoi per litre were considered as evidence of
current cigarette consumption and classified patients as current
smokers irrespective of their claimed smoking habit.
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3.4.6. Hypothalamic-Pituitary-Adrenal Function.
Hypothalamic-Pituitary-Adrenal function (HPA) was
assessed by the measurement of 24 hour urinary free Cortisol and by
the adrenal response to an injection of tetracosactrin.
24 hour urinary Cortisol measurement.
Patients were asked to collect urine over the 24 hours prior to
their laboratory visit. This was done on one occasion during the
baseline and after each of the active treatment phases. The patients
were instructed to empty their bladders on rising on the morning of
the day of collection. This urine was discarded and all subsequent
urine passed for the next 24 hours was collected in the container
provided. At the end of the 24 hour period the patients were asked to
empty their bladder and to save the urine in the bottle, and then to
collect no further samples.
Tetracosactrin test.
10ml of venous blood was withdrawn in to a heparinized tube
via a 21 or 19 gauge butterfly needle. The patient then received a
slow intravenous injection of 0.25 mg Tetracosactrin over 10 to 15
minutes. 30 minutes after the end of the injection a further 10 ml
sample of venous blood was withdrawn. Serum Cortisol levels were
measured on these samples.
In patients who objected to an injection, a single baseline
venous blood sample was withdrawn for the estimation of random
unstimulated serum Cortisol.
Cortisol in urine and serum was measured in the Department
of Clinical Chemistry, East Birmingham Hospital, by a in house
radioimmunoassay. Unfortunately this test showed interference with
metabolites of oral prednisolone in the urinary samples collected at
the end of the third treatment phase.
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3.4.7. Skin prick tests.
As part of the baseline investigations all patients had a series
of standard skin prick tests performed to D.Pteronyssinis,
Aspergillusfumigatus, cat fur, dog hair, grass pollens, Cladosporium
sp. and Penicillium, to a negative (diluent) and a positive
(histamine) control. A positive test was considered to be a wheal of
greater than 3 mm diameter over that seen to the negative control.
3.4.8. Assessment of Oral Candidiasis.
On the final pre treatment visit during the baseline period
and on each post treatment visit an assessment of oropharyngeal
candidiasis was made by simple visual inspection of the oropharynx.
A five point scale was used to score the appearances. This was as
follows;
0 = normal mucosa,
1 = small isolated patches of reddened mucosa (less
than 0.5 cm diameter),
2 = larger confluent reddened areas,
3 = areas of white exudate,
4 = frank alteration,
Swabs were taken if clinically indicated.
3.4.9. Assessment of dysphonia.
In addition on the final baseline visit and each subsequent
visit patients were asked if they had experienced any persistent







3.4.10. Modified Respiratory Symptom Questionnaire.
(see appendix I).
At the start of the study the patients completed a doctor
administered questionnaire concerning respiratory symptoms. This
included modified questions from the MRC respiratory symptoms
questionnaire, in addition to questions taken from a questionnaire of
Mortagy et al(165), which purport to detect bronchial
hyperresponsiveness in patients.
Patients were defined as suffering from chronic bronchitis if
they answered positively to questions three and six.
A breathlessness score was derived from the answers to
questions 7 to 9. For each positive answer to the graded questions 7
to 9 a score of one was deducted from a maximum score of three.
Hence severely disabled patients scored zero, whereas patients with
relatively few symptoms from their disease could score 2 or 3.
The answers to questions 16 and 17 were combined to give an
indication of a possible 'asthmatic' element to their disease. Patients
answering yes to both questions, 'Have you ever had attacks of
shortness of breath with wheezing?' and 'Is/was your breathing
absolutely normal between attacks?' were classed as having
asthmatic features to their disease, all other patients as having no
asthmatic features.
Bronchial irritability was defined as described by Mortagy et
al(165). Any patient reporting wheeze or breathlessness or both to
any of the factors detailed in question 27 were defined as having
bronchial irritability.
3.4.11. Quality of Life Questionnaire.
(see appendix II).
On the final baseline visit and after each of the treatment
phases the patients answered a doctor administrated quality of life
questionnaire. This was developed in Canada by Guyatt et al(166) in
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a group of patients with chronic airflow obstruction. This was kindly
supplied by this group with an instruction manual and tape for use
in this study. The questionnaire consisted of five questions designed
to measure the dyspnoea experienced by the patient during every day
activities. A further fifteen questions covered three further broad
areas of the patients life. These were mastery over the disease,
emotional function and fatigue. Questions were read by the
investigator word for word from the questionnaire, and the patient
answered by indicating from cards the response which best described
him/her. Responses where structured on a seven point Likert scale.
The activities causing dyspnea in each patient were
volunteered or selected by the patient from a list of activities of daily
living. This section of the questionnaire was thus individualised.
Patients with milder disease were in some cases unable to select five
activities consistently causing breathlessness. In individuals who
selected less than five activities the score for this dimension was
adjusted for the purposes of presenting the results, by dividing the
total score by the number of dyspnea questions answered and
multiplying the result by five.
It would be incorrect to compare the results of the dyspnea
dimension between patients because the questions are not
standardised, as a consequence of the individualisation of the
activities. Thus the dyspnea induced by making a cup of tea in a
patient with severe disease may be the same as that caused by
walking 100 yards briskly in a patient with mild disease. The nature
of the dyspnea dimension of the questionnaire is such that the
magnitude of the task attempted is not taken into account, and
hence only within patient comparisons are possible.
3.4.12. Oxygen Cost Diagram.
(see appendix III).
On two occasions during the baseline period and at the end of
each treatment phase patients were asked to complete a modified
oxygen cost diagram(167). This consists of a visual analogue scale
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with descriptive phrases at various points along the line
corresponding to the oxygen requirements of the activities. The top
of the line represented 'no breathlessness', the bottom 'the greatest
breathlessness'. The patient was instructed to 'mark the line at a
point above which you would become breathless'. The original oxygen
cost diagram measured 100mm in length, that used in this study was
elongated to 198mm to improve clarity, but the relative position of
the phrases along the elongated line was maintained. The distance
from the bottom of the scale to the patients mark provided an
measure of the patients dyspnea.
3.4.13. Diary Card Data.
(see appendix IV).
Throughout the study, from day 1 of the baseline period to
the end of the follow-up period, patients were asked to record various
items on a diary card on a daily basis. These were
a) Peak expiratory flow rate (PEF).
Patients were provided with a new Mini Wright peak flow
meter and instructed in its use. They were asked to record the PEF
on 4 hourly, starting immediately on rising. They were instructed to
make 3 readings, and only if the two top readings were within 20
1/min of each other, to record the highest 3 readings. If this criteria
was not met they were asked to take further readings until this
criteria could be fulfilled. The result was recorded in the appropriate
space in the diary card.
b) Breathlessness Score.
At the end of the day patients were asked to record their
breathlessness on a 7 point open ended scale. The lowest value of the
scale 1, was chosen to represent a state of not at all breathless,
where as the maximum score 7, was described as the worse
breathlessness the patient had ever experienced. Patients were
instructed to record the number which best described them over the
previous 24 hours at the end of the day.
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c) Sputum Assessment.
Sputum production was assessed simply on a 4 point scale
as follows:
0 = none
1 = on rising only
2 = less than one egg cup full all day
3 = greater than one egg cup full all day.




3 = yellowish green
4 = green.
Patients were instructed to record both sputum production
and sputum colour at the end of the day.
d) Medicine for Bronchitis.
The investigator recorded on the diary card all medication
taken for the patients chest complaint. Patients were instructed to
record at the end of the day the amount (number of tablets or puffs)
of each medication taken in the previous 24 hours.
3.5. DATA HANDLING AND ANALYSIS.
Data was recorded directly at the time of the visit in
individual patient booklets. At the end of the study the data collected
was extracted manually onto a spreadsheet and subsequently entered
on to a data base on an Elonex 386 laptop personal computer. Data
entry was performed in duplicate. The duplicate data entry was cross
checked for data entry mistakes, and data ranges for each variable
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examined for possible errors in extracting data from booklet to
spread sheet.
The subjective data recorded on diary cards was averaged
over the final seven days of each phase, and the mean used for
subsequent analysis. Peak flow readings were analysed daily,
calculating the mean, maximum, and minimum for each day. The
diurnal variation was calculated daily as the difference between the
daily maximum and minimum divided by the daily mean, expressed
as a percentage.
ie, daily diurnal variation in PEF
= daily max PEF - daily minimum PEF x 100%
daily mean PEF
The calculated daily values were averaged over the final
seven days of each treatment period to give the diurnal variation (%
mean), used in subsequent analysis. The mean diurnal variation
calculated in this way was also expressed as a percentage of the
predicted PEF for each individual patient,
diurnal variation in PEF (% predicted) =
diurnal yarn in PEFf% mean) x mean weekly PEFtl/min)
predicted PEF (1/min)
Preliminary data from the diary cards concerning use of
medication and sputum production and colour showed little effect of
treatment, and had a large percentage of incomplete data, hence no
further analysis was performed on this data.
3.5.1. Statistical Analysis.
The aims of the study described above were analysed using
end points defined during the design of the study to enable the
primary and subsidiary aims to be assessed. The actual analysis
employed is described in each chapter.
Analysis was carried out using the Solo(168) and SPSS-
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PC(169) statistical programs on an Elonex 386 laptop personal
computer. A probability level of 0.05 was considered statistically
significant.
Predicted lung function values were derived from the
published equations of the European Community for Coal and
Steel(l70).
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4. DEMOGRAPHIC DETAILS, LUNG FUNCTION AND RESULTS
OF BASELINE SYMPTOM QUESTIONNAIRE.
4.1. ANALYSIS.
Data for continuous normally distributed data is presented
as the mean (SEM), or geometric mean for serum IgE level, and
PD20 which showed a log normal distribution. Ranges for continuous
data are also presented. Possible relationships between baseline
variables were investigated by deriving Pearson or Spearman
correlation coefficients as appropriate. Differences between groups of
patients (eg; smokers and ex-smokers) in continuous variables were
investigated by unpaired Student t tests, or Mann Whitney U test as
appropriate, and for categorical data by a Chi squared test.
Patient groups were defined on the basis of answers to
questions in the baseline symptom questionnaire that suggested
asthmatic features to the disease. Affirmative answers to questions
16 'Have you ever had attacks of shortness of breath with wheezing ?'
and question 17 'Is/was your breathing normal between attacks ?'
when combined were considered suggestive of significant asthmatic
features, and patients responding positively to both questions were
classed as having asthmatic features present. In addition patients
were classified into the presence or absence of bronchial irritability
as defined by Mortagy et al(165).
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4.2. RESULTS.
One hundred and twelve patients entered the baseline period
of the study. Seven did not continue into the placebo period because
of inability to complete the diary card or follow the protocol (3
patients), or due to an infective exacerbation of their disease during
the baseline period requiring treatment with antibiotics and oral
corticosteroids (4 patients).
4.2.1. Demographic data.
The demographic, smoking and atopic characteristics of the
105 patients who were recruited to the study are shown in table 4.1..
The majority of the study group were male, and nearly one
half were current smokers. The average cigarette consumption of
those smokers and ex-smokers was moderately high at nearly 50
pack years (1 pack year equals smoking twenty cigarettes per day for
one year).
Table 4.1. Demographic data, smoking details and atopic
characteristics of the 105 patients at baseline.
Mean (SEM) Range
or number


























The results of the skin testing and serum IgE estimations
indicate heterogeneity with respect to these allergic characteristics.
Twenty three of the patients had positive skin tests to common
airborne allergens. No relation between age, or smoking habit and
skin test reactivity was seen (mean [95% CI] age (years); skin test
positive 66 [64.5-67.5], skin test negative 65 [62-67.5]: % group skin
test positive; current smokers 23%, ex smokers 21 %). The geometric
mean serum IgE level was raised above the laboratory normal upper
limit at 75 ku/1. Thirty six patients had a serum IgE level over 100
ku/1. IgE levels in smokers and ex smokers were similar ( geometric
mean [range] serum IgE ku/1; current smokers 80 [25-4810], ex
smokers 72 [25-860]).
4.2.2. Baseline pulmonary function.
The details of the baseline prebronchodilator pulmonary
function tests are given in tables 4.2 and 4.3, and the distribution of
the mean baseline prebronchodilator FEV1, and volume corrected
carbon monoxide gas transfer (KCO) in figures 4.1. and 4.2.. The
latter are shown as the percentage of the predicted value.
The results of the baseline spirometry show a wide range of
airflow obstruction (table 4.2.). A few patients had extremely severe
obstruction with FEV1 values of less than 500ml, and FEV1/FVC
ratios of less than 25%. The average FEV1 and FEV1/FVC ratio
indicate that the group studied had moderately severe disease. There
was no significant difference in the absolute level of FEV1 between
smokers and ex smokers ( mean [95% CI] FEV1 (litres); current
smokers 1.08 [0.95-1.22], ex smokers 1.03 [0.9-1.14]), neither was a
correlation between the amount smoked, as estimated from the
questionnaire in pack years, and FEV1 or FEV1/FVC ratio observed
(FEV1 r=0.05; FEV1/FVC r= -0.09). Ex smokers did show a slightly
lower FEV1/FVC ratio however ( mean(SEM) FEV1/FVC ratio,
smokers 41.7%, ex smokers 37.0%; 95% confidence limits for
difference -3.7 to 9.5%).
Static lung volumes in general showed hyperinflation and a
raised residual volume reflecting the severity of the airflow
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obstruction.
Table 4.2. Prebronchodilator spirometry and static lung volumes

































Single breath carbon monoxide gas transfer measurements
were impaired in the majority of the patients studied (table 4.3.).
This was true both for the diffusion coefficient for the whole lung,
TLCO, and the volume corrected value, KCO. Again however a wide
range of values were recorded reflecting the spectrum of disease seen
in the clinic setting (figure 4.2.).
No correlation was seen in the baseline data between smoking
category and KCO (mean [95% CI] KCO (mmol/kPa/min/1);
current smokers 1.03 [0.91-1.15], ex smokers 1.02 [0.92-1.12]), or
between the past cigarette consumption and this measure of gas
transfer (r = -0.12).
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Table 4.3. The results of single breath carbon monoxide gas
















Figure 4.1. The distribution of prebronchodilator FEV1 (as %
predicted) in the patients studied.
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Figure 4.2. The distribution of the volume corrected carbon
monoxide gas transfer (KCO), as a percentage of the predicted
value.
4.2.3. Variability and reversibility of airflow obstruction, and
bronchial hyperresponsiveness to inhaled histamine.
Measurements of variability in lung function, both
spontaneous and drug induced are given in table 4.4.. These might
be considered a measure of the asthmatic component of the airflow
obstruction in the group.
The diurnal variation in PEF was over 15% in the majority of
patients when expressed as a percentage of the mean PEF. Flowever
as a percentage of the predicted PEF the average diurnal variation in
PEF was only 11%.
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Table 4.4. Peak expiratory flow, reversibility and variability of
lung function, and bronchial responsiveness to inhaled histamine
in those patients with data (as mean (SEM) and range in 105
patients unless indicated).
Mean (SEM) Range








Diurnal variation in PEF
as % mean


































The reversibility in FEV1 to both bronchodilators also
depends on the method used to express this, but the average absolute
change was small (less than 150ml). Frequency histograms of the
change in FEV1 following 200mcg salbutamol, as the four
expressions of reversibility calculated are shown in figure 4.3. and
4.4.. Only two patients showed an improvement in FEV1 of over
450ml after salbutamol (figure 4.3.). Although when expressed as a
percentage of the prebronchodilator FEV1 a number of patients
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appear to have reversible airflow obstruction, when the effect of a low
prebronchodilator FEV1 is removed by expressing the change as a
percentage of the predicted FEV1, the group show little reversibility
(figure 4.4.). The expression of reversibility as a percentage of the
capacity to respond, % 'possible' (change in FEV1 / predicted -
prebronchodilator FEV1), showed only one patient who improved his
FEV1 by over 50% of this measure after salbutamol.
The mean (SEM) FEV1 after 200 meg salbutamol was 45.4
(1.5) percent of the predicted value, indicating that the majority of
patients had a significant degree of irreversibility to their airflow
obstruction. A frequency histogram of post salbutamol FEV1 values
is shown in figure 4.5..
Bronchial responsiveness to inhaled histamine (PD20) was
measured in 74 patients who had an FEV1 greater than 0.75 litres.
In 3 patients the FEV1 fell by less than 20% after the highest dose
given, and the value for these patients was derived by further
extrapolation as explained in the methods. In one patient the value
was truly censored, in that a value could not be obtained by
extrapolation, therefore a value of 16 micromol, the maximum
possible, was assigned to this patient. As a group bronchial
hyperresponsiveness was moderate. Further details of bronchial
hyperresponsiveness to inhaled histamine in this group of patients is
given in chapter 8.
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Chang* In FEV1 (ml*)
Change In FEV1 (* possible)
Figure 4.3. The distribution of reversibility of FEV1 after 200mcg
salbutamol, shown as the absolute change ( upper graph), and as
a percentage of the 'possible' reversibility (lower graph).
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Change In FEV1 (% pre-bronchodllator FEV1)
Change In FEVt (« predicted FEV1)
Figure 4.4. The distribution of reversibility of FEV1 after 200mcg
salbutamol, as a percentage of the pre-salbutamol FEV1 (upper
graph), and as a percentage of the predicted FEV1 (lower).
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Figure 4.5. The distribution of post salbutamol FEV1 (as %
predicted) in the 105 patients studied.
4.2.4. Baseline respiratory symptom questionnaire data.
Responses to selected questions of the baseline questionnaire
are tabulated in table 4.5.. The majority of the patients studied had a
chronic productive cough for at least three months of the year. Just
over a third of patients experienced breathlessness walking at their
own pace on level ground. Only 7 patients, with less impaired lung
function, felt free of significant symptoms.
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Table 4.5. Responses to selected questions of the baseline
respiratory questionnaire (as number[%]).
Chronic productive cough on most days
for at least three months of the year) 69 (66%)









'Have you ever had attacks of shortness of breath





Was your breathing absolutely normal between



















For breathlessness score lower scores indicate breathlessness on lighter
exertion.
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4.2.5. Comparison of lung function in the defined subgroups.
The answers to questions 16 'Have you ever had attacks of
shortness of breath with wheezing ?' and question 17 'Is/was your
breathing normal between attacks ?' when combined could be treated
as an indicator of an underlying 'asthmatic' element to the disease.
Just over half the patients experienced wheezy attacks, but only 38 of
the 53 patients reporting such attacks felt that their breathing was
normal between attacks. These 38 patients showed no significant
differences in any objective measure of baseline lung function
including reversibility and variability or carbon monoxide gas
transfer compared to the remaining patients (table 4.6.). Of the 38
patients 29 reported a chronic productive cough in addition to the
complaints of wheezing. Serum IgE levels were also similar in
patients with and without asthmatic features (geometric mean serum
IgE (ku/1) asthmatic features present 92; absent 67).
Bronchial irritability as defined by Mortagy et al(165) was
present in 43 patients, in 29 of these patients the answers to question
16 and 17 were also positive, that is they reported asthmatic features
to their disease. Twenty five of the 43 patients reported a chronic
productive cough in addition to symptoms of bronchial irritability.
The patients with bronchial irritability showed lower mean FEV1
values, more airflow obstruction, and a decreased mean PEF
compared to the patients without this syndrome. Measurements of
reversibility and PEF variability were similar in both groups (table
4.7.).
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Table 4.6. Lung function in patients with and without asthmatic
features. Patients answering questions 16 and 17 (see text)
positively classed as asthmatic features present. (As mean (SEM)
unless indicated).
Asthmatic features Present Absent
(n=38) (n—67)
FEV1 litres 1.12(0.08) 1.01 (0.06)
FEV1/FVC % 40.4 (2.0) 38.6 (1.5)
mean PEF 1/min 247 (13.5) 226(11.3)
PD20 umol




absolute change (ml) 155 (23) 138 (16)
as % predicted FEV1 5.9 (0.9) 5.6 (0.7)
Diurnal variation in PEF
as % mean 21 (1.9) 21 (1.2)
as % predicted 11(1.1) 10.6(0.7)
TLCO (mmol/kPa/min) 5.2 (0.3) 5.8(0.4)
as % predicted 66.2 (3.4) 71.2 (4.2)
KCO (mmol/kPa/min/1) 1.01 (0.05) 1.06 (0.06)
as % predicted 56.5 (2.9) 61.1 (3.5)
No significant differences.
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Table 4.7. Lung function in patients with and without 'bronchial
irritability' as defined. (As mean (SEM) unless indicated).
Bronchial Irritability
Present Absent
(n=43) (n = 62)
FEV1 litres 0.91 (0.06) 1.15 (0.06) *
FEV1/FVC % 34.5 (1.8) 42.5 (1.5) *
mean PEF 1/min 212(13.3) 249 (11.23)*
PD20 umol




absolute (ml) 138 (17) 149 (19)
% predicted 5.6 (0.7) 5.8 (0.8)
Diurnal variation in PEF
% mean 21(1.5) 20(1.4)
% predicted 10(0.8) 11.2 (0.8)
* p<0.05, all other comparisons non significant.
71
4.3 DISCUSSION.
The patients were recruited from a heterogeneous clinic
population in an attempt to reflect the clinical problem facing
physicians. The major cause of their airflow obstruction was
cigarette smoking, but a few patients had other current or past
medical problems which may have contributed to the airflow
obstruction seen. Three patients in addition to past or current heavy
cigarette consumption also had post tuberculous scarring of the
lungs, two had coexistent rheumatoid arthritis - another possible
cause of airflow obstruction - and two patients produced copious
amounts of sputum, suggesting bronchiectasis as an additional
underlying pathology.
It could be argued that the 'lumping' of different pathologies
together is counterproductive. The effects of treatment may not be
the same in different disease states, and by including in the study
population patients who may not have 'pure' smoking related airflow
obstruction the effects of treatment on this group may be less
obvious. However distinguishing between the different causes, or the
contribution of different pathological processes in an individual
patient with chronic airflow obstruction is difficult(171). The
overriding concern must be to ensure that the patient receives the
most effective treatment. The aim of this study therefore was to
examine the effects of treatment in a group of patients with chronic
airflow obstruction in whom the primary diagnosis was not asthma,
but who would normally undergo a 'trial of steroids'(41). By
excluding patients with asthma in whom the benefit of such
treatment is not in doubt, the patients studied formed a well defined
group familiar to clinicians.
Definitions of asthma vary widely, from vague statements
about symptoms to more specific physiological criteria. The
American Thoracic Society (A.T.S.) definition is lengthy, and is not
easily translated into clinical practice,
'
..a clinical syndrome characterised by increased
responsiveness of the tracheobronchial tree to a variety
of stimuli. The major symptoms of asthma are
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paroxysms of cough, which may vary from mild and
almost undetectable to severe and unremitting (status
asthmaticus). The primary physiological manifestation
of this hyperresponsiveness is variable airways
obstruction '(37).
Later statements in the same document suggest the age at onset of
symptoms, family and personal history of allergic disease, and
identified specific precipitators to bronchoconstriction may help
suggest the diagnosis in a patient with wheeze, chest tightness and a
reduced FEV1/FVC ratio.
In a study of the factors that determine diagnostic labelling of
patients with chronic airflow obstruction a large degree of
reversibility in FEY1, and a return of the airways obstruction to
normal or near normal values either spontaneously or after a
bronchodilator appeared to be the major diagnostic criterion
used(172). The authors of this study later proposed a classification
system for patients with chronic airflow obstruction in which asthma
was favoured if symptoms resolved rapidly, if the variability in PEF
was greater than 15% of the mean PEF, if markers of atopy were
present in the patient, and if the patient exhibited marked bronchial
hyperresponsiveness to inhaled agents(172). These criteria are
similar to those proposed by the A.T.S., quoted above.
It may therefore be instructive to examine the population
under study for these characteristics, to determine if, inadvertently,
undiagnosed asthmatics have been included in the study group. A
later chapter will examine the influence of such features on response
to inhaled beclomethasone.
The patients studied for this thesis were elderly reflecting the
insidious onset and progression of the process producing chronic
airflow obstruction. In all patients studied the symptoms had begun
late in adult life, and had been present for over five years. All but one
had been or were cigarette smokers (the single never smoker
complained of persistent breathlessness, and cough and sputum
production, but denied wheeze or acute attacks of breathlesness).
The proportion of smokers and ex smokers, and their cigarette
consumption were similar to that seen in longitudinal studies of
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chronic airflow obstruction in the population(36).
The prevalence of positive skin tests, and the apparently high
mean serum IgE level in the patients may indicate that a high
proportion of atopic individuals have been recruited to the study,
and be construed as evidence for the inclusion of a significant
number of asthmatics into the study population. However the
prevalence of positive skin tests in this group is again similar to that
seen in Burrows subjects with 'pure' chronic obstructive pulmonary
disease (COPD) in the Tucson longitudinal study(173). It is much
less than the prevalence of skin test positivity in subjects with
asthma from the same study(174), and appears to be similar to the
prevalence of skin test positivity in the general population of Tucson
aged 50 years and over(175). Hence on these considerations the
number of patients with positive skin tests is not unexpected, and
does not suggest the inclusion in my study population of
undiagnosed asthmatics.
Serum IgE levels fall with age(175), and are increased by
smoking(176). Burrows et al have shown that in older skin test
negative smokers with chronic cough and sputum production higher
IgE levels correlate with reduced FEV1 levels(177). However they have
also demonstrated a correlation between age-sex standardised serum
IgE and a diagnosis of asthma. Hence it is clear that the relationship
between serum IgE and respiratory dysfunction is complex, and not
simply because of asthma. Because of differences in the technique
used to measure serum IgE it is difficult to compare levels in this
study with values reported in the literature. It may be that chronic
airflow obstruction associated with smoking operates via an IgE
dependent mechanism, or that the increase in serum IgE seen in
smokers is a paraphenomenon. However the serum IgE level in a
patient with chronic airflow obstruction is a poor indicator of an
asthmatic component to the disease.
Reversibility of FEV1 to bronchodilators and diurnal
variation in PEF are often suggested as markers of asthma(37). Both
reversibility and PEF variability are usually expressed as a
percentage of the prebronchodilator or mean value respectively.
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However by expressing a change in the variable as a percentage of
the starting level, small changes in the variable take on undue
significance in patients with low starting values. This applies both to
reversibility of FEV1 to bronchodilators and PEF variability. Hence
a 200ml improvement in FEV1 after salbutamol is a 20% increase in
a patient with a starting FEV1 of 1000ml, but only 5% in a patient
with an FEV1 of 4000ml. In patients with more impaired lung
function the normal values for FEV1 reversibility derived from
relatively normal populations may not be applicable. Expressing
change in these patients as a percentage of the predicted value is
independent of the initial value, and probably preferable(159,178).
The measured reversibility to a beta 2 agonist and an
anticholinergic agent in this group of patients showed mean absolute
changes which were less than the short term variability in
measurement of FEV1 and FVC previously published(94,179),
although some individual patients did show greater changes (figure
4.3.). Only one patient had airflow obstruction which could have been
considered reversible (figure 4.5.), in that the post salbutamol FEV1
was greater than 80% of the predicted FEV1. However this individual
had a FEV1/FVC ratio of less than 50%, unchanged by
bronchodilation, and a volume corrected carbon monoxide gas
transfer (KCO) of less than 50% predicted, suggesting significant
non asthmatic disease. As a group the mean post salbutamol FEV1
was less than half the predicted value.
Expressing the reversibility of FEV1 as a percentage of the
'possible' reversibility may also give an indicator of the asthmatic
nature of the disease. Patients with high values of this index could be
considered asthmatic, in that their airflow obstruction is close to
fully reversible, a feature which many physicians feel suggests
asthma as the underlying diagnosis(171). The mean value for this
expression of FEV1 reversibility was less than 10%, and 75% of the
patients studied had values for this index of less than 15%. These
results do not suggest the inclusion of a significant number of
undiagnosed asthmatics in the study population.
In a study of patients with asthma and non asthmatic chronic
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airflow obstruction Meslier et al suggested that an increase in FEV1
of over 15% of the predicted FEV1, or 450ml in absolute terms was
relatively specific for identifying patients with asthma(180). Although
such strictly defined limits are probably too rigid, only 6 patients
showed an improvement in FEV1 of greater than 15% of the
predicted FEV1 after salbutamol and only 2 patients showed an
increase in FEV1 of over 450ml after salbutamol. Hence the
reversibility characteristics of the group as a whole do not suggest a
significant proportion of the patients studies have undiagnosed
asthma.
The reversibility of FEV1 to bronchodilators in the patients
studied was similar to that reported from larger studies of patients
with chronic airflow obstruction published in the literature(181,182).
In the large IPPB trial in the US the mean change in FEV1 following
bronchodilator was 15% as a percentage of the initial
prebronchodilator value, or 5.1 % as a percentage of the predicted
FEV1(180). A wide range of reversibility was seen in the IPPB study
with the standard deviation of the distribution approximating the
mean, similar to the results reported here.
Hetzel and Clark suggested a diurnal variation in PEF of over
20% of the mean value was suggestive of asthma(183). However
Lebowitz et al have recently found in a larger study, that the upper
limit of normal for variability in PEF was 19% of the mean PEF(184).
Hence Hetzel and Clark's earlier conclusions may not be correct, and
in terms of diurnal variation in PEF, the daily variability in PEF
seen in my study, when expressed as a percentage of the mean daily
value, is probably just outside the normal range. It is similar to that
reported by Dawkins and Muers in a smaller number of patients
with chronic airflow obstruction, 24% of the mean daily value(185). It
is also similar to the diurnal variation in PEF seen in a large Dutch
study of patients with asthma and chronic airflow obstruction
recently reported(186). This study found similar values for diurnal
variation in PEF in patients with asthma and chronic airflow
obstruction, with a mean diurnal variation in PEF in all the patients
of 15% of the mean daily value. Their results would suggest that PEF
variability is not a good discriminator between asthma and non
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asthmatic chronic airflow obstruction.
On the basis of objective tests of lung function therefore the
majority of patients appeared to have a non asthmatic form of
chronic airflow obstruction. In terms of symptoms it could be argued
that positive answers to questions 16 and 17 may indicate possible
underlying asthma. A history of wheezing is not specific for asthma,
but this in addition to 'normal' breathing between attacks may
signify asthma. Only 38 patients gave positive answers to both
questions, and 29 of these also complained of a chronic productive
cough, suggesting coexistent chronic bronchitis. However the
baseline lung function of the two groups so defined (table 4.6.) shows
no differences. In particular both groups show impairment of carbon
monoxide gas transfer, suggesting a similar degree of emphysema in
both. In addition reversibility of FEV1 to salbutamol, and variability
in PEF were similar between the two groups.
Mortagy et al defined a syndrome of bronchial irritability
which they implied may predispose to asthma(165). They also
suggested patients exhibiting this syndrome with chronic airflow
obstruction may show a response to corticosteroids, inferring these
are the patients with 'missed asthma' as the cause of the chronic
airflow obstruction. The baseline lung function of patients showing
the features of this syndrome in my study suggest that in patients
with severe chronic airflow obstruction, the main factor relating to
the presence of this syndrome is the level of impairment of lung
function. Those patients with bronchial irritability had more severe
impairment of FEV1 and FEV1/FVC. The two groups showed a
similar impairment of carbon monoxide gas transfer however, and
FEV1 reversibility to salbutamol, and PEF variability was equivalent
between these groups. Like non specific bronchial
hyperresponsiveness to inhaled agents, bronchial irritability in
patients with severe chronic airflow obstruction appears to reflect
the severity of the airflow obstruction rather than hinting at the
underlying pathological mechanism.
These comparisons of patient groups defined on symptoms
also indicate the difficulty in defining asthma in smokers and ex
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smokers with severe chronic airflow obstruction. In this group of
patients variability of symptoms, either spontaneous or induced,
does not correlate with variability in objective measures of lung
function. The main determinant of whether a patient reports certain
symptoms appears to be related to the psychological and physical
factors which govern the perception of breathlessness and wheeze. It
would therefore be unjustified to label a patient asthmatic on the
basis of subjective criteria alone, and the objective measures of
asthma considered suggest that the criteria for inclusion into this
study satisfactorily excluded patients with asthma.
It is difficult to define asthma in clinical and physiological
terms in elderly patients for the purposes of selecting patients for
clinical trials. Although the criteria chosen for this study were
clinically based the analysis performed suggests that the majority of
the patents studied did not have what is usually considered to be
asthma. They had demographic, atopic and physiological
characteristics similar to groups of patients with non asthmatic
chronic airflow obstruction studied by other workers. Furthermore
the analysis presented in chapter 10 shows that the presence of
features commonly thought to indicate asthma does not predict
response to steroids in an individual patient.
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5. RANDOMISATION, WITHDRAWALS AND COMPLIANCE
WITH TREATMENT
5.1 RANDOMISATION AND WITHDRAWALS.
Fifty three patients were randomised at the end of the placebo
period to receive 1500mcg per day of inhaled beclomethasone, and
the remainder to receive the higher dose of 3000mcg per day. In total
seven patients were withdrawn during the placebo phase, six from
the lower dose group, only one from the higher dose group. The
reasons for withdrawal are given in appendix V.
All patients entering the first active treatment phase (inhaled
beclomethasone alone) completed that phase successfully, and
produced evaluable data. Hence 47 patients completed treatment
with 1500mcg per day beclomethasone for the three week period, and
51 with 3000mcg per day.
During the second active treatment phase when oral
prednisolone 40 mg per day was added to the regime in two thirds of
patients, a further six patients were withdrawn (details in appendix
V). The number of patients entering and completing each treatment
phase is shown in figure 5.1..
The baseline physiological characteristics of the 13 patients
withdrawn from the trial were not significantly different from the
patients who successfully completed the trial (table 5.1.).
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Figure 5.1. Diagrammatic representation of number of patients
entering and completing each treatment phase.
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Table 5.1. Baseline physiological characteristics in patients
withdrawn from the trial, and those completing all three







































Compliance with prescribed trial medication was assessed by
weighing inhaler cannisters after return and counting tablets
returned.
Full inhaler cannisters weighed approximately 28 grammes,
and patients were supplied with two inhalers for each treatment
phase. The weight of drug inhaled was calculated by simple
subtraction, combining the change in weight for both cannisters.
Cannisters were weighed to 0.1 gram.
Two hundred and twenty four tablets were supplied to each
patient at the start of each phase of treatment. Returned tablet
count gave an estimate of compliance with oral therapy.
For each measure of compliance allowance was made for
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differing treatment periods. The trial design allowed a tolerance of
+ /- seven days for treatment periods, ie treatment periods could last
from 14 to 28 days. Therefore the weight of inhaled drug used, and
the number of tablets consumed was expressed per day of treatment.
RESULTS.
The median daily change in the weight of the two inhalers was
1 gram, with a 10th centile of 0.77g. For oral therapy the median
number of tablets consumed per day was 7.6, with a lower 10th
centile of 7.1.
For the purposes of assessing the effect of compliance with
treatment on end points, it was decided to classify all patients with a
change in weight of both inhalers combined of less than 0.7g as non
compliant with inhaled therapy, and all patients taking less than 6
tablets per day as non compliant with oral therapy. On this basis 92
of 98 patients were compliant with inhaled placebo therapy, and 86
of 98 with inhaled therapy during the first active (inhaled
beclomethasone) treatment phase. For the final treatment phase 78
of the 92 patients completing this phase were compliant with inhaled
therapy, and 86 with oral therapy.
The analysis of effect of treatment was performed on an
intention to treat basis. Compliance to treatment appeared good,
and preliminary analysis omitting non compliant individuals had
little effect on the results and conclusions. Therefore only the
intention to treat analysis with all patients included is presented for
the remainder of the thesis.
The timing of assessments was within the limits specified in
all but two of 282 visits. As this was such a small percentage of the
total, this was ignored for the subsequent analysis.
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6. THE EFFECT OF TREATMENT ON LUNG FUNCTION.
6.1. ANALYSIS.
A comparison of the baseline characteristics of the dosage
groups was performed to detect differences in possible confounding
factors affecting response to treatment. Unpaired Student t tests
were used to compare normally distributed continuous data, Mann
Whitney U test for non parametric continuous data, and chi squared
test for categorical data.
To compare the efficacy of placebo, inhaled beclomethasone
and oral prednisolone on lung function, the FEV1, and FVC,
recorded pre bronchodilator on the final day of each treatment
phase, and mean PEF recorded over the last 7 days of the treatment
phase, were selected as end points. The response to treatment in
these physiological variables after inhaled BDP was assessed by a
repeated measures analysis of variance, with dose of drug entered as
a factor. Where significant effects were detected a Fisher's least
significant differences (LSD) test was used to determine which
comparisons were significant.
For analysis of the data after the final phase of active
treatment, when two thirds of the patients received oral prednisolone
in addition to inhaled beclomethasone, the change in each variable
from the previous phase was calculated. The change was compared
between patients receiving or not receiving prednisolone by an
unpaired Student t test, combining the inhaled beclomethasone dose
groups.
In addition a 'categorical analysis' was undertaken after
classifying each patient as a treatment responder or non-responder
for each of the three treatment phases.
Response to treatment was defined as an improvement in pre
bronchodilator FEV1, or FVC recorded on the final day of each
treatment phase, or mean PEF over the last 7 days of the treatment
phase of at least 20% when compared to the baseline value. The
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difference in response rates to placebo, and inhaled beclomethasone
was assessed by a McNemar test. The response rate after the final
treatment phase was compared using a Chi squared test for the two




6.2.1. The effect of inhaled beclomethasone.
a. Characteristics of the two inhaled beclomethasone dosage
groups.
No significant differences in the baseline characteristics of
the two beclomethasone dosage groups were detected (table 6.1. and
6.2.). In particular the two groups were well matched in terms of
degree of airflow obstruction, smoking status and past cigarette
consumption, 'asthmatic' variables - diurnal variation in PEF, and
reversibility to salbutamol - and atopic characteristics.
Table 6.1. The baseline physiological characteristics of the two


































in PEF(% predicted) 10.4(0.8) 11.0 (0.9)
FEV1 reversibility to
200mcg salbutamol
as % predicted FEV 1 6.4 (0.6) 5.6 (0.9)
No significant differences.
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Table 6.2. The atopic and smoking characteristics of the two










(geometric mean) 83 64
Number with positive
skin tests (%) 10 (21) 10 (20)
Smoking status [as number (%)]
Current smokers 17 (36)
Ex smokers 29 (62)





(pack years) 51 (5.0) 46(4.1)
No significant differences.
b. The effect of inhaled beclomethasone on FEV1, FVC and mean
PEF.
A small but statistically significant effect of inhaled beclomethasone
on all three physiological measures was seen (table 6.3.). There was
no significant difference between the two doses of BDP, and no dose-
treatment interaction was detected for any of the three end points
used. For both BDP dose groups combined the mean improvement
from the baseline value after active treatment was 48ml for FEV1,
120ml for FVC and 12.4 1/min for mean PEF. The average values in
each beclomethasone dose group for the three prebronchodilator
parameters is shown in table 6.3., with the results of the analysis of
variance. For all three variables the results after active treatment
with inhaled beclomethasone were significantly higher than those
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recorded at baseline or after placebo therapy. In this analysis no
statistically significant differences between placebo and baseline
were observed.
Table 6.3. Mean (SEM) values for lung function variables at
baseline, after placebo and inhaled beclomethasone.
BDP dose Baseline Placebo BDP
FEV1 (litres)
750mcg b.d. 1.07(0.07) 1.07 (0.07)
1500mcg b.d. 1.05 (0.07) 1.01 (0.07)
1.11 (0.07)
1.10 (0.07)
Treatment Effect F-ratio= 11.14, DF=2,192 p< 0.0001.
Interaction F-ratio= 1.35, DF=2,192, ns.
FVC (litres)
750mcg b.d. 2.58 (0.11) 2.58 (0.10)
1500mcg b.d. 2.76 (0.12) 2.78 (0.12)
2.68 (0.11)
2.90 (0.11)
Treatment Effect F-ratio= 8.63, DF=2,192, p<0.0005.
Interaction F-ratio=0.14, DF=2,192, ns.
Mean PEF (1/min)
750mcg b.d. 231 (12.6) 235 (13.0)
1500mcg b.d. 237 (14.0) 235 (14.4)
243 (13.6)
250 (14.9)
Treatment Effect F-ratio= 16.5, DF=2,188, p<0.0001.
Interaction F-ratio= 1.14, DF=2,188, ns.
The mean change in each variable after placebo and BDP is
illustrated graphically in figure 6.1. For this graphical presentation
both beclomethasone dose groups have been combined. The
scatterplots (figures 6.2. and 6.3.) show the change from baseline in
FEV1, FVC and mean PEF in individual patients after treatment
with inhaled beclomethasone. These show a unimodal distribution of
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Figure 6.1. Error bar plot showing the change from baseline
values in FEV1, FVC, and mean PEF after placebo or inhaled
beclomethasone (BDP). The error bars represent the mean (and
95% confidence intervals for the mean) of the differences. For
FEV1 and FVC differences the left axis shows the values, for
mean PEF the right hand axis.
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Figure 6.2. Scatterplots of change from baseline in FEV1 and
FVC after inhaled beclomethasone for the two dose groups. Error
bars show mean and 95 % confidence intervals for the mean of the
difference.
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Figure 6.3. Scatterplot of change from baseline in mean PEF
after inhaled beclomethasone for the two dose groups. Error bars
show mean and 95 % confidence intervals for the mean of the
difference.
Further analysis was undertaken to answer the question - do
responders to inhaled beclomethasone show an increased effect of
the higher dose of BDP ? It would not be surprising to find no
detectable differences in the effect on lung function of the two doses
of inhaled beclomethasone when the majority of patients show no
response to treatment on an individual level. The lack of effect of
treatment in non responders may mask a greater effect of the higher
dose on responders to treatment.
The difference between placebo and inhaled beclomethasone
values was compared for the two dose groups by an unpaired
Student t test, for FEV1 in patients who showed a change in FEV1 of
greater than 180ml, for FVC in patients showing a change in FVC
greater than 300ml, and for mean PEF in patients where the mean
PEF improved by at least 15 1/min. No significant differences were
found (table 6.4.).
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Table 6.4. Mean (95% confidence limits) for the difference
between placebo and inhaled beclomethasone values for FEV1,
FVC and mean PEF in patients showing large improvements in
these variables (see text).
BDP dose
750mcg b.d. 1500mcg b.d.
FEV1 290(170 to 410) 320 (257 to 382)
(litres) n=5 n = 11
FVC 588 (383 to 792) 508 (401 to 615)
(litres) n=9 n = 15
mean PEF 28 (18 to 37) 36 (29 to 43)
(1/min) n= 12 n—21
No significant differences.
c. The effect of inhaled beclomethasone on post bronchodilator
spirometry and other measures of lung function.
The effect of inhaled beclomethasone on the post
bronchodilator FEV1 and FVC was also examined, although this was
not a primary end point of the trial. It was possible that the
results of reversibility tests would be affected by measurement of
bronchial hyperresponsiveness to inhaled histamine immediately
prior to the bronchodilator test. Therefore an initial analysis
compared the absolute change in FEV1 after both salbutamol and
ipratropium bromide, measured during the baseline period, in
patients who had bronchial hyperresponsiveness measured
immediately prior to reversibility testing (group 1) and those who
did not have this test performed (group 2). This showed no effect of a
prior histamine test on reversibility to either drug. The change in
FEV1 following salbutamol was (as mean [95% confidence interval])
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group 1, 150 [ 114 to 186]ml, group 2, 142 [108 to 176] ml, following
ipratropium bromide, group 1, 93 [59 to 127]ml, group 2, 141 [101
to 182]ml. As no significant effect of a prior histamine inhalation
test was detected, the post bronchodilator FEV1 and FVC data was
analysed ignoring this difference in protocol.
After the baseline period 49 of the 98 patients who completed
the inhaled beclomethasone phase had reversibility of FEV1 and
FVC measured to salbutamol, the remainder to ipratropium
bromide. To look at the effect of inhaled beclomethasone on post
bronchodilator spirometry the change from the post bronchodilator
value at the end of the placebo phase was compared in patients for
the two inhaled beclomethasone dosage groups. An unpaired Student
t test was used for this comparison, and the test performed
independently in patients who received salbutamol as the
bronchodilating drug, and in the patients in whom ipratropium
bromide was used.
Forty nine patients had FEV1 and FVC measured after
salbutamol after both placebo treatment, and active treatment with
inhaled beclomethasone. 26 patients received the higher dose of
inhaled beclomethasone, the remainder 750mcg b.d.. In patients
taking 1500mcg b.d. BDP, the post salbutamol FEV1 was a mean
(95% CI) of 93.5 (26.7 to 160)ml higher at the end of the inhaled
beclomethasone treatment phase when compared to the value seen
after placebo. For post salbutamol FVC the value was a mean of 118
(12.6 to 223)ml higher after inhaled beclomethasone. In the lower
BDP dose group the post salbutamol FEV1 and FVC did not change
significantly, for FEV1 the difference from placebo was -3.9 (-55 to
47)ml, for FVC -17.4 (-114 to 78.9)ml. The higher dose had a
significantly greater effect on post bronchodilator FEV1 (p<0.03),
but the difference between the effect of the two doses on post
bronchodilator FVC just failed to reach conventional levels of
statistical significance (p=0.058).
In the remaining patients in whom post bronchodilator
spirometry was measured after ipratropium bromide, only the post
bronchodilator FEV1 in the 1500mcg b.d. BDP dose group showed a
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significant improvement following inhaled beclomethasone ( mean
change in FEV1 91.6 [21.1 to 162]ml). In the 750mcg b.d. group the
mean change in FEV1 was 3.5 (-66 to 73)ml, the mean change in FVC
was 39.6 (-17.9 to 100)ml. The mean change in post bronchodilator
FVC for the patients treated with 1500mcg b.d. inhaled
beclomethasone was 29.6 (-79 to 139)ml. The effect of the two doses
on post ipratropium bromide spirometry was not significantly
different. The mean post bronchodilator FEV1 and FVC after
placebo and inhaled beclomethasone are shown in table 6.5..
There was no significant effect of placebo or inhaled
beclomethasone on gas transfer measurements. At baseline the mean
(SEM) carbon monoxide gas transfer for the whole lung (TLCO) was
5.38 (0.23) mmol/min/kPa, the volume corrected value was 1.03
(0.04) mmol/min/kPa/1. After placebo the respective values were
5.37 (0.24) mmol/min/kPa, and 1.02 (0.04) mmol/min/kPa/1, after
inhaled beclomethasone 5.49 (0.24) mmol/min/kPa and 1.03 (0.04)
mmol/min/kPa/1.
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Table 6.5. The mean (SEM) post bronchodilator FEV1 and FVC
at the end of the placebo and BDP treatment phases, for patients





750mcg b.d. 1.25 (0.10) 1.24 (0.10)
1500mcg b.d. 1.15 (0.09) 1.25 (0.09)
FVC (litres)
750mcg b.d. 3.02(0.16) 3.00 (0.16)
1500mcg b.d. 3.10(0.19) 3.22(0.19)
2. Ipratropium bromide.
FEV1 (litres)
750mcg b.d. 1.16(0.08) 1.15 (0.08)
1500mcg b.d. 1.10(0.10) 1.19 (0.11)
FVC (litres)
750mcg b.d. 2.85 (0.16) 2.78 (0.15)
1500mcg b.d. 3.00 (0.15) 3.03 (0.14)
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d. Response to inhaled beclomethasone in individualpatients.
To assess response to treatment in individual patients the
response rate to the two doses of inhaled beclomethasone was
compared. In the patients receiving 750mcg b.d. 16/47 (34%) showed
a response, in the 1500mcg b.d. group 17/51 (33%) responded (Chi
squared=0.06,ns). To assess the efficacy of inhaled beclomethasone
against placebo both beclomethasone dose groups were therefore
combined.
In individual patients a response to placebo therapy occurred
in 15 patients (15%), but in 33 patients after inhaled beclomethasone
(34%). The difference in response rates was statistically significant
(table 6.6.).
Figure 6.4. shows the measures in which a response was
noted. In 27 patients the response was seen in only one of the three
primary end points, in two measures in 4 cases and in all three
measures in the remaining two responses.
For patients showing a response in a measure the
distribution of absolute change is shown in figure 6.5. for FEV1 (18
cases), FVC (12 cases) and PEF (11 cases).
In the 18 patients showing a response in FEV1 the mean (95 %
CI) change in FVC was 14.6 (10.2 to 19.1)%, in mean PEF 10.5 (3.4 to
17.6)%. Only 2 of the 18 patients failed to show an improvement in
FVC or mean PEF of at least 10%. In the 12 FVC responders the
change in FEV1 was 18.9 (10.9 to 26.8)%, and 9.2 (-0.6 to 19.1)% in
mean PEF. In 9 of these 12 FVC responders the change in FEV1 or
mean PEF exceeded 10%. For the 11 patients showing a response in
PEF the changes in FEV1 and FVC were 10.6 (-0.5 to 21.1)% and 2.8
(-7.9 to 13.5)% respectively, but 4 of these patients failed to show an
improvement in FEV1 or FVC of at least 10%.
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Figure 6.4. Pie chart illustrating the measure or measures in




0-90 91-100 101-270 271-3*0 3*1-450 451-540
Chtiift (mil)
0-200 201-400 401-40O *01-000 001-1000
Chug* (mil)
■mm fear
0-20 21-40 41-40 *1-00 01-100
Changi (1/mln)
Figure 6.5. Distribution histograms of the absolute change in
each measure, in patients classified as showing a response to
treatment in that measure.
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6.2.2. The effect of oral prednisolone.
a. Characteristics of the two final phase treatment groups.
The characteristics of the patients who received oral
prednisolone 40mg per day for the final treatment phase, and the
smaller number who continued on inhaled beclomethasone are given
in table 6.7.. The two treatment groups were well matched in terms of
most of the likely confounding factors. The patients receiving oral
prednisolone showed a higher mean level for the serum IgE, but
similar levels of skin test reactivity.
b. The effect oforal prednisolone on FEV1, FVC and mean PEF.
There was no significant difference in the change in FEV1 or
mean PEF from that recorded at the end of the second (inhaled
beclomethasone) treatment phase, between the two groups. Those
receiving prednisolone showed a small mean (95% CI) fall in FEV1
of 19 (-59 to 20)ml, the 31 patients continuing on inhaled
beclomethasone alone showed a mean fall of 26 (-69 to 18)ml. The
change in mean PEF was 3.1 1/min (-1.6 to 7.8) for the prednisolone
group, 2.8 1/min (-6.0 to 11.6) for the inhaled beclomethasone group.
The patients continuing on inhaled beclomethasone alone showed a
larger fall in FVC during the third treatment phase although the
difference was not statistically significant, oral prednisolone -5.0 (-94
to 84)ml, inhaled beclomethasone -98 (-208 to ll)ml. The changes in
each parameter are shown as an error bar plot in figure 6.6., and as
scatterplots for each variable in figure 6.7., and 6.8..
When the post bronchodilator FEV1 and FVC were examined
no difference in the change in this value during the third phase of
treatment was seen between patients receiving oral prednisolone and
those continuing on inhaled beclomethasone [mean (95 % CI)
change; FEV1 prednisolone group 23(-23 to 69)ml, beclomethasone
alone group -25(-69 to 20)ml; FVC prednisolone group 53(-56 to
lll)ml, beclomethasone alone group -9(-l 16 to 98)ml.
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Table 6.7. Baseline characteristics of the two final treatment

































in PEF(% predicted) 11.5 (0.8) 9.9 (1.0)
FEV1 reversibility to
200mcg salbutamol as
% predicted FEV 1 5.8 (0.7) 5.6(1.0)
Serum IgE (ku/1)
(geometric mean) 86 54 *
Number with positive
skin test (%) 11(18) 7(22)
Smoking status [as number (%)]
Current smokers 26 (42)
Ex smokers 34 (56)





(pack years) 47 (4.4) 49 (4.7)




























Figure 6.6. Error bar plot showing the mean change in FEV1,
FVC, and mean PEF during the final active treatment phase. The
error bars show the mean and 95 % confidence intervals for the
mean of the differences.
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Figure 6.7. Scatterpiots of the change in FEV1 and FVC during
the final treatment phase in individual patients for the two
treatment groups. The error bars show the mean and 95%
confidence intervals for the mean of the difference.
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Figure 6.8. Scatterplot of the change in mean PEF during the
final treatment phase in individual patients for the two treatment
groups. Error bars show the mean and 95% confidence intervals
for the mean of the difference.
Table 6.8. Response to inhaled beclomethasone and combined
treatment with oral prednisolone and inhaled beclomethasone in





alone Responder Non responder
Responder 11 5
Non responder 8 37
McNemar test non significant.
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c. Response to final phase treatment in individual patients.
The categorical analysis showed that after the final treatment
phase the response rate, defined with respect to baseline values, was
similar in the two treatment groups. Of the patients receiving oral
prednisolone in addition to inhaled beclomethasone 19 (31%)
showed a response to the combined final treatment (when compared
to baseline values), whilst 10 (32%) of the inhaled beclomethasone
alone group showed a response as defined (chi squared=0.01;
DF=l;ns). The response category to both the second (inhaled
beclomethasone) and final treatment phases of the 61 patients who
received oral prednisolone and inhaled beclomethasone during the
final stage is shown in table 6.8.. By the McNemar test the difference
in response rate was not statistically significant.
Figure 6.9. shows the measure in which a response was noted
for the two final phase treatment groups. In the combined treatment
group 11 responses occurred in only one measure, 6 in two, and two
in all three measures used to define response. In the group receiving
inhaled beclomethasone alone 7 responses were seen in one measure
only, the remaining three responders showing a greater than 20%
response in two of the parameters. For patients classified as a
responder to a particular measure after the final treatment phase,
the distribution of the absolute change in that measure is shown in
figure 6.10.. Individuals from each of the two treatment groups are
indicated.
In the 18 patients showing a response after either of the final
treatments in FEV1 the mean (95% CI) change in FVC was 19.9 (15
to 24.8)% and 12.9 (4.2 to 21.6)% in mean PEF. In all 18 FEV1
responders the FVC or mean PEF improved by at least 10%. For the
9 patients showing a response after the final treatment phase in FVC
the change in FEV1 was 28.7 (12.5 to 44.9)% and 11 (-1.6 to 23.6)%
mean PEF, with 7 patients improving in either FEV1 or mean PEF
by at least 10%. The 15 PEF responders showed a change in FEV1
and FVC of 15 (4.1 to 25.3)% and 11.8 (3.7 to 19.8)% respectively.
Eleven of the 15 PEF responders showed an improvement in FEV1 or











Figure 6.9. Pie chart illustrating the measure or measures in
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Figure 6.10. Distribution histograms of the absolute change in




The results have shown that inhaled beclomethasone
dipropionate is effective in producing improvement in physiological
parameters in patients with chronic airflow obstruction. Both in a
'group' analysis and a 'categorical' analysis inhaled beclomethasone
was more effective than placebo in improving pre bronchodilator
FEV1 and FVC on the final day of treatment, and mean PEF over the
final seven days of the treatment period. The analysis detected no
difference between the two doses of inhaled beclomethasone used in
producing improvement in the parameters used as a primary end
point. The categorical response in both doses was virtually identical
with just over 33 % of patients showing a response to treatment as
defined. However when post salbutamol FEV1 and FVC were
analysed there seemed to be a greater effect of the higher dose of
BDP on these secondary end points.
When oral prednisolone was added during the final active
treatment phase to two thirds of the patients no significant
improvement was noted when the changes over the final treatment
phase in each of the primary end points were compared to that seen
in the one third of patients who continued on inhaled
beclomethasone alone. The results did show a larger fall in FVC in
the group on inhaled beclomethasone, but this failed to reach
statistical significance. At the end of the final treatment phase a
similar proportion of patients responded to continued treatment
with inhaled beclomethasone alone (32%) as did to combined
treatment with oral prednisolone and inhaled beclomethasone
(31%). When the 61 patients who received combined therapy as the
final treatment phase were analysed alone, the response rate to
inhaled beclomethasone at the end of the second treatment phase
was similar to that seen at the end of the final treatment phase.
Hence, both a 'group' and a 'categorical' analysis showed no further
beneficial effect of oral prednisolone in this group of patients over 3
weeks.
The absolute changes from baseline in the three end points
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after inhaled beclomethasone were small. This reflects the fact that
nearly two thirds of the patients were unresponsive, as defined, to
three weeks treatment with the drug. The effect of this is to reduce
the overall mean change in each of the parameters when the group is
considered as a whole. The mean improvement in FEV1 after inhaled
beclomethasone is within the 95 % confidence limits of the
improvement in FEV1 seen after oral prednisolone in similar
patients in two previous trials(83,87). Two further studies reported
significant effects of oral prednisolone which were about three times
that seen after inhaled beclomethasone in this study(88,90).
Although the mean change is small, when patients who show
a change in FEV1 and FVC which is greater than the short term
variability in these end points are examined(94), the mean change in
FEV1 in these patients is approximately 25% of the mean baseline
FEV1, and the change in FVC seen approximately 20% of the mean
FVC of the patients studied (table 6.4.). Changes of this degree are
undoubtedly of clinical significance.
Criticism may be levelled at the design of the study. A
sequential design with all patients receiving placebo as the initial
treatment followed by two active treatment periods was chosen
because of our own work showing that the beneficial effects of
corticosteroids on PEF may last for well over 2 weeks after the drugs
had been withdrawn(78). Indeed further unpublished analysis of this
work suggests that oral prednisolone may have effects lasting for up
to 6 weeks after withdrawal of the drug. Hence, in any double blind
cross over trial the washout period should be 4 to 6 weeks in order to
eliminate any carry over effect of active treatment on the following
treatment phase. With a three week treatment phase this would have
entailed a trial of approximately 6 months. This was felt to be
impracticable, and the low drop-out rate seen in this study would
have been much more exaggerated if such a design had been
followed.
The patients were unaware of the sequential nature of the
trial, and each treatment given appeared identical. The dose
allocation, and allocation to the final treatment phase group was
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made on a double blind basis. Strict objective criteria were used for
the measurement of lung function, hence any unintentional bias
introduced because of trial design is likely to have been small. The
comparisons between the two beclomethasone dose groups, and
between the two treatment groups in the final phase are statistically
'pure' as effectively this comparison was done on a double blind
basis.
The response rate to both inhaled beclomethasone alone, and
combined treatment with inhaled beclomethasone and oral
prednisolone was just over 30%. This compares favorably to response
rates reported in the literature and reviewed in the introduction.
These show quite marked variability, between 6 and 56% of patients
showing a response to oral prednisolone. Part of the variability may
be explained by differences in trial design and patient selection. The
response rate seen in this study is at the upper end of that quoted in
published papers, as was the response rate seen in our previous
study(95). This probably reflects the choice of three end points to
determine response, In the majority of previous studies only 1 or
possibly 2 objective measures of lung function have been used to
judge response. In particular, very few trials have used domiciliary
PEF monitoring as an objective measure of treatment effect. Mitchell
et al found that of 13 patients showing a response to treatment with
oral prednisolone in mean PEF 6 responded in FEV1, and only 5 in
FVC(93). They concluded that domiciliary PEF monitoring was the
most sensitive of the three parameters. If this had been omitted from
our study design then 8/33 responses would have been missed. The
placebo response rate in this study is again similar to that seen in
the published literature (10-40%).
Comparison of the results in the present study to that to
inhaled corticosteroids in published studies is difficult because of the
shortcomings of the published work. Harding & Freeman and
Wardman et al, studied only small numbers of patients(100,102). In
Wardman's studies is appeared that all patients who responded to
inhaled beclomethasone also showed a response to oral
prednisolone. Oral prednisolone produced a slightly greater
response in the patients classified as responders but no group effect
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of either inhaled beclomethasone or oral prednisolone was seen. The
changes in FEV1, FVC and mean PEF seen in this study in the
responders was large, suggesting undiagnosed asthmatics may have
inadvertently been included.
In the study of Williams and Shim interpretation is extremely
difficult as all patients continued on a small dose of oral
prednisolone and the dose of inhaled beclomethasone used was very
small(lOl). This may explain the fact that inhaled beclomethasone
only produced a categorical response in 50% of the patients who
responded to prednisolone. Our own previous study suggested that
response to inhaled beclomethasone occurred in about half as many
patients as a response to oral prednisolone(95). Forty-two percent of
patients responded to oral prednisolone whereas only 24%
responded to inhaled beclomethasone.
The response rate to beclomethasone in this earlier study is
less than that seen in the current study. One of the major differences
between the previous study and the current investigation is in the
mode of delivery of drug. Spacing devices (Volumatic) were used by
all patients in the current study, to ensure optimal delivery of the
inhaled drug to the airways, whereas the earlier trial used a metered
dose inhaler alone. It is possible that the difference in response rate
to inhaled beclomethasone between the two studies, and the
difference in response to inhaled beclomethasone and oral
prednisolone seen in the previous study was due primarily to poor
deposition of the inhaled drug in the earlier study. The results of the
current study would support this suggestion. When drug delivery was
optimized by use of a spacing device, no difference was seen between
the effect of the two doses of inhaled beclomethasone, neither was
any additional effect of oral prednisolone noted. If this is the reason
for the disparate results then by implication the dose response
characteristics for inhaled beclomethasone shows a plateau above a
dose of 1500mcg per day.
Another possible explanation for the difference in response
rates between the two studies may be the longer duration of
treatment used in the current study. Our previous analysis suggested
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that up to 20% of responders may not have reached the peak
response at two weeks(78). The extra weeks treatment used in the
current study may account for the higher response rate to inhaled
beclomethasone.
The slightly lower response rate overall in the current study
may be explained by differences in the patients studied. The
population in the previous study had more life long non smokers,
more patients with positive skin tests, and the serum IgE level was
higher (see table 10.10.). In other studies response to corticosteroids
is at least partially related to the atopic characteristics of the
patients studied(69,71).
Defining response in terms of percentage change in a variable
risks selecting responders from patients with low values of the
variable chosen(85). Small changes which may be within the
measurement error of the variable used to define response assume
undue significance when the starting level of that variable is low. In
the present study 6 of the 18 responses seen in FEV1 were within the
short term variability limit quoted by Tweeddale et al(94), although
only 1 of the FVC responses to inhaled beclomethasone had a
change in absolute terms within the short term variability of this
measure. There is no data available to judge the significance of the
absolute changes in mean peak flow seen. Redefining response to
exclude patients with percentage changes which fulfil the criteria, but
with small absolute changes within the short term variability of the
measures as suggested by others(73), does not alter the conclusions
of the study significantly. Although the overall response rate to
inhaled beclomethasone and oral prednisolone is reduced slightly,
inhaled beclomethasone at both doses used is still more effective
than placebo in producing response , there is no difference between
the two doses of inhaled beclomethasone and the addition of oral
prednisolone does not improve the response rate over that seen to
inhaled beclomethasone alone.
The role of asthmatic features in determining response to
inhaled and oral corticosteroids will be investigated later in the
thesis.
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7. THE EFFECT ON SYMPTOMS AND QUALITY OFLIFE.
7.1. ANALYSIS.
The effect of placebo, and the two doses of inhaled
beclomethasone on the scores derived from the quality of life
questionnaire^ 67), diary card breathlessness scores and the results
of the oxygen cost diagram were assessed by a repeated measures
analysis of variance, with dose of drug entered as a factor. Where
significant effects were detected a Fisher's LSD test was used to
determine which comparisons were significant. The effect of
treatment on subjective measures was also analysed in patients
classified as responders to treatment on the basis of changes in
objective lung function tests.
To analyse the effect of adding oral prednisolone to the
inhaled drug during the third and final treatment phase, the change
in each subjective measures from the previous phase was compared
between the two thirds of patients who received oral prednisolone
and inhaled beclomethasone, and the remaining third who continued
on inhaled beclomethasone alone. An unpaired Student t test was
used for this part of the analysis.
Correlations between measures of lung function and the
subjective measures at baseline were assessed by Pearson's
correlation coefficient. Likewise associations between changes in
lung function variables and subjective measures after treatment with
inhaled beclomethasone were assessed by calculation of the Pearson
correlation coefficient.
The quality of life questionnaire dyspnea element requires the
patient to identify 5 activities of daily living which induce
breathlessness. In patients who were unable to identify five activities,
the dyspnea score was standardised by dividing the total dyspnea
score by the number of activities, and multiplying by five. For the
dyspnea score of the quality of life questionnaire high scores indicate
less breathlessness, higher scores with the oxygen cost diagram also
indicate less breathlessness, whereas diary card breathlessness
scores are lower the less breathless the patient feels.
in
The quality of life questionnaire measures physical and
emotional function. The physical function element consists of the
responses to the dyspnea and fatigue components. A subjective
response to treatment was defined in terms of response in physical
function, as an improvement in the combined dyspnea and fatigue
scores of at least 4 compared to baseline(187). The number of
subjective responders in each of the inhaled beclomethasone dose
groups was compared by a chi square test, and comparison of the
subjective response to placebo and inhaled beclomethasone by
McNemar test. Changes in objective lung function measures after
inhaled beclomethasone in the two subjective response groups were
compared by an unpaired Student t test.
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7.2. RESULTS.
7.2.1. The relation between Quality of Life and baseline lung function
variables.
Correlations between spirometric variables, lung volumes,
carbon monoxide gas transfer and diurnal variation in PEF and
subjective measures of dyspnea are given in table 7.1.. The dyspnea
score from the quality of life questionnaire correlated poorly with all
objective measures of lung function, whereas the results of the
oxygen cost diagram, and the diary card breathlessness score showed
stronger correlations with spirometric measures and carbon
monoxide gas transfer.
Table 7.1. Pearson correlation coefficients for the association
between subjective measures of breathlessness used and various
measures of lung function.
Dyspnea SOB 02cost
FEV1 0.08 -0.34** 0.45***
FVC 0.06 -0.16 0.18
mean PEF 0.14 -0.36*** 0.37***
diurnal variation
in PEF (% mean) 0.13 -0.21* 0.17
TLC -0.05 -0.01 -0.08
FRC -0.11 0.09 -0.22*
RV -0.14 0.12 -0.22*
TLCO 0.16 -0.59*** 0.55***
logPD20 0.13 -0.14 0.11
Pimax 0.12 -0.23* 0.19
Pemax 0.13 -0.15 0.14
Dyspnea - quality of life questionnaire dyspnea score
SOB - diary card breathlessness score
02cost - oxygen cost diagram score
* p<0.05, ** p<0.01, *** p<0.001
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7.2.2. The effect of inhaled beclomethasone.
A small but significant improvement in the dyspnea score
from the quality of life questionnaire was seen after treatment with
inhaled beclomethasone. No difference between the two doses given
was detected. Placebo therapy also improved this measure
significantly over the baseline score, but treatment with inhaled
beclomethasone caused a further small but statistically significant
increase (table 7.2.).
The three non respiratory components of the quality of life
questionnaire showed variable changes. Only the 'mastery' questions
showed a significant improvement after inhaled beclomethasone
when compared to both placebo and baseline answers. The 'fatigue'
element of the questionnaire showed a significant difference between
placebo scores and those recorded after inhaled beclomethasone, but
no difference between baseline and active treatment. The answers to
the 'emotional function' questions improved after both placebo and
active therapy, but only the difference between responses at baseline
and after inhaled beclomethasone was statistically significant. This
element also showed a significant dose treatment interaction, with
the lower dose having more effect. All other analyses revealed no
significant difference between the effect of the two doses of inhaled
beclomethasone given. The change in the scores for all four
dimensions of the quality of life questionnaire from that after
placebo to that after inhaled beclomethasone are shown in figure
7.1..
The results of the oxygen cost diagram showed a significant
improvement over baseline with both placebo and inhaled
beclomethasone, but no difference between the active drug and
placebo therapy. However diary card breathlessness scores fell with
inhaled beclomethasone but showed a small rise from baseline
values after placebo. Both doses of inhaled beclomethasone were as
effective at improving this measure (table 7.3.).
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Table 7.2. The mean (SEM) scores for the components of the
quality of life questionnaire at baseline, and after treatment with
placebo and inhaled beclomethasone.
Baseline Placebo BDP
Dyspnea
750mcg b.d. 18.0(0.8) 19.0(0.9)
1500mcg b.d. 17.7 (0.7) 19.4 (0.9)
20.4 (1.0)
21.3 (1.0)
Treatment effect F-ratio=24.96, DF=2,91 p<0.0001
Interaction F-ratio=0.92, DF=2,91 ns.
Fatigue
750mcg b.d. 17.6(0.7) 17.8(0.7)
1500mcg b.d. 17.4 (0.8) 16.9 (0.7)
18.8 (0.8)
17.3 (0.8)
Treatment effect F-ratio=3.61, DF=2,94 p<0.03.
Interaction F-ratio=2.76 DF=2,94 ns.
Emotional Function
750mcg b.d. 33.4 (1.2) 35.1 (1.2)
1500mcg b.d. 32.8 (1.3) 33.1 (1.3)
36.6 (1.2)
32.9 (1.5)
Treatment effect F-ratio=4.89, DF=2,94 p<0.01
Interaction F-ratio=4.2, DF=2,94 p<0.02
Mastery
750mcg b.d. 19.7(0.9) 20.1(0.8)
1500mcg b.d. 20.0(0.8) 20.9 (0.8)
20.3 (0.9)
21.8 (0.8)
Treatment effect F-ratio=9.25, DF=2,94 p< 0.0001.
Interaction F-ratio=2.75, DF=2,94 ns.
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Table 7.3. The mean (SEM) scores for the oxygen cost diagram
(O2cost), and diary card breathlessness score (SOB), at baseline
and after placebo and inhaled beclomethasone.
Baseline
02cost
750mcg b.d. 121 (5.5)
1500mcg b.d. 118(5.4)
Placebo BDP
127 (6.2) 124 (5.5)
124 (5.4) 130(5.8)
Treatment effect F-ratio=5.8, DF=2,89 p<0.005.
Interaction F-ratio=2.34, DF=2,89 ns.
SOB
750mcg b.d. 3.1(0.2) 3.2(0.2) 2.9(0.2)
1500mcg b.d. 2.8(0.2) 3.0(0.2) 2.6(0.2)
Treatment effect F-ratio=9.52, DF=2,88 p<0.00002.
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Figure 7.1. The change from placebo scores in the four
dimensions of the quality of life questionnaire, for the two BDP
dose groups. M =mastery, F=fatigue, EF=emotional function,
D = dyspnea. Error bars show mean and 95% confidence intervals
for the mean of the difference.
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The correlation between the change in FEV1, FVC and mean
PEF from baseline after inhaled beclomethasone and the change
seen in the four dimensions of the quality of life questionnaire, in the
oxygen cost diagram, and diary card breathlessness scores was poor
(table 7.4.).
Both responders and non responders to inhaled
beclomethasone, classified on the basis of changes in FEV1, FVC
and mean PEF, showed significant improvements in quality of
life questionnaire dyspnea scores, but only responders showed an
effect of active treatment in the other three components of the
questionnaire. The diary card breathlessness scores improved in
physiological responders, but there was no significant difference
from baseline values in the non responders. Oxygen cost diagram
scores were improved after both placebo and inhaled
beclomethasone in non responders, but there was no significant
difference from placebo after active therapy. In responders no
significant change after either placebo or inhaled beclomethasone
was detected (table 7.5.).
Table 7.4. Spearman rank correlation coefficients for the
association between the change from baseline after inhaled
beclomethasone in subjective measures and in FEV1, FVC, and
mean PEF.
Change in FEV1 FVC mean PEF
Dyspnea 0.17 0.16 0.26*
Fatigue 0.23* 0.20 0.10
Emotional function 0.17 0.14 0.19
Mastery 0.29* 0.24* 0.17
SOB -0.11 -0.11 -0.25*
02cost -0.01 0.06 0.03
Dyspnea - quality of life questionnaire dyspnea score
SOB - diary card breathlessness score
02cost - oxygen cost diagram score
* p<0.05.
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Table 7.5. The mean (SEM) scores for the four components of the
quality of life questionnaire, the oxygen cost diagram (02cost),
and diary card breathlessness score (SOB). At baseline, after
placebo and inhaled beclomethasone, in responders and non
responders defined on the basis of lung function changes, (see
























































Ninety three of the 98 patients completing the second
treatment phase had complete data for classification into subjective
responders or non responders. Forty one patients showed an
increase in the physical function dimension of the quality of life
questionnaire of greater 4 after inhaled beclomethasone, and were
classed as subjective responders. Of these 19 were in the 750mcg b.d.
group, and 22 in the 1500mcg b.d. The difference between the
subjective response rate to the two doses was not significant (chi-
squared=0.28,DF=l,ns).
Twenty three patients showed a subjective response after
placebo. The difference between the subjective response to placebo
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and both doses of inhaled beclomethasone was statistically
significant (table 7.6.).
When the change in FEV1, FVC, and mean PEF after inhaled
beclomethasone from baseline were compared in the two subjective
response groups, no significant differences were seen. However in
every objective physiological measure the subjective responders did
show a larger mean improvement (figure 7.2.).
The change in the physical function score (the sum of the
dyspnea and fatigue elements ) was correlated poorly with the
change in each of the objective measures of lung function,(Pearson
correlation coefficients were FEV1 0.16, FVC 0.14, mean PEF 0.19).
Table 7.6. Subjective response to inhaled beclomethasone and





Non responder 22 48
McNemar test p< 0.001
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-60 FEV1 FVC PEF
Figure 7.2. The change from baseline after treatment with
inhaled beclomethasone in FEV1, FVC and mean PEF in
subjective responders(R) and non responders(NR) to treatment
classified according to change in quality of life questionnaire
scores.(Error bars show mean and 95% CI for the difference).
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7.2.3. The effect of oral prednisolone.
The change in the dyspnea, fatigue and emotional function
elements of the quality of life questionnaire, from that recorded at
the end of the second treatment phase, was not significantly different
in the patients receiving oral prednisolone during the third
treatment phase and those patients continuing on inhaled
beclomethasone alone (table 7.7). The latter group showed larger
mean changes in the three area of the quality of life questionnaire,
but the mastery dimension was the only component in which the
differences between the dose groups were statistically significant.
The changes in the oxygen cost diagram and diary card
breathlessness scores were also similar between the two third phase
treatment groups.
Of the patients completing the final treatment phase 89 had
data to allow classification of subjective response. A subjective
response was seen in 14/30 of the patients continuing on inhaled
beclomethasone alone, and in 31/59 of the patients who received
both oral prednisolone and inhaled beclomethasone during the third
treatment phase. The difference was not significant (chi
squared=0.27, DF=1, ns).
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Table 7.7. The changes in each of the subjective measures over
the third treatment phase. BDP - inhaled beclomethasone alone,






(0.9 to 2.9) (-0.1 to 1.5)
Fatigue 1.1 0.5
(0.05 to 2.2) (-0.4 to 1.4)
Emotional 1.7 0.4
Function (-0.08 to 3.5) (-0.9 to 1.6)
Mastery 1.1 -0.1 *
(0.4 to 1.7) (-0.7 to 0.5)
02cost 4.9 2.3
(-5.1 to 14.9) (-3.8 to 8.5)
SOB -0.1 0.1
(-0.4 to 0.2) (-0.05 to 0.3)
* p<0.05
Dyspnea - quality of life questionnaire dyspnea score
SOB - diary card breathlessness score
02cost - oxygen cost diagram score
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7.3. DISCUSSION.
This is the first study which has looked at the effects of
inhaled and oral corticosteroids on physiological function in chronic
airflow obstruction and has also assessed subjective response by
using a formal 'quality of life' instrument. In past studies
therapeutic benefit has usually been assessed in terms of
physiological change, with some studies also assessing change in the
subjective sensation of breathlessness, and global assessments of
general well being(83,84,90,92).
The relationship between decreased lung function and
impaired well being in day to day functioning is complex and
incompletely understood. Previous studies have shown a poor
correlation between measures of airflow obstruction and simple
measures of disability, such as the MRC breathlessness score,
oxygen cost diagram and Mahler dyspnea index (83,167,188).
Individual variability in the perception of breathlessness seems to be
more important than differences in the degree of airflow obstruction
in determining disability. It therefore seems appropriate to include
in the assessment of effects of therapy a measure of the change in the
patients life and perceived well being, in addition to symptom
indices. The use of such a 'quality of life' instrument gave additional
information in a previous study looking at the effects of oral
theophylline and inhaled salbutamol in patients with chronic airflow
obstruction(187).
The results of the measures of dyspnea used show an
improvement in the dyspnea index of the quality of life questionnaire
and the diary card breathlessness scores after inhaled
beclomethasone, but a marked placebo effect in the results of the
oxygen cost diagram. As with objective measures of lung function, the
effect of the two doses of inhaled beclomethasone used was broadly
similar. The lack of a dose effect is probably a reflection of the mode
of delivery of the drug, and the dose response characteristics of
inhaled beclomethasone as outlined in the previous chapter.
The remaining components of the quality of life questionnaire
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showed variable placebo effects but the mastery element, the feeling
of control over the disease process, was the only component showing
a significant effect of treatment with inhaled beclomethasone. The
addition of oral prednisolone over the final treatment phase caused
no further significant change in any of the indices of dyspnoea, or
the fatigue and emotional function components of the quality of life
questionnaire, but patients continuing on inhaled beclomethasone
alone showed an increase in the mastery score, not seen in patients
receiving both oral prednisolone and inhaled beclomethasone.
Our definition of a subjective response to treatment was
based upon Guyatt's unsupported comments that an improvement of
4 or more in the physical function element of the questionnaire
represents a clinically important difference. Using his definition of
subjective response, inhaled beclomethasone produced more
subjective responders than placebo therapy and no differences in the
subjective response rate to the two doses of beclomethasone was
seen. After the addition of oral prednisolone to the regime of 2/3 of
the patients during the final treatment phase, the subjective
response rate was similar between those continuing on inhaled
beclomethasone alone and those receiving oral prednisolone and
inhaled beclomethasone.
The mean changes seen in all the subjective measures used
were small in absolute terms. The mean improvement in the dyspnea
and mastery dimensions of the quality of life questionnaire were
similar however to that seen with treatment with simple
bronchodilators( 187).
Studies of corticosteroids which have formally assessed
change in subjective measures have shown variable, and usually low
order correlations between changes in the subjective measures and
changes in lung function variables. This divergence emphasises the
indirect link between measures of airflow obstruction and disability.
Williams & McGavin found a reasonably strong correlation between
changes in FVC and a visual analogue assessment of what appears to
be global well being(75). However in Lam et al's study the change in
FVC showed the weakest correlation with the change in dyspnoea
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score, with larger significant correlations seen between change in
FEV1 and change in peak flow(90). The strongest correlation was
seen between the change in FEV1 and change in dyspnea score, but
only 40% of the variance in the dyspnoea score was explained by the
change in FEV1. O'Reilly et al used a subjective assessment of
walking ability, the oxygen cost diagram(167), and the Borg rating of
perceived exertion to assess subjective response(83). In their study
the only significant correlation seen between change in FEV1 or FVC
and subjective measures was that between change in FEV1 and the
improvement in the oxygen cost diagram. Other investigators in a
slightly larger group of patients found the change in a breathlessness
score and the oxygen cost diagram correlated significantly but
weakly with the change in FVC and the change in the breathlessness
score alone with the change in FEV1(92). An assessment of well being
using a visual analogue scale correlated poorly with changes in
objective measures. However all these studies contained relatively
small numbers of patients, and used crude unrefined instruments to
measure subjective aspects of disease.
In the larger NOTT study which looked at the relationship
between a general quality of life instrument, the Sickness Impact
Profile (SIP)(189), and lung function in over 200 patients with COPD
the correlations between physiological measures of disease severity
and the results of the quality of life instrument were also of a low
order(190). A further study designed to specifically evaluate the
usefulness of the same quality of life instrument in patients with
chronic airflow obstruction looked at 141 patients with a wider range
of disability(191). In this study the correlation between spirometric
measures, peak flow and the quality of life scores were again low with
the largest correlation being seen between FVC and quality of life.
Even with this spirometric measure, less than 20% of the variance of
the quality of life score was explained by the FVC. The largest
correlation in this study was seen between 6 minute walking distance
and quality of life score, suggesting that the same attitudes and
expectations which predict walking speed and distance appear to
influence patients perception of their quality of life.
The authors showed that this general quality of life
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questionnaire (SIP) appeared to be a relatively insensitive tool in
patients with mild airflow obstruction. Patients with breathlessness
scores indicating moderate disability showed no difference in SIP
scores, but as disability scores worsened so the difference in SIP
scores became more marked. In addition 20% of all the items in the
SIP questionnaire were left unanswered by patients with chronic
airflow obstruction as they were irrelevant to their daily life. The
implication is that a disease specific quality of life questionnaire may
provide more information than a general measure.
The quality of life instrument used in the present study was
developed in Canada in a population of patients with chronic airflow
obstruction and is disease specific unlike the quality of life
instrument used in the studies quoted above(166). As such the noise
in any treatment effect should be less, and hence the instrument
should be more sensitive than the general quality of life measures.
Guyatt has shown that the instrument is responsive to change in
disease state and that it appears to be a valid measure. The
coefficient of variation for repeated administration at 2 week
intervals is 6% for the dyspnoea dimension, 9% for both fatigue and
emotional function and 12% for mastery. This compares favorably
for the coefficient of variation for the measurement of FEV1 (15%),
FVC (11 %) and single breath carbon monoxide gas transfer (15%) in
patients with chronic airflow obstruction(192).
That this quality of life questionnaire measures something in
addition to lung function changes is clear from the poor correlation
seen between changes in the elements of the quality of life
questionnaire and changes in FEV1, FVC and mean peak flow.
Although Guyatt claims in his hands to see moderate correlations
between changes in the quality of life questionnaire and changes in
the lung function, the actual correlations have not been fully
published and hence it is difficult to compare the results in this
study with his own. The strongest correlations between the quality of
life elements and objective measures of lung function in the present
study were seen between FEV1 and FVC, and mastery, and between
the change in mean peak flow and the change in the dyspnoea
dimension score. In addition, the change in mean peak flow showed a
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moderate correlation with the diary card breathlessness score
changes but no correlation at all with the changes in the oxygen cost
diagram. It is my impression that patients have difficulty
understanding the instructions for completing the oxygen cost
diagram, often requiring further explanation and assistance in
completing it and this may be why this particular instrument
appears to be relatively insensitive.
The improvement seen in the quality of life elements,
although statistically significant were small. Compared to the
improvement seen by Guyatt et al after a rehabilitation program,
the effect of inhaled beclomethasone appears to be much
smaller(166). However they are only slightly less than the changes
seen after oral and inhaled bronchodilator treatment187,193). It is
difficult to truly compare the results of this present study with those
of Guyatt et al as information on the age, sex and lung function of
the patients studied by Guyatt et al is not available. It may be that
my study investigated patients with more severe disease, who had,
therefore, a smaller potential for improvement with treatment. It
also seems likely that such features as reversibility of airflow
obstruction and possibly smoking habit would also affect the
response in terms of quality of life to various treatments. In addition
many of the patients recruited to my trial had other coexistent
medical problems (eg; angina, osteoarthritis, depression) which may
have a bearing on their responses to the quality of life questionnaire.
It is also likely that improvement in quality of life will lag
behind any improvement in physiological measures. Patients will
require time to adapt to the improved physiological function, and to
regain confidence. Many of the factors relating to impaired quality of
life will only be indirectly related to airflow obstruction, eg exercise
limitation due to breathlessness causing disuse atrophy of limb
muscles. Another possible explanation for the small improvements
seen in the present study is that in addition to being disease specific,
the quality of life questionnaire of Guyatt et al may also have
cultural specificity. It is possible that patients in the UK perceive
functional disability in a different manner to those in North
America.
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Although change in the objective physiological measures used
did not correlate well with changes in the quality of life or
breathlessness assessments, there was a difference in the effect of
treatment on subjective measures in patients classified as
physiological responders to treatment compared to those who did not
respond to treatment in term of change in FEV1, FVC or mean peak
flow. On first sight, this is surprising, but one explanation may be
that physiological response was based upon the change on three
objective variables, hence a simple correlation with change in single
variables may well be lacking. The fact that a subjective response to
treatment was seen in all dimensions of the quality of life
questionnaire in physiological responders seems to justify the
somewhat arbitrary traditional definition of physiological response
used. The classification adopted does appear to differentiate between
patients showing an improvement in subjective measures, and those
not. Only the oxygen cost diagram, with the problems attached to its
completion noted above, failed to show any difference between
physiological responders and non-responders.
Conversely, defining response on the basis of subjective
measures alone, using Guyatt's cut-off, of an improvement of 4 in the
physical function element of the questionnaire, did not produce two
distinct patient populations in terms of treatment effect on
physiological variables. Although subjective responders did show
higher mean changes after treatment with inhaled beclomethasone
in FEV1, FVC and mean PEF, there was no statistically significant
difference between the two subjective response groups. That aside,
only the subjective responders showed a change in each of the three
objective parameters which is significantly different from zero after
treatment. Guyatt et al's justification for a cut off of 4 is not clear,
but re-analysis of the data in this study shows similar results,
whether the cut off is raised to 5 or 6.
It is perhaps not surprising that the addition of oral
prednisolone caused no significant improvement in the subjective
measures investigated. As no significant improvements in the
objective measures were seen with oral prednisolone and one may
presume that the other factors affecting response to subjective
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measures were constant, it is likely that no change would be detected
in the subjective measures. The mastery dimension of the quality of
life questionnaire did show differences between the final treatment
groups, but the effect was small. Studies looking specifically at
prednisolone induced mood changes in this group of patient, have
come to conflicting conclusions. Mitchell et al failed to distinguish
between a euphoriant action of prednisolone and a placebo
effect(194), although Swinburn et al detected a mild inappropriate
well being after treatment with oral prednisolone(77). The results
seen in the present study would also suggest that any euphoriant
effect of prednisolone is mild.
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8. THE EFFECT ON BRONCHIAL RESPONSIVENESS TO
INHALED HISTAMINE.
8.1. ANALYSIS.
Comparison of the effect of placebo and inhaled
beclomethasone dipropionate on bronchial responsiveness to inhaled
histamine was assessed by a repeated measures analysis of variance
with dose of inhaled drug entered as a factor. A logarithmic
transformation of PD20 was used in the analysis.
The additional effect of treatment with oral prednisolone was
determined by comparing the change in bronchial responsiveness to
inhaled histamine from that recorded after the inhaled
beclomethasone treatment phase to that at the end of the final
treatment phase, in patients receiving oral prednisolone and those
continuing on inhaled beclomethasone alone. For this analysis
bronchial responsiveness as measured by the method of Yan(163),
PD20, at the end of each treatment phase was used.
The correlation between the degree of airflow obstruction and
bronchial responsiveness to inhaled histamine, and between the
three baseline measures of bronchial responsiveness was
determined by estimation of the Pearson correlation coefficients.
Repeatability of PD20 measurements was expressed in terms of the
95 % range for a single measurement.
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8.2. RESULTS.
8.2.1. Distribution of bronchial hyperresponsiveness to inhaled
histamine, correlation with baseline variables, and repeatability of
the measure.
Seventy four patients with an FEV1 greater than 0.75 litres
had bronchial responsiveness to inhaled histamine measured during
the baseline period. After placebo treatment and the inhaled
beclomethasone treatment phase PD20 was measured in 65 of these
patients, and after the final treatment in 60 subjects. In three of the
74 patients the fall in FEV1 after the final dose of histamine
(7.8umol) was less than 20%. Extrapolation allowed a value to be
determined in two cases, in the third a value for PD20 of 16
micromol was used in the analysis.
The majority of patients showed a moderate degree of
bronchial hyperresponsiveness to inhaled histamine, with only 19
patients having a PD20 value of less than 0.24umol histamine. The
median PD20 value was 0.45umol histamine, and the geometric mean





Figure 8.1. The distribution of PD20 values in the 74 patients at
baseline.
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Moderate correlations between the severity of bronchial
hyperresponsiveness to inhaled histamine and the severity of airflow
obstruction measured as FEV1/FVC ratio, FEV1 alone or PEF were
seen (table 8.1.). Lower order correlations were seen between indices
of reversibility and PD20, but no significant correlation was seen
between PD20 and diurnal variation in PEF. The relationship
between PD20 and FEV1/FVC is shown in figure 8.2..
The correlation between the logarithm of bronchial
responsiveness to inhaled histamine measured by the two different
methods was, perhaps not surprisingly, high (r=0.81). The
correlation between bronchial hyperresponsiveness to inhaled
histamine, measured by the Yan method, and responsiveness to
ultrasonically nebulised distilled water was much less. In 38 patients
in which the result of the test of bronchial responsiveness to
ultrasonically nebulised distilled water was not censored the Pearson
correlation coefficient between the log transformed values was 0.34.
Table 8.1. Pearson correlation coefficients between various lung
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Figure 8.2. Scatterplot of the relationship between the degree of
airflow obstruction, as FEV1/FVC ratio, and the severity of
bronchial hyperresponsiveness, PD20.
In the 66 patients who had PD20 measured at baseline and
after placebo treatment, the standard deviation for the difference
between repeat PD20 measurements was 0.97 loglO units, giving a
95% range for a single estimation of PD20 of 1.99 doubling
concentrations of histamine. The values for individual patients are
shown in figure 8.3.
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Figure 8.3. Relation between PD20 values from tests at baseline
and after placebo treatment. The solid line is the line of identity
and the dotted lines indicates one doubling dose from the line of
identity.
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8.2.2. The effect of inhaled beclomethasone.
After treatment with placebo or inhaled beclomethasone
there was no significant change in bronchial responsiveness to
inhaled histamine from that measured during the baseline period.
Table 8.2. shows the geometric mean PD20 value for the two inhaled
beclomethasone dose groups. The lack of any improvement in PD20
was despite a small improvement in FEV1 with treatment in both
dose groups. In patients receiving 750mcg b.d. inhaled BDP the
FEV1 improved from a mean (95% CI) at baseline of 1.29 (1.19 to
1.39) litres, to 1.34 (1.24 to 1.44) after inhaled beclomethasone. After
placebo treatment the FEV1 was not significantly different from
baseline ( placebo FEV1, mean 1.27 (1.17 to 1.37)). In those
receiving the higher dose of inhaled beclomethasone the FEV1
increased from a baseline value of 1.27 (1.15 to 1.38) litres to 1.32
(1.19 to 1.45) after active treatment, the mean (95% CI) FEV1 after
placebo were not different from baseline ( 1.27 (1.14 to 1.41) litres).
Figure 8.4. shows the change in PD20 values in individual
patients after placebo and inhaled beclomethasone, with the change
expressed as doubling doses of histamine. Form this it is clear that
very few patients had changes in PD20 after active treatment greater
than the 95% limits for repeatability of the measurement.
To exclude an effect of measurement error on PD20 in patients with
the lowest FEV1 values, ie FEV1 0.75 to 1.2, where a 20% fall in FEV1
approximates the short term limits of repeatability of measurement
of FEV1 (94) , the analysis was repeated on patients with an FEV1 of
greater than 1.2 litres. In this subgroup there was no detectable
effect of inhaled beclomethasone on bronchial responsiveness to
inhaled histamine. The geometric mean PD20 values at baseline (for
both dose groups combined) were 0.84umol, after placebo 0.28 umol,
and after inhaled beclomethasone 1.08umol.
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Table 8.2. Geometric mean PD20 values at baseline, after









Treatment effect F-ratio 1.5, ns








Figure 8.4. The change from baseline in individual PD20 values
after placebo and inhaled beclomethasone. Error bars show
mean and 95% confidence limits for mean of the difference. The
change in PD20 values is expressed in doubling doses (log2 units)
of histamine.










It might be argued that patients with little or normal
bronchial responsiveness to inhaled histamine would be expected to
show small or no treatment effects. Hence an analysis was performed
after classifying patients into severe and moderate bronchial
hyperresponsiveness. Patients with a PD20 of lumol or less at
baseline were classed as severe bronchial hyperresponsiveness. In
this group a small but statistically significant improvement in
bronchial responsiveness was seen after treatment with inhaled
beclomethasone. The geometric mean PD20 improved from 0.26umol
at baseline, and 0.28umol after placebo to 0.40 after inhaled
beclomethasone (treatment effect F-ratio=3.88, p<0.03). However in
those with less severe bronchial hyperresponsiveness (PD20 greater
or equal to 1 umol) PD20 values fell significantly after placebo
(geometric mean (umol); baseline 2.41, placebo 1.39, BDP 1.40
Treatment effect F-ratio = 6.9, p<0.01), suggesting the effect seen in
the group with severe bronchial hyperresponsiveness may simply
represent regression to the mean.
The effect of treatment on bronchial responsiveness to
inhaled histamine in patients who had shown a response to inhaled
BDP was examined by comparing the change in PD20, expressed in
doubling concentrations, from the end of the placebo period to that
measured after inhaled beclomethasone. In the 18 patients classed
as responsive to BDP the PD20 improved by a mean (95% CI) 0.37 (-
0.66 to 1.4) doubling concentrations, in the non responders the
improvement was similar, mean 0.31 (-0.08 to 0.71).
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8.2.3. The effect of oral prednisolone.
Of the 60 patients who had PD20 measured after the final
treatment phase, 38 received oral prednisolone in addition to
inhaled beclomethasone at the dose taken during the second
treatment period. The remaining 22 continued on inhaled
beclomethasone alone, 11 in each beclomethasone dose group.
After six weeks treatment with inhaled BDP alone there was
no detectable effect of treatment on PD20. The geometric mean PD20
values in the two dose groups are shown in table 8.3..
Oral prednisolone 40mg per day for three weeks also had no
significant effect on bronchial responsiveness to inhaled histamine.
In the 38 patients who received both oral prednisolone and inhaled
beclomethasone the geometric mean PD20 value fell from 0.62umol
after inhaled beclomethasone alone, to 0.59umol after oral
prednisolone (/=0.284,ns).
In the 22 patients receiving inhaled beclomethasone alone the
PD20 value fell on average by 0.41 doubling concentrations of
histamine, in the patients receiving both oral prednisolone and
inhaled beclomethasone the mean change was an improvement of
0.06 doubling concentrations. The changes in individual patients are
shown in figure 8.5..
The effect of oral prednisolone was similar in patients with a
PD20 value less than 1 umol, and in patients in whom the FEV1 was
greater than 1.2 litres at baseline.
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Table 8.3. The geometric mean PD20 values at baseline, after
placebo and after three and six weeks treatment with inhaled




3 weeks BDP 0.68 umol




3 weeks BDP 0.51 umol
6 weeks BDP 0.28 umol
Treatment effect F-ratio 0.58, ns








Figure 8.5. The effect of treatment with oral prednisolone on
PD20 values. The change in doubling doses of histamine from the
value recorded after BDP alone, and after the final treatment
phase is shown for individual patients. The error bars show the
mean change and 95% confidence limits for the mean.











BDP alone Pred + BDP
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8.3. DISCUSSION.
The results show no significant effect of inhaled
beclomethasone or oral prednisolone on bronchial
hyperresponsiveness to inhaled histamine in these patients with
chronic airflow obstruction. The lack of any effect is despite a small
increase in FEV1 in the patients, which because of the correlation
between FEV1 and PD20 would tend to decrease bronchial
hyperresponsiveness(124). In a post hoc sub-group analysis a
statistically significant but small effect was seen in patients with
more severe bronchial hyperresponsiveness. However this change
may be explained by regression to the mean, and the increase in
mean PD20 values was considerably less than one doubling
concentration of histamine.
The measurement of bronchial responsiveness to inhaled
histamine is usually restricted to patients with less severe chronic
airflow obstruction, partly because of theoretical safety concerns,
and also because of difficulty in interpreting the results of tests. In
patients with an FEV1 less than one litre a 20% fall in FEV1 induced
by histamine will produce an absolute fall which is just greater than
the short term variability of the measurement, so that the validity of
the measurement of PD20 may be open to question. However the
repeatability of the measurement in all the patients studied for this
thesis is similar to that seen in asthmatics(195), and in
epidemiological studies of normal subjects, where concerns about the
valididty of a 20% fall in FEV1 do not occur. It would appear
therefore that the measurement of PD20 in these patients with
severe chronic airflow obstruction is valid. In addition the reanalysis
of the data excluding patients with an FEV1 of less than 1.2 litres did
not significantly affect the conclusions of the effect of treatment on
bronchial hyperresponsiveness.
A number of studies have shown an improvement in
bronchial hyperresponsiveness after treatment with inhaled
corticosteroids in patients with asthma(l 13,115,196). However none of
the four published studies investigating the effect of corticosteroids
on bronchial hyperresponsiveness in patients with chronic bronchitis
and or chronic airflow obstruction has reached positive
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conclusions(132-134,197).
There are a number of possible explanations for the different
effect of inhaled corticosteroids in asthma and chronic airflow
obstruction. Recent histological studies have suggested that in
asthma the cellular component of bronchial wall inflammation is
primarily eosinophilic(32,33), whereas in chronic airflow obstruction
the inflammation in the bronchial wall appears to be mainly
composed of neutrophils(139,148). It is possible that the lack of an
effect of corticosteroids on bronchial hyperresponsiveness in chronic
airflow obstruction is explained by a reduced sensitivity of
neutrophilic inflammation to suppression with corticosteroids.
In this study treatment was given for 2 sequential three week
periods. It is possible a longer period of treatment would produce
changes in bronchial responsiveness to inhaled histamine. In asthma
the effect of eight weeks treatment with inhaled corticosteroids is far
greater than the effect seen at 2-3 weeks(113). In Postma et al's
retrospective study the beneficial effects of oral corticosteroids on
decline in FEV1 were not seen until at least 6 months after treatment
was instituted, suggesting prolonged treatment with corticosteroids
may be required to observe a beneficial effect(57). However one may
have expected a trend towards improvement in bronchial
hyperresponsiveness to be apparent after six weeks, and this is not
evident either in my data, nor in a study where the effect on PD20 of
eight weeks treatment with inhaled budesonide was assessed(134).
Other workers did not detect any effect of treatment with inhaled
budesonide at a dose of 600mcg twice daily on bronchial
hyperresponsiveness in an open study of smokers with a documented
accelerated decline in FEV1(133). A prospective study investigating
the effect of inhaled beclomethasone on bronchial
hyperresponsiveness over two years is currently underway in our
centre.
An alternative explanation for the lack of an effect of
treatment on bronchial hyperresponsiveness in chronic airflow
obstruction may be that the primary determinant of bronchial
hyperresponsiveness in chronic airflow obstruction is geometric
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rather than inflammatory. In asthmatic patients the degree of
bronchial hyperresponsiveness and airway obstruction are largely
independent, that is many patients show normal FEV1 values but
severe bronchial hyperresponsiveness. In patients with chronic
airflow obstruction the degree of bronchial responsiveness correlates
strongly with the degree of airflow obstruction. Yan et al found a
correlation between FEV1/FVC ratio and PD20 of r=0.7(124). The
correlation was less in my study, but still highly statistically
significant, suggesting a close link between bronchial
hyperresponsiveness and airflow obstruction.
A number of other observations suggest bronchial wall
inflammation is not the major cause of bronchial
hyperresponsiveness in the patients studied. The two doses of
inhaled beclomethasone used would be expected to have significant
anti-inflammatory effects on the bronchial mucosa, but despite this
no significant change in PD20 was seen. In smokers bronchodilators
alone, with no anti-inflammatory properties, improve bronchial
hyperresponsiveness over the short term, probably as a result of the
bronchodilation induced(133). The lack of any major effect of
corticosteroids on PD20 in patients classed as responders to
treatment in my study would also support the argument that
geometric factors are the primary determinant of bronchial
hyperresponsiveness in chronic airflow obstruction. It also implies
that the underlying pathology in the bronchial wall is not asthmatic,
ie; eosinophilic, and supports the contention that the patients
studied are not simply 'missed asthmatic'.
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9. THE EFFECT ON GLOBAL RESPIRATORYMUSCLE
STRENGTH AS MEASURED BYMAXIMAL STATIC MOUTH
PRESSURES.
9.1. ANALYSIS.
In order to eliminate any possible learning effect in the
measurement of maximal static mouth pressures(198), the baseline
values were taken as those recorded on the latter of the two baseline
days when mouth pressures were measured. The change in maximal
inspiratory mouth pressure, Pimax, and maximal expiratory mouth
pressure, Pemax, after inhaled beclomethasone was assessed by a
repeated measures analysis of variance, with dose of drug entered as
a factor. Where significant effects were detected a Fisher's LSD test
was used to determine which comparisons were significant. For
analysis of the data after the final phase of active treatment, when
two thirds of the patients received oral prednisolone in addition to
inhaled beclomethasone, the change in each variable from the
previous phase was calculated. The change was compared between
patients receiving or not receiving prednisolone by an unpaired
Student t test, combining the inhaled beclomethasone dose groups.
Pearson correlation coefficients between baseline
physiological variables and maximal static mouth pressures were
calculated to assess associations.
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9.2. RESULTS.
9.2.1. Data collection, and baseline correlations.
Measurement of both maximal inspiratory mouth pressure
(Pimax), and maximal expiratory mouth pressure (Pemax) was
performed in 103 patients at baseline (2 patients were unable to
perform the test adequately). After placebo therapy values for both
variables were available in 97 patients, and after inhaled
beclomethasone in 96 patients for Pimax, and 95 for Pemax. After
the final treatment phase measurements were available in 90
patients for Pimax, and 89 patients for Pemax.
The association between Pimax and Pemax, and various baseline
lung function measurements and body mass index is shown in table
9.1.. Correlations are significantly lower when allowance is made for
age and height by expressing lung function variables as a percentage
of the predicted value.
Evidence for a small learning effect in the measurement of
maximal static mouth pressures was obtained by comparing the
values obtained on the first baseline occasion with those from the
second measurement. Pimax improved by a mean (95% CI) of 3.2
(5.3 to 1.1) cm H20, and Pemax by a mean of 5.3 (8.4 to 2.1) cm H20.
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Table 9.1. Pearson correlation coefficients between Pimax and
Pemax, and various measures of lung function and body mass
index.
Pimax Pemax
FEV1 (litres) 0.35 *** 0.24 *
as % predicted 0.18 0.01
FVC (litres) 0 44 *** 0.39 ***
as % predicted 0.21 * 0.02
FEV1/FVC 0.06 -0.05
TLC 0.35 *** 0.38 ***
as % predicted 0.06 -0.04
RV/TLC -0.24 * -0.16
mean PEF q 44 *** 0.46 ***
as % predicted 0.32 *** 0.33 ***
BMI (wt/ht2) 0.12 0.33 ***
RV- residual volume (litres)
TLC- total lung capacity (litres)
BMI- body mass index = weight (kg)/ height (kg) squared.
*** p< 0.001, * p<0.05.
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9.2.2. The effect of inhaled beclomethasone.
a. Maximal inspiratory mouth pressure.
In the 96 patients in whom Pimax was measured at baseline,
and after placebo and inhaled beclomethasone there was a
significant, though small increase after active therapy. There was no
significant difference between the two dose groups detected (table
9.2.). The change from baseline after placebo and inhaled
beclomethasone for the two dose groups is shown graphically in
figure 9.1..
b. Maximal expiratory mouth pressure.
For maximal expiratory mouth pressure no significant effect
of treatment with inhaled BDP was noted (table 9.2.).
Table 9.2. The mean (SEM) for maximal inspiratory mouth
pressure, and maximal expiratory mouth pressure at baseline,
and after placebo and inhaled beclomethasone.
BDP dose Baseline Placebo BDP
Pimax
750mcg b.d. 56.6 (3.3) 57.4 (3.3)
1500mcg b.d. 58.0 (2.7) 57.3 (2.6)
60.0 (3.6)
61.5 (3.1)
Treatment effect F-ratio = 8.7, DF=2, p<0.0003.
Dose effect F-ratio=0.45, DF=2, ns.
Pemax
750mcg b.d. 128 (6.2) 127 (6.0)
1500mcg b.d. 133 (5.4) 134 (2.6)
130 (6.2)
135 (5.9)
Treatment effect F-ratio=0.92, DF=2, ns.



















Figure 9.1. The change from baseline in Pimax after placebo and
inhaled beclomethasone in individual patients for the two BDP
dose groups. Error bars show mean change and 95% confidence
interval for mean.
9.2.3. The effect of oral prednisolone.
a. Maximal inspiratory mouth pressure.
In the thirty one patients who continued on inhaled
beclomethasone alone for the final treatment phase, there was no
significant change in maximal inspiratory mouth pressure (both
dose groups combined). The mean change (95% CI) from the value
recorded after three weeks inhaled beclomethasone was 0.5 (-2.2 to
3.2) cmH20. In the 59 patients who received oral prednisolone in
addition to inhaled BDP, Pimax improved by a mean (95% CI) of
2.02 (-0.8 to 4.8) cmH20, not statistically significant. The difference
between the two final phase treatment groups was not statistically
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significant ( mean [95% CI] difference 1.5 [5.8 to -2.7] cm H20, t—
-0.8, DF= 84.2, ns).
b. Maximal expiratory mouth pressure.
Pemax improved in the 31 patients continuing on inhaled
beclomethasone by a mean (95% CI) of 2.5 (-3.4 to 8.3) cmH20, non
significant. However the 58 patients who received oral prednisolone
and inhaled beclomethasone for the final treatment phase showed a
small but significant improvement in maximal expiratory mouth
pressure ( mean (95% CI) 8.4 (3.5 to 13.2) cmH20, p<0.001). The
difference between the groups did not reach statistical significance




The measurement of maximal static mouth pressures is a
valid and sensitive index of global respiratory muscle
dysfunction(199). Initial reports of respiratory muscle function in
chronic airflow obstruction suggested that muscle strength was
increased compared to normal(200). However as subsequent
investigators have pointed out these conclusions were erroneous as
the normal ranges for respiratory muscle strength used were
uncorrected for the effect of the static recoil of the respiratory system
at high lung volumes. This tends to decrease the measured
inspiratory muscle strength when measured at high lung volumes,
and correcting for this suggests the initial report showed similar
respiratory muscle strength in normals and patients with chronic
airflow obstruction(201). Subsequent reports however, have
concluded that both maximal inspiratory mouth pressure, and
maximal expiratory mouth pressure are reduced in patients with
significant chronic airflow obstruction(201,202,203,204).
The reason for the reduced muscle strength seen appears to
be a combination of local mechanical and generalised nutritional
factors. The airflow obstruction of chronic obstructive pulmonary
disease produces hyperinflation of the lungs which causes shortening
of the inspiratory muscles and places them at a mechanical
disadvantage(205). Such mechanical considerations do not apply to
the expiratory muscles, and some investigators have found a
correlation between body mass and maximal mouth
pressures(204,206), although others find no relationship at all(207).
The results of this study show baseline values of both
maximal inspiratory mouth pressure, and maximal expiratory
mouth pressure which are lower than the published normal
ranges(208,209). A weak correlation between Pimax and
hyperinflation as measured by the RV/TLC ratio was apparent,
patients with higher ratios, ie more hyperinflation showing reduced
inspiratory muscle strength. Both Pimax and Pemax showed a
correlation with the mean PEF recorded over the week preceding the
measurement, and in this group of patients body mass index, an
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index of nutritional status, showed a correlation with expiratory
muscle strength.
Myopathy of the skeletal muscles is a recognised
complication of an excess of glucocorticoid, either endogenous or
exogenous(210,211). Myopathy of the respiratory muscles has been
described in case reports of patients with connective tissue diseases
receiving high dose oral prednisolone^ 12), and in patients requiring
ventilation for status asthmaticus(213,214). However in the first
report it is possible that the underlying disease was responsible at
least in part for the respiratory muscle weakness seen, and in the two
asthmatics the doses of hydrocortisone used to treat the asthma were
excessive. Whether oral or inhaled corticosteroid therapy in patients
with no other cause for respiratory muscle weakness can cause a
myopathy of the respiratory muscles is not clear.
Surveys of asthmatics treated with varying doses of oral
corticosteroids have reached differing conclusions with regard to
skeletal muscle myopathy. Bowyer et al found detectable weakness of
the hip flexor muscles in asthmatics receiving greater than 40mg
oral prednisolone per day(215). A more recent study in asthmatics
treated with lower doses of oral prednisolone, a mean of 13 mg per
day for nearly 10 years, detected no myopathy of skeletal or
respiratory muscles(216).
A number of workers have examined the effect of
glucocorticoids in animals, and usually have detected weakness
and/or biochemical or histological changes of myopathy(217,218),
usually within two weeks of the start of treatment. However the
majority of such studies have used doses of corticosteroids far in
excess of those used therapeutically in humans, and there may well
be species differences in the susceptibility to steroid myopathy.
A study on normal human subjects published whilst this work
was in progress provides more relevant information. In a parallel
group study of 16 normal subjects no effect of oral prednisolone 20
mg per day for 2 weeks on respiratory muscle strength or endurance
was noted(219). However there is a lack of information on the dose
response characteristics and time course of the development of
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corticosteroid myopathy and it is possible a longer period of
treatment or a higher dose would induce detectable myopathy.
The current study has investigated a slightly longer treatment
period and a higher dose of oral prednisolone, and also the effects of
high dose inhaled corticosteroid over six weeks. The doses of inhaled
beclomethasone used do produce systemic side effects, as judged by
adrenal suppression (vide infra) and changes in calcium
metabolism(220,221), so it is plausible that they may also produce
effects on muscles.
The results show no detrimental effects of either six weeks
treatment with inhaled beclomethasone, or three weeks treatment
with both oral prednisolone and inhaled beclomethasone. Indeed
Pimax improved after three weeks treatment with inhaled
beclomethasone, and Pemax showed a small increase in the patients
who received oral prednisolone for the final treatment phase. The
magnitude of these change was small and would not be of clinical
significance. The improvement in Pimax after three weeks treatment
with inhaled beclomethasone may have been due to a continued
learning effect rather than a true effect of treatment. However
irrespective of any methodological problems the study was unable to
show any untoward effect of treatment with both oral and inhaled
corticosteroids over the short term. Whether long term treatment
with high dose inhaled corticosteroids is at risk of inducing either
skeletal or respiratory muscle myopathy will only be answered by
further prospective studies.
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10. BRONCHIAL RESPONSIVENESS TO ULTRASONICALLY
NEBULISED DISTILLED WATER AND PREDICTION OF
RESPONSE TO INHALED BECLOMETHASONE IN PATIENTS
WITH CHRONIC AIRFLOW OBSTRUCTION.
10.1 ANALYSIS.
Response to ultrasonically nebulised distilled water in the 49
patients tested was not normally distributed, and hence for all
analysis in which response to ultrasonically nebulised distilled water
was entered as a continuous variable a logarithmic transformation
was used. Patients with a PD20 to ultrasonically nebulised distilled
water of less than 2ml water were classified as responsive to
ultrasonically nebulised distilled water(120), and those with values
above this level as non responders to ultrasonically nebulised
distilled water.
Comparisons of the baseline characteristics of the two
ultrasonically nebulised distilled water response groups was carried
out using an unpaired t test, and chi squared test where appropriate.
To ensure patients in whom ultrasonically nebulised distilled water
responsiveness was measured were representative of the whole study
group, the baseline characteristics of those in whom the test was
performed were compared by an unpaired t test and chi squared test
to the patients who did not undergo this test.
The role of responsiveness to ultrasonically nebulised
distilled water in predicting an individuals response to inhaled and
oral corticosteroids was assessed by a variety of ways. The response
to both active treatments was compared in the two ultrasonically
nebulised distilled water response groups defined above by a chi
squared test. In addition the change in FEV1, FVC and mean PEF
after each treatment was correlated in individual patients with the
measured responsiveness to ultrasonically nebulised distilled water.
Finally as a secondary analysis the response to ultrasonically
nebulised distilled water was entered as one factor in a discriminant
analysis.
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Prediction of response to inhaled beclomethasone in an
individual was assessed by comparing baseline characteristics,
including answers to the baseline questionnaire, in the
beclomethasone responders and non responders, using an unpaired t
test, and a chi squared test as appropriate. In addition a
discriminant analysis was carried out on a cohort of similar patients
who underwent a comparable trial 4 to 6 years previously. The
results of this trial have been published(95). The analysis was
performed using SPSS-PC, in a stepwise manner. The discriminant
function obtained was applied to the current study group, and a new
discriminant function was developed using variables that had not
been measured in the first study.
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10.2. RESULTS.
10.2.1. Bronchial responsiveness to ultrasonically nebulised distilled
water.
Forty nine patients had bronchial responsiveness to
ultrasonically nebulised distilled water (PD20 USDW) determined.
There were no significant differences between the baseline
characteristics of these 49 patients and the 25 patients who had
bronchial responsiveness to inhaled histamine measured but not
bronchial responsiveness to ultrasonically nebulised distilled water
(table 10.1).
In 38 patients the FEV1 fell to less than 80% of the pre
challenge value before 380 litres of nebulised mist had been delivered
to the patient. In the remaining 11 patients the FEV1 did not fall by
20%, even after 380 litres of mist had been delivered. These patients
had censored values, and in order that the maximum amount of data
be available for analysis, where correlations were measured the non
parametric Spearman's rho was utilised, with PD20 USDW entered
as the untransformed value. The distribution of PD20 values to
ultrasonically nebulised distilled water is shown in figure 10.1..
Fourteen patients had a PD20 USDW of less than 2ml water and
were classified as responsive to ultrasonically nebulised distilled
water.
Statistically significant correlations were found between
PD20 USDW and the degree of airflow obstruction, as measured by
the FEV1 and FEV1/FVC ratio, but not with mean baseline PEF,
diurnal variation in PEF or reversibility to 200 meg salbutamol
(table 10.2.). Significant correlations were also seen between the
bronchial responsiveness to ultrasonically nebulised distilled
water, and that measured to inhaled histamine by both of the
methods used.
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Table 10.1. Characteristics of patients in whom bronchial
responsiveness to ultrasonically nebulised distilled water was
measured (USDW +), and in those in whom only bronchial
responsiveness to inhaled histamine was determined (USDW -).




Number (female) 49 (9) 25 (7)
Age (yrs) 67 (65 to 68) 64 (61 to 67)
Mean FEV1 (1)
as % predicted
1.3 (1.2 to 1.4)
48 (45 to 51)
1.15 (1.0 to 1.3)
43 (38 to 49)
Mean FVC (1)
as % predicted
2.8 (2.5 to 3.0)
86 (82 to 90)
3.0 (2.8 to 3.2)
83 (78 to 89)
Mean FEV1/FVC (%) 45 (42 to 48) 42 (37 to 47)
Mean PEF (1/min) 269 (247 to 292) 262 (228 to 296)
FEV1 reversibility to
200 meg salbutamol as
absolute (ml)
% pred FEV1
134 (90 to 179)
6.2 (3.9 to 8.5)




histamine (umol) 0.59 0.41
Smoking status [as number (%)]
Current 24 (49)





Number(%) skintest positive 12 (24) 4(16)
i




PD20 USDW obtalaad E2Z1 PD20 USDW ciiHik
PD20 USDW (mis H2Q)
Figure 10.1. Distribution of PD20 USDW values for the 49
patients who had this measured. In 11 patients the value was
censored, and in these cases the amount of ultrasonically
nebulised distilled water inhaled is indicated.
Table 10.2. Spearman rank correlation coefficients between PD20






Mean baseline PEF (1/min)
PEF diurnal variation
(as % mean PEF)
0.16
-0.24
Reversibility to 200 meg salbutamol
as absolute change (ml)
as % predicted FEV1
0.16
0.13
Bronchial responsiveness to histamine
PC20 (Yan method) (umol)
PD20 (Cockroft method) (mg/ml)
0.57 **
0.54 **
** p<0.05. * p<0.01.
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Patients who were classified as responsive to a mist of
ultrasonically nebulised distilled water, ( a PD20 USDW of less than
2ml water), had more severe airflow obstruction and were more
responsive to inhaled histamine than the remaining 35 patients
unresposive to the mist (table 10.3.).
Of the 49 patients who had bronchial responsiveness to
ultrasonically nebulised distilled water measured, eleven showed a
response to inhaled beclomethasone as defined (an improvement in
FEV1, FVC or mean PEF of at least 20% compared to baseline
values). There was no difference in the response rate to inhaled
beclomethasone in the two ultrasonically nebulised distilled water
response groups (figure 10.2.).
The correlation between the change in FEV1, FVC and mean
PEF from baseline, after inhaled beclomethasone, and PD20 USDW
was poor (table 10.4.). No statistically significant associations were
seen.
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Table 10.3. The baseline characteristics of the two ultrasonically
























































skin tests (%) 2(14) 10 (29)




Figure 10.2. The percentage of patients in each ultrasonically
nebulised distilled water response group showing a response to
inhaled beclomethasone after the first active treatment phase.
Table 10.4. Spearman rank correlation coefficients between PD20
USDW and the change in FEV1, FVC and mean PEF from
baseline after treatment with inhaled beclomethasone from the









10.2.2. Prediction of response to inhaled beclomethasone
dipropionate.
The differences in baseline characteristics between the 33
patients classified as responders to inhaled beclomethasone after the
first active treatment phase and the non responders are tabulated in
tables 10.5 to 10.8. Response to inhaled beclomethasone was defined
as an increase in FEV1, FVC or mean PEF of at least 20% compared
to baseline values.
Responders to inhaled beclomethasone had significantly
greater airflow obstruction as measured by FEV1, more
hyperinflation of the lungs as indicated by the raised functional
residual capacity, residual volume and total lung capacity. There
were no significant differences in measures of allergy, ie; skin test
reactivity or serum IgE level, between the inhaled beclomethasone
response groups. Similarly the answers to selected questions from
the baseline respiratory symptom questionnaire showed no
difference between the two response groups.
Correlations between baseline physiological variables and the
absolute change, from baseline values, in FEV1, FVC, and mean PEF
after three weeks treatment with inhaled beclomethasone are shown
in table 10.9.. The correlations were of a low order, and in most cases
failed to reach conventional levels of statistical significance.
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Table 10.5. Baseline spirometric measurements, peak expiratory
flow variability, reversibility of FEV1, and bronchial
responsiveness to inhaled histamine and ultrasonically nebulised
distilled water in the two beclomethasone response groups. As
mean (95% CI) unless indicated.
Non Responders Responders
Number (female) 65 (17) 33 (12)




































histamine (umol) 0.59 0.40
Geometric mean PD20
USDW (ml H20) 4.95 4.26
* p<0.05 by unpaired t test.
Values for FEV1, FVC, and FEV1/FVC ratio are the mean of the three
baseline measurements.
For definition of indices of reversibility and diurnal variation see Methods.
161
Table 10.6. Results of static lung volumes and carbon monoxide






































* p<0.05 by unpaired Student t test.
Values for carbon monoxide gas transfer (TLCO) and the KCO carbon
monoxide gas transfer coefficient (KCO) are the mean of the two baseline
values.
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Table 10.7. Details of markers of allergy, and smoking history of






WCC (xl09/l) 7.7 (7.2-8.2) 7.7 (7.1-8.3)
Eosinophil
count (xl09/l) 0.12(0.08-0.16) 0.17 (0.12-0.22)
Geometric mean
serum IgE (ku/1) 83 55
Number with positive
skin tests (%) 15 (23) 5 (33)
Cigarette consumption
(pack years) 52 (44-61) 42 (32-51)







WCC- peripheral white blood cell count.
No significant differences between groups.
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Table 10.8. Answers to selected questions from the baseline
respiratory symptom questionnaire in the two inhaled
beciomethasone response groups. Expressed as the number (% of
response group) giving a positive answer unless indicated
otherwise.
Non Responders Responders














Are you worse in any one
season than another ? 34 (54) 12 (36)
Ever wheezy or whistling ?
(question 15) 57 (88) 29 (88)
Possible 'asthma'
(questions 16 & 17) 23 (35) 10 (30)
Prolonged morning chest
tightness (> 60 minutes)
(question 23 & 24) 16 (25) 6(18)
Bronchial irritability 28 (43) 11 (33)
Positive answers to














For definition of possible 'asthma', bronchial irritability, and breathlessness
scores see Methods.
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Table 10.9. Correlation coefficients between various baseline
physiological variables and the change from baseline in FEV1,















Diurnal variation in PEF
as % mean







logPD20 -0.20 -0.20 -0.01
PC20 to ultrasonically nebulised
distilled water -0.11 -0.02 -0.05
loglOlgE -0.03 -0.13 -0.03
Pack years 0.01 0.10 -0.23*
TLCO -0.12 -0.27** 0.08
* p<0.05, ** p<0.01.
Pearson correlation coefficients are shown for all except PC20 to
ultrasonically nebulised distilled water, where Spearman's rho is given.
logPD20 = bronchial responsiveness to inhaled histamine by the method of
Yan.
Pack years = cigarette consumption.
TLCO = carbon monoxide gas transfer.
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A discriminant function to predict response to inhaled
beclomethasone was derived using the database from a previous
study(95). The baseline characteristics of this patient group are given
in table 10.10.
Table 10.10. Baseline characteristics of the patients from the
earlier study(95), used to develop the discriminant function. As
mean (SEM) unless indicated.
Number (females) 107 (25)












Mean PEF (% predicted) 52(1.7)
















(pack yrs) 38 (2.6)
Serum IgE (ku/1)
as geometric mean (range) 74 (3-4500)
Skin test positive (no [%]) 46 (43)
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Exploratory analyses were performed to assess the possible
significance of various variables, and finally the following variables
were selected from which to define a discriminant function.
1. age (years);
2. sex ( as a dichotomous variable);
3. FEV1 (in litres);
4. FVC (in litres);
5. KCO -the carbon monoxide gas transfer coefficient (as
percentage of the predicted value);
6. TLC -total lung capacity (as percentage of the predicted value);
7. RV -residual volume (as percentage of the predicted value);
8. PEF diurnal variation as a percentage of the mean PEF;
9. FEV1 reversibility to 200 meg salbutamol, expressed as
percentage of the predicted FEV1 value (% pred);
10. PC20 histamine, entered after logarithmic transformation;
11. Serum IGE level, entered after logarithmic transformation;
12. Skin test reactivity, 0=negative, l=positive;
13. Smoking status, entered as two variables, variable 1
1 = current and ex smoker, 0=never smoker; variable 2
1 = current smoker, 0=ex and never smokers.
14. Answer to the question 'Do you wheeze on going form warm to
cold air ?' 0=no, 1 =yes.
15. Answers to the questions 'Have you ever had attacks of
shortness of breath with wheezing ?', and 'Was your breathing
absolutely normal between attacks ?' (asthma?) 1 =positive
answers to both questions, 0= either question answered no.
Seventy three of the 107 cases had complete data and were
used in defining the discriminant function. The final function
correctly classified 65% of the cases. The discriminant function
derived was,
(0.056 x age) + (0.67 x loglgE) + (1.06 x smoking [variable 2])
-(0.98 x sex) -(0.39x asthma) -(0. 75 x skin test)-3. 64.
(Scores of less than zero indicated non responders to inhaled
beclomethasone, above zero responders).
The other variables, including all physiological variables
used, did not significantly improve the prediction of corticosteroid
response in this patients group.
This discriminant function was used to predict response to 3
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weeks treatment with inhaled beclomethasone in the current patient
cohort. Unfortunately the function proved to be a poor discriminator.
Although only six of the 33 actual responders to inhaled
beclomethasone were not identified correctly by the discriminant
function, 55 of the 65 patients who showed no response to inhaled
beclomethasone were assigned to the response group by the
discriminant function.
The data generated by the current study was then used to
define a second discriminant function to predict response to inhaled
beclomethasone. For this exercise analyses were carried out using
various combinations of the baseline variables. In all analyses
bronchial responsiveness to ultrasonically nebulised distilled water
did not enter the final predictor equation.
The 'best' equation obtained was
(0.012 x pack years) + (1.01 x smoking variable 2) + (0.057x
FVC) + (0.073 x SVC) + (0.075 x RV) + (0. 72 x bronchial
irritability) -(3.56x smoking variable 1) -(0.18 x TLC) -(0.027x
FRC) +3.29.
(Scores of less than zero indicated non responders to inhaled
beclomethasone, above zero responders).
Where ;
pack years = cigarette consumption,
smoking status entered as above,
FVC, TLC, SVC, FRC, RV are entered as percentage of predicted
values,
bronchial irritability as defined above (page 65).
This discriminant correctly classified 74% of the patient
population from which it was derived. If only patients scoring over 1
were given a 'trial of steroids', only 38 patients would be tested. Of
these 23 would respond to inhaled beclomethasone, but 10 inhaled
beclomethasone responders would not be offered a 'trial of steroids'.
168
10.3. DISCUSSION.
a. Bronchial responsiveness to ultrasonically nebulised distilled
water.
Bronchial responsiveness to ultrasonically nebulised distilled
water has been investigated fairly extensively in asthma, but there
has been little published work on the response of the bronchi in
patients with chronic airflow obstruction to the same stimulus.
The characteristics of bronchial responsiveness to hypotonic
and hypertonic aerosols in asthma has been reviewed by
Anderson( 120,222). The test appears to be reproducible over
time(223), but is less sensitive than metacholine challenge testing in
detecting asthma. In 89 patients with symptoms of asthma, 11 had a
PD20 USDW of over 15ml water whereas all patients showed
bronchial hyperresponsiveness to inhaled metacholine within the
asthmatic range(223). Significant correlations were seen in this study
and another(224) between bronchial responsiveness to metacholine
and ultrasonically nebulised distilled water.
It has been suggested that bronchial hyperresponsiveness to
ultrasonically nebulised distilled water is specific for asthma. Whilst
it is possible to induce bronchoconstriction in normal subjects to
either histamine or metacholine provided a large enough dose is
given(107), it is unusual to see a response to ultrasonically nebulised
distilled water in normal subjects. Anderson's study failed to elicit a
response in 12 normal subjects(224), and in a larger study only 1 of
26 normal or 'allergic' subjects reacted to ultrasonically nebulised
distilled water(225).
The response to ultrasonically nebulised distilled water in
asthma is blocked by sodium cromoglycate, and shows
tachyphylaxis(223), suggesting the mechanism involved is not a direct
action on bronchial smooth muscle. After bronchoconstriction
induced by ultrasonically nebulised distilled water plasma histamine
levels increase, and the neutrophil chemotactic activity of serum is
enhanced(226). In addition, in asthmatics challenge of isolated
airway segments with hypotonic solutions results in the release of
mast cell mediators(227), suggesting the main effect of such
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challenges is via the mast cell population of the bronchi.
Although bronchial hyperresponsiveness to ultrasonically
nebulised distilled water has been claimed to be specific to asthma,
there are reports of bronchoconstriction in response to hypo- and
hypertonic aerosols in patients with non asthmatic chronic airflow
obstruction. These reports suffer from poor patient characterisation,
and use challenge methods which are cruder than that developed by
Anderson, but there appears to be no doubt that ultrasonically
nebulised distilled water can induce bronchoconstriction in patients
with airflow obstruction not due to asthma. Cheney and Butler
showed an increase in airways resistance in ten patients with chronic
bronchitis after inhalation of mists of distilled water, half normal
saline, and normal saline(228). Another study in thirty patients with
chronic bronchitis and airflow obstruction showed a hypotonic
solution, 0.45% sodium chloride, caused a fall in FEV1 and FVC, and
in some patients a fall in arterial blood gas tensions(229). A further
study confirmed the changes seen in arterial blood gas tensions, on
this occasion after nebulisation of normal saline(230). Other workers
found an increase in airway resistance and a fall in FEV1 following
inhalation of ultrasonically nebulised distilled water in patients with
chronic airflow obstruction(231). More recently Anderson et al have
confirmed that a proportion of patients with chronic airflow
obstruction not due to asthma do show bronchoconstriction after
inhalation of non isotonic solutions(232).
Our results confirm that some patients with chronic airflow
obstruction, not clinically asthmatic, develop bronchoconstriction in
response to the inhalation of ultrasonically nebulised distilled water.
In our group the proportion in whom the FEV1 falls by at least 20%
is higher (77%) than that seen in Anderson's study (65%)(233). A
moderate, albeit statistically significant, correlation was seen
between bronchial responsiveness to the osmotic stimulus and that
measured to inhaled histamine, by either of the methods used. The
degree of correlation was similar to that seen in asthma between
ultrasonically nebulised distilled water and metacholine by
Anderson's group (r=0.6)(223), and in Hopp et al's study
(r=0.62) (226).
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Although a high percentage of the study group reacted to
ultrasonically nebulised distilled water, it is possible that bronchial
hyperresponsiveness to ultrasonically nebulised distilled water is an
indicator of 'asthmatic' airflow obstruction. However our results do
not support this. The correlation between diurnal variation in PEF,
and FEV1 reversibility to beta 2 agonists, often considered markers
of and used to define asthma, was poor. The strongest correlation
was between the degree of airflow obstruction, as measured by the
FEV1, and bronchial responsiveness to ultrasonically nebulised
distilled water. This suggests that in the patients studied the
strongest determinant of an individuals response to ultrasonically
nebulised distilled water are geometric factors, as appears to be the
case with responsiveness to inhaled histamine.
In addition if as many authorities believe a response to
inhaled beclomethasone over the three week treatment period
indicates a predominantly 'asthmatic' element to the airflow
obstruction, then patients who show bronchial hyperresponsiveness
to ultrasonically nebulised distilled water should show a greater
response to treatment with the inhaled corticosteroid. However this
was not found to be the case. The response rate to inhaled
beclomethasone in the two 'mist' response groups was similar, and
the correlation between PD20 to ultrasonically nebulised distilled
water and the change in FEV1, FVC or mean PEF after treatment
was poor. Hence the hypothesis that bronchial responsiveness to
ultrasonically nebulised distilled water could be used to select
patients more likely to respond to corticosteroids is not supported by
this study.
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b. Prediction of response to inhaled beclomethasone dipropionate.
It was not possible to predict response to inhaled
beclomethasone in this group of patients. Both a simple comparison
of physiological variables and symptoms, and the more complex
discriminant analysis were unable to satisfactorily separate
responders to inhaled beclomethasone from non responders.
Other studies have also attempted to identify features which
may indicate a likely response to corticosteroids, but only the study
of Harding and Freedman(lOO), used an inhaled corticosteroid as the
treatment. They reported that patients with eosinophilia in the
peripheral blood were more likely to show a response to
corticosteroids, but found no effect of a personal or family history of
allergy, skin test reactivity, or bronchodilator responsiveness on
steroid responsiveness. The features considered by other authors,
and the results are tabulated below in table 10.11..
The results of this study indicate that responders to inhaled
beclomethasone had more severe disease, as indicated by a lower
FEV1, a reduced FEV1/FVC ratio, and increased static lung
volumes. The inverse association between the starting level of FEV1,
and the response rate to corticosteroids has been commented upon
before(85). The likeliest explanation is that most studies, as the
current one, have used percentage change in FEV1 to define response
to treatment. This means that patients with more severe airflow
obstruction need show a smaller absolute increase in the variable
after treatment to be classed as a responder, and hence these
patients are preferentially selected for the response group.
Peak flow variability, measured as the diurnal variation in
PEF, and reversibility of airflow obstruction are often used to define
asthma(182,183). In this study the two inhaled beclomethasone
response groups showed similar levels of variability in PEF.
Although responders did show greater FEV1 reversibility, the
difference did not reach statistical significance because of the wide
range of values seen. This criteria would not reliably separate
response groups.
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Table 10.11. Studies showing positive or negative associations
between various features and steroid response. Studies indicated
by reference number.
Positive Negative
Bronchodilator response 88,89,91. 66,74,83,
90,95,100.
Blood eosinophilia 71,100. 88,89,90,
92.
Sputum eosinophilia 88. 89,90,92.
Family or personal history
of allergic disease 69,71. 81,92,100.
Positive skin tests 71. 90,92,100.
Increased serum IgE level - 90,92.
Reduced TLCO - 91.
Bronchial hyperresponsiveness
to histamine - 74.
TLCO carbon monoxide gas transfer.
Bronchial hyperresponsiveness to inhaled histamine is
present in both asthma and chronic airflow obstruction, where it
probably reflects different underlying pathogenic mechanisms.
Bronchial responsiveness to inhaled histamine or ultrasonically
nebulised distilled water was not different between inhaled
beclomethasone response groups.
Allergic features have previously been suggested as indicative
of response to corticosteroids. In this study this was not the case.
Although the responders to inhaled beclomethasone had a higher
blood eosinophil count, there was a wide overlap between the two
inhaled beclomethasone response groups. Non responders showed a
slightly higher serum IgE level, the percentage of each response
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group with positive skin tests was comparable, and similar numbers
reported a history of allergic disease. Despite previous reports
allergic features did not predict response to corticosteroids in this
study.
It is of interest that the discriminant function derived from
the database of the earlier study included three variables which may
reflect underlying allergy, ie;serum IgE level, skin test reactivity, and
attacks of wheezing with normal breathing in between attacks. The
lack of any difference between response groups in these variables in
the present study probably explains the poor predictive value of the
discriminant function derived. The population from which the
discriminant function was derived had more skin test reactors, and a
higher mean serum IgE level, and had smoked less than the current
study population. This suggests the population may have
inadvertently included missed asthmatics, and hence the
discriminant function may only be applicable to a similar patient
population. It also suggests that previous studies which have shown
'asthmatic' features to be predictive of a response to corticosteroids
have probably also included some undiagnosed asthmatics in the
population studied.
Mortagy et al suggested that the presence of their bronchial
irritability syndrome should alert the clinician to the possible
benefits of treatment with corticosteroids(165). The results from my
study suggest that in this group of patients the presence of bronchial
irritability as defined dose not relate to response inhaled
beclomethasone. The percentage of patients with this syndrome was
similar in the two inhaled beclomethasone response groups. The
answers to other questions did not reliably distinguish between the
response groups either.
Bronchial irritability was one of the variables included in the
second discriminant function derived from the current study
database. The remaining variables included described either
smoking status, or physiological measures. The final function only
predicted three quarters of responders and non responders correctly.
If used to select patients for a 'trial of steroids' nearly one third of
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inhaled beclomethasone responders would not be identified. If
applied to another population it is likely the ability of the
discriminant function to predict inhaled beclomethasone response
group would be less. The clinical usefulness of such a function is
poor, but the difficulty obtaining an adequate function does illustrate
the heterogeneous nature of the disease. It is probable that
identification of short term response to corticosteroids will always
require an empirical trial in all patients. The usefulness of
identifying short term response to corticosteroids however is
increasingly being questioned(234) (vide infra).
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11. SIDE EFFECTS OF TREATMENT:
A.HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
SUPPRESSION.
B. LOCAL ORO PHARYNGEAL EFFECTS -CANDIDIASIS
-DYSPHONIA.
11.1. ANALYSIS.
The effect of treatment with inhaled beclomethasone and oral
prednisolone on tests of hypothalamic-pituitary-adrenal (HPA) axis
function has been assessed by analysing the change in;
(a) the unstimulated pre tetracosactrin serum Cortisol,
(b) the stimulated post tetracosactrin Cortisol, and
(c) the increment in serum Cortisol following tetracosactrin,
(d) and the 24 hour urinary free Cortisol measurement.
Although because of practical difficulties the timing of sample
collection for the unstimulated Cortisol was not standardised
between patients, for individual patients the samples were collected
at the same time of the day, hence a within patients assessment of
effect of treatment is appropriate. Unfortunately interference from
metabolites of prednisolone in the assay for urinary free Cortisol, an
unexpected problem, meant that urinary free cortsiol measurements
measured after the oral prednisolone phase gave unreliable
estimates of Cortisol excretion, and this data has not been analysed.
A repeated measures analysis of variance, with dose of inhaled
beclomethasone entered as a factor, was used to assess the effect of
inhaled beclomethasone on the above parameters, and to look for
any difference between the effect of the two dose of inhaled
beclomethasone used. For the effect of the final phase of treatment
on measures of HPA axis function, a paired t test was used to
compare the values obtained after three weeks treatment with
inhaled beclomethasone alone, to that measured after the final
treatment phase, when two thirds of patients received oral
prednisolone in addition to inhaled beclomethasone.
In addition the results of individual tests on patients were
classified into 'passes' or 'failures' using predetermined criteria.
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Both the post tetracosactrin serum Cortisol and the increment in
serum Cortisol following tetracosactrin were used in this analysis.
The criteria used were a post tetracosactrin serum Cortisol level
greater than 550 nmol/1, and an increment in serum Cortisol at 30
minutes following injection of tetracosactrin of greater than
200nmol/l. The number of individuals failing each test after each
active treatment was compared using a chi squared test, or a
McNemar test as appropriate.
For the analysis of the oral Candida scores, the number of
patients with visible candidiasis, was compared with the number
without visible Candida, that is scores 0 to 2, and 3 and 4 were
combined into two categories. The comparisons between scores on
placebo and after inhaled beclomethasone, and between scores after
the first three weeks of inhaled beclomethasone and those after the
second active treatment phase in individual patients were carried out
using McNemar's test. Differences in scores between the two
beclomethasone dose groups after inhaled beclomethasone, and after
the final treatment phase between those patients receiving oral
prednisolone and those continuing on inhaled beclomethasone alone,
were assessed by using a chi squared test. For the dysphonia scores a




11.2.1. HPA axis function.
a. Data collection.
A number of patients declined to undergo venepuncture for
the estimation of serum Cortisol on each trial visit. As this was not
the primary objective of the study these patients were allowed to
continue in the remainder of the study. Two patients suffered
vasovagal reactions following the slow intravenous injection of
tetracosactrin and this test was not repeated in these two
individuals.
Ninety eight patients had unstimulated Cortisol values
available for analysis at baseline and after inhaled beclomethasone.
Post tetracosactrin levels were available after both phases in 87
patients, and urinary free Cortisol measurements in 89 individuals.
After the final treatment phase unstimulated serum Cortisol
levels were available in 32 of the 33 patients who received inhaled
beclomethasone only for this phase, and post tetracosactrin Cortisol
were measured in 28 of these patients. Urinary free Cortisol levels
were available in 29 of the patients receiving inhaled beclomethasone
alone as the final treatment. In the patients receiving oral
prednisolone in addition to inhaled beclomethasone, for the final
treatment phase unstimulated serum Cortisol levels were measured
in 58 of the 65 patients, post tetracosactrin levels in 52 patients, and
the urinary free Cortisol estimations were not analysed because of
interference in the assay.
b. The effect of inhaled beclomethasone.
There was no detectable effect of treatment with inhaled
beclomethasone on unstimulated serum Cortisol levels (table 11.1.).
However the three other indices of HPA axis function showed
significant suppression after treatment for three weeks with inhaled
beclomethasone. The effect of the higher dose of inhaled
beclomethasone was significantly greater for the post tetracosactrin
Cortisol and the increment in serum Cortisol. Urinary free Cortisol
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levels were suppressed to a greater extent in the higher BDP dose
group, but not significantly so. For the increment in serum Cortisol
following tetracosactrin, the effect of treatment in the 750mcg b.d.
group was not statistically significant when assessed by a paired
Student t test.
A further three weeks treatment with inhaled beclomethasone
alone during the final treatment phase produced no further evidence
of HPA axis suppression (table 11.2.).
The change from baseline after three weeks treatment with
inhaled beclomethasone in unstimulated and post tetracosactrin
serum Cortisol levels is shown in figure 11.1..
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Table 11.1. The mean (95 % confidence limits for mean) for the
results of the tests of HPA function, at baseline and after three








Treatment effect F-ratio=1.83, DF = l,ns.
Interaction F-ratio=0.12, DF= l,ns.
Stimulated Cortisol.




Treatment effect F-ratio=38.9,DF = l,p<0.0001.






Treatment effect F-ratio=24.5, DF = l,p<0.0001.
Interaction F-ratio=9.33, DF= l,p<0.004.
Urinary free Cortisol.
750mcg b.d.(n=41) 167 (138-195)
1500mcg b.d.(n=48) 152 (131-172)
134 (112-156)
90 (76-103)
Treatment effect F-ratio=33.5, DF= l,p<0.0001.
Interaction F-ratio=3.05, DF=l,p=0.08.
Unstimulated Cortisol- pre tetracosactrin injection.
Stimulated Cortisol- post tetracosactrin injection.
Increment- difference between stimulated and unstimulated levels.
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Table 11.2. The mean values (95% CI) and the mean difference
(95% CI) between values at three and six weeks, for the four tests
of HPA function, in the patients who received beclomethasone
alone for the final treatment phase, for the two BDP dose groups.
3 weeks 6 weeks
Unstimulated Cortisol.
750mcg b.d.(n = 16) 332 (274 to 389) 338 (276 to 400)
(mean difference -6.3 (-60 to 48), ns.)
1500mcg b.d.(n = 16) 332 (263 to 402) 334 (233 to 435)
(mean difference -1.25 (-105 to 102), ns.)
Stimulated Cortisol.
750mcg b.d.(n= 14) 806 (724 to 888) 791 (691 to 890)
(mean difference 15.3 (-78 to 108), ns.)
1500mcg b.d.(n = 14) 684 (589 to 780) 719 (600 to 837)
(mean difference -34 (-142 to 73), ns.)
Cortisol increment.
750mcg b.d.(n= 14) 469 (413 to 525) 438 (329 to 547)
(mean difference 31.6 (-73 to 136), ns.)
1500mcg b.d.(n = 14) 358 (262 to 454) 358 (265 to 451)
(mean difference 0.2 (-65 to 66), ns.)
Urinary free Cortisol.
750mcg b.d.(n = 13) 157 (114 to 200) 174 (113 to 235)
(mean difference -17 (-74 to 39), ns.)
1500mcg b.d.(n = 16) 85 (58 to 112) 110 (78 to 141)








750mcg b.d. 1500mcg b.d.
400
200














750mcg b.d. 1500mcg b.d.
Figure 11.1. The change from baseline values of both
unstimulated, and post tetracosactrin serum Cortisol levels for
the two BDP dose groups, after the first three weeks treatment.
Error bars show the mean change and 95 % confidence limits for
the mean.
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At baseline one patient in the 750 meg b.d. group had an
increment in serum Cortisol post tetracosactrin of less than 200
nmol/1, and 2 patients in the 1500 meg b.d. group had post
tetracosactrin serum Cortisol levels less than 550 nmol/1. However
when 'failure' was assessed on the results of both tests, no patient
failed both test at baseline.
After inhaled beclomethasone for three weeks the absolute
level of serum Cortisol post tetracosactrin was above 550nmol/l in all
of the patients in the lower dose group, but was below this level in 7
of the 44 patients receiving 1500mcg b.d. ( chi squared=7.26, DF=1,
p=0.007). The increment 'test' was failed by one patient in the 750
meg b.d. dose group, and by 5 in the higher dose group (chi
squared=2.67, DF= 1, ns). However when the results of both tests
were combined no patient in the 750 meg b.d. group failed, and only
one of the 44 patients receiving 1500mcg b.d..
In the 28 patients who received inhaled beclomethasone alone
for the final treatment phase, there was no significant difference
between the dose groups for the number of patients failing the tests
of HPA function. The number of patients failing each 'test' were -
post tetracosactrin Cortisol; 750mcg b.d. group 1/14, 1500mcg b.d.
group 4/14 (chi squared=2.19,ns): - Cortisol increment post
tetracosactrin; 750mcg b.d. group 2/14, 1500mcg b.d. group 2/14:
both tests combined; 750mcg b.d. group 1/14, 1500mcg b.d. group
2/14.
c. The effect oforal prednisolone.
Three weeks treatment with oral prednisolone 40 mg per day
in addition to inhaled beclomethasone, produced a significant fall in
all three parameters of HPA axis function measured (table 11.3.).
The number of patients 'failing' each of the tests of HPA axis
function increased after the addition of oral prednisolone to the
treatment regime. In the patients receiving inhaled beclomethasone
at a dose of 750mcg b.d., 20 of the 23 patients had a post
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tetracosactrin serum Cortisol of less than 550 nmol/1, in twelve the
increment was less than the normal 200nmol/l, and when both tests
were combined 11 patients failed this assessment of HPA axis
function.
Table 11.3. The mean (95% CI) values for the measures of HPA
axis function after three weeks treatment with BDP, and a
further three weeks combined treatment with oral prednisolone
and BDP, in those patients treated with oral prednisolone during




750mcg b.d.(n=26) 386 (324-447) 208 (136-280)
(mean difference -178 (-100 to -256), p<0.001)
1500mcg b.d.(n=32) 320 (260-380) 165 (113-216)
(mean difference -155 (-80 to -231), p<0.0001)
Stimulated Cortisol.
750mcg b.d.(n=23) 820(763-877) 403 (307-498)
(mean difference -418 (-332 to -504), p<0.0001)
1500mcg b.d.(n=29) 705 (635-775) 431 (336-526)
(mean difference -274 (-182 to -366), p<0.0001)
Cortisol increment.
750mcg b.d.(n=23) 425 (380-469) 221 (179-263)
(mean difference -204 (-151 to -256), p<0.0001)
1500mcg b.d.(n=29) 393 (340-447) 279 (225-333)
(mean difference -115 (-58 to -173, p< 0.001)
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For the 29 patients receiving 1500mcg b.d. 22 had post
tetracosactrin serum Cortisol levels of less than 550 nmol/1, and 11
had an increment of less than 200 nmol/1. When the results of both
tests were combined 11 of the 29 patients failed the tests of HPA axis
function.
To try to determine the relative effect of oral prednisolone
and inhaled beclomethasone on HPA axis function, the change
between baseline and post treatment stimulated Cortisol levels was
compared in the patients receiving oral prednisolone and inhaled
beclomethasone for the final treatment phase. The mean change
(95% CI) in the 23 patients in the low BDP dose group after inhaled
beclomethasone alone for three weeks was -43 (-114 to 28) nmol/1,
and after the addition of oral prednisolone to the regime was -465 (
-557 to -372) nmol/1. In the higher dose group the corresponding
figures were, after BDP alone -118 (-167 to -70) nmol/1, and after
both BDP and oral prednisolone -418 (-340 to -495) nmol/1.
Hence oral prednisolone 40 mg per day for three weeks in
combination with inhaled beclomethasone appears to cause
approximately ten times the suppression of the HPA axis as three
weeks treatment with inhaled beclomethasone 750 meg b.d. alone,
and four times that caused by 1500 meg b.d. alone.
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11.2.2. Local side effects.
a. Oro-pharyngeal candidiasis.
For this analysis scores from the five point scale used (page
50) were combined to separate patients into those with visible oro¬
pharyngeal candidiasis (scores 3 and 4), and those with no visible
candidiasis (scores 0 to 2).
After three weeks treatment with inhaled beclomethasone
one patient (2%) receiving 750mcg b.d. BDP had evidence of oral
candidiasis, compared to 5 (9.8%) in the higher dose group. This
difference was not statistically significant (chi squared — 1.35,ns).
Therefore both doses were combined to assess the effect of inhaled
BDP on the incidence of oral Candida. After placebo no patients had
evidence of candidiasis, whereas 6 had visible candidiasis after
inhaled BDP (McNemar test p<0.05).
Of the patients receiving both inhaled beclomethasone and
oral prednisolone for the final treatment phase, 24% had visible oral
Candida, compared to 3% of the patients continuing on inhaled
beclomethasone alone (chi squared = 5.4, p<0.04). Of the 15
patients with oro-pharngeal candidiasis taking both oral
prednisolone and inhaled beclomethasone during the final
treatment, only 2 had evidence of this problem after three weeks
treatment with inhaled beclomethasone alone (McNenar test
p< 0.003).
b. Dysphonia.
After three weeks treatment with inhaled beclomethasone
only 2 patients, in the lower inhaled beclomethasone dose group
complained of severe hoarseness of the voice. The distribution of
dysphonia scores is shown in table 11.4.. There was no significant
difference in the distribution of scores between the two inhaled
beclomethasone dose groups after three weeks of active treatment
(Mann Whitney U test Z = -0.13, n= 98, ns), and within each dose
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group no detectable difference in scores between placebo therapy
and inhaled beclomethasone ( 750mcg b.d. group; Z = -1.33,
n=47,ns: 1500mcg b.d. group; Z = -0.6, n=54,ns).
Table 11.4. Distribution of dysphonia scores after placebo and
inhaled beclomethasone in the two BDP dose groups, as
percentage of each dose group.
Dysphonia scores
BDP dose Placebo BDP
0 1 2 3 0 1 2 3
750 meg b.d. 85 15 0 0 85 7 4 4
1500 meg b.d. OOOO00 4 0 78 22 0 0
There was no detectable difference in the distribution of
dysphonia scores after the final treatment phase between the
patients continuing on inhaled beclomethasone alone, and those
receiving both oral prednisolone and inhaled beclomethasone as the
final treatment ( Mann Whitney U test Z = -0.13, n= 93, ns). The
distributions are tabulated in table 11.5..
Table 11.5. Distribution of dysphonia scores after the final
treatment phase in the two treatment groups, as percentage of
each treatment group.
Treatment group.







It is well recognised that inhaled corticosteroids are much
safer than oral corticosteroids, and in asthma equivalent therapeutic
efficiency can be achieved with much less evidence of systemic side
effects(34). However at higher doses both the systemic and local side
effects may be significant and limit the usefulness of such therapy.
This part of the study aimed to address this question, and the results
show no significant adrenal suppression with the lower dose of
inhaled beclomethasone used, and a very low frequency of local side
effects with either dose. Inhaled beclomethasone at a dose of
1500mcg b.d. did produce detectable and probably significant
adrenal suppression, but this was still less than that seen after oral
prednisolone.
Systemic side effects described after treatment with inhaled
beclomethasone include suppression of the HPA axis(235,236),
changes in calcium and phosphate metabolism (221,222,237) purpura
and reduced skin thickness(238), and increases in the levels of
cholesterol and insulin in serum(239). In addition inhaled
corticosteroid therapy has been implicated in the development of
posterior subcapsular cataracts in the eye(240). Local side effects are
oro-pharnygeal candidiasis, and dysphonia(241), and rarely patients
experience marked cough and bronchospasm after inhalation of
beclomethasone, the cause of which is not clear(242).
The results of this study do show adrenal suppression with
both doses of inhaled beclomethasone when judged by the change in
mean values. However the degree of suppression after three weeks
treatment was not great. For unstimulated Cortisol the mean values
fell by 6.6% in the 750mcg b.d. group and 4.6% in the 1500mcg b.d.
group. For the increment in serum Cortisol following tetracosactrin
the decrease was 6.8% and 27% respectively, and for urinary free
Cortisol 20% and 40%. In previous studies in normal volunteers
treatment with 2000 micrograms per day inhaled beclomethasone
depressed basal Cortisol levels by 15%, and 4000 micrograms per day
by 50% of pre treatment levels(243). The mean post tetracosactrin
Cortisol levels for both inhaled beclomethasone dose groups seen in
my study were well above the lower cut off for a normal response.
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This suggests that the adrenal suppression caused by the treatment
regimes used is relatively minor.
However when assessed on an individual basis adrenal
suppression appears to be more of a problem, especially with the
higher dose of inhaled beclomethasone, on which 15% of patients
had a stimulated cortsiol level lower than the 'pass' level. This
measure is probably the best indicator of adrenal suppression,
although many endocrinologists include the Cortisol increment in
assessing the HPA axis(244). As a negative correlation has been
reported between the increment in serum Cortisol and the starting
level of serum Cortisol, an association which was also apparent in
this study (r= -0.43), patients with high basal Cortisol levels may 'fail'
if undue weight is given to the increment in Cortisol.
When a more classical approach to the definition of adrenal
suppression in individuals is followed, that is the use of both
measures(245), then only one patient failed the assessment of HPA
axis short term reserve. Although clinically high dose inhaled
corticosteroid therapy does not appear to cause Addisonian
problems, it would probably be wise if patients receiving doses in
excess of 1500 micrograms per day of inhaled beclomethasone
carried steroid warning cards, and in times of prolonged
physiological stress, such as trauma or surgery received additional
systemic steroids.
The urinary free Cortisol results showed the greatest degree of
suppression with the higher dose of inhaled beclomethasone.
Although there are problems in ensuring a complete 24 hour
collection in outpatients, there would be no reason to suppose that
these problems would be different at the three stages of the trial.
Hence the comparison within patients of the change with active
treatment seems to be valid. As the 24 hour urinary free Cortisol
measurement reflects adrenal secretion of Cortisol over a whole day,
it may provide different information to that obtained by
tetracosactrin tests, and may indicate that the ability of the adrenals
to respond to prolonged stress is impaired(246), and that longer term
treatment will result in more pronounced suppression. Unfortunately
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because of interference by metabolites of prednisolone in the assay
the comparison of suppression of the two doses of inhaled
beclomethasone and oral prednisolone was not possible.
Previous studies have usually examined the effects of high
dose inhaled corticosteroids on adrenal function in normal
volunteers or patients with asthma. Interpretation of the results of
such studies is difficult as normals may well react differently to
patients, and many of the asthmatic patients studied had been or
were taking oral corticosteroids in addition to inhaled
corticosteroids. Studies on normal volunteers indicate no HPA axis
suppression in doses up to 1000 micrograms per day(247), but
adrenal suppression is detectable in normals in doses above 2000
micrograms(244).
In a review of all published studies on patients treated with
inhaled beclomethasone only 25 previous studies were identified in
which patients were not taking any form of corticosteroid prior to the
study(248). Of these only six publications used doses in excess of 1000
micrograms per day(237,249,250,251,252,253). The reviewers suggested
that in general studies showed that doses of inhaled beclomethasone
up to 1200 micrograms per day have no significant effect on HPA
axis function, but in doses above this level adrenal suppression may
be detected. The majority of these studies used treatment periods of
less than 6 weeks, and did not study the effect of longer term
administration of corticosteroids. A recently published study has
shown a correlation between the duration of treatment with inhaled
corticosteroids and the degree of HPA axis suppression(255). In
Smith and Hodson's study patients had been taking inhaled
beclomethasone for 6 to 60 months in doses from 500 to 2000
micrograms per day, and although their results may have been
influenced by short course of oral corticosteroid taken in the
preceding year, they are in broad agreement with the shorter term
studies(34). Adrenal suppression was only apparent in patients
taking more than 1500 micrograms per day of inhaled
beclomethasone.
The patients studied for this thesis had not taken any oral or
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inhaled corticosteroids within three months of recruitment, indeed
most had taken none at all. Despite this difference in patient
characteristics the results are generally similar to the studies quoted
above.
Another point of interest was the marked individual variation
in the susceptibility to adrenal suppression. This has been described
previously(256), and may reflect differences in drug
pharmacokinetics, HPA axis sensitivity, variation in drug deposition
within the lung, and possible differences in compliance. This
individual variability makes broad generalisations about the safety
of high dose inhaled corticosteroids very difficult.
The use of a spacing device to deliver the inhaled drug will
theoretically have reduced the oral deposition of the drug
considerably, and led to less systemic absorption via the
gastrointestinal tract, but greater systemic absorption via the lungs.
The effect of a spacer will therefore depend upon the relative
contribution of each mode of absorption to the systemic levels seen.
This may differ for different inhaled corticosteroids, and
pharmacokinetic differences may partly explain the conflicting
evidence on the effect of spacing devices on HPA axis suppression
with high dose inhaled corticosteroids(255,257). The use of spacers in
this study may account for the low incidence of adrenal suppression
seen in individuals on the higher dose of inhaled beclomethasone.
Although local side effects may not be as serious as adrenal
suppression, they nevertheless may prevent patients from taking
therapy. Toogood et al have previously shown that the frequency of
oropharyngeal candidiasis is increased in patients on inhaled
corticosteroids when oral prednisolone is given concomitantly(258).
However oral corticosteroid therapy had no influence on the
occurrence of dysphonia, a problem which reflects vocal cord
dysfunction, probably a local steroid induced vocal cord
myopathy(259). The results in my group of patients are in
concordance with these earlier observations in asthmatics. In the
patients studied however I did not observe a relationship between the
occurrence of local side effects and the dose of inhaled
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beclomethasone taken. Toogood's group have shown a small dose
effect, at least in the dose range 400 to 1600 micrograms per day of
inhaled beclomethasone(260). The dose effect was more convincing
for oropharyngeal candidiasis, and the patients studied were treated
with oral prednisolone in addition to inhaled beclomethasone. The
use of spacer devices did reduce the occurrence of local side effects
in other studies(242,261). It seems likely that the lack of a detectable
dose effect in terms of local side effects in our study is due to the use
of spacing devices, and possibly because the doses used are at the
plateau range of the dose response relationship. Treatment with oral
prednisolone did increase the occurrence of oro-pharyngeal
candidiasis, so that it appears that systemic steroids augment the
local effect of inhaled corticosteroids.
Another difference between this study and many in the
literature is in the definition of candidiasis. Our definition was
clinically based, that is visible Candida colonies had to be present for
definite candidiasis. Other studies have shown that Candida may be
cultured from the mouth swabs from up to 57 % of normal
subjects(262). Hence interpretation of culture findings is difficult,
and clinically based scoring systems are probably more useful.
There have been few reports of the incidence of oropharyngeal
candidiasis in patients treated with high dose inhaled corticosteroids
that are comparable to the doses used in our study. Most studies
have used up to 800 micrograms per day inhaled beclomethasone.
The results in this study show a lower incidence of candidiasis than
those quoted by Cayton et al, of 77% at a dose of 800 micrograms per
day inhaled beclomethasone, or 45% at 400 micrograms per day(263).
The likeliest reason for this is the diagnostic criteria used, the use of
spacing devices by our patients and perhaps the shorter duration of
treatment.
In summary although systemic side effects from the doses of
inhaled beclomethasone used were detectable, only a minority of
patients showed significant adrenal suppression, less pronounced
with the lower dose of inhaled beclomethasone used. This dose was
as effective as the higher dose in improving lung function and
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symptoms (see chapter 6), so that 750mcg b.d. inhaled
beclomethasone appears to be the best compromise between
therapeutic efficiency and side effects.
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12. THE EFFECT OF INHALED BECLOMETHASONE ON
PERIPHERAL NEUTROPHIL ACTIVATION, SPUTUM
CHEMOTACTIC ACTIVITYAND SPUTUMALBUMIN
CONCENTRATION.
This section of the thesis reports the results of a study on the
effect of treatment with inhaled beclomethasone on peripheral
neutrophil function and bronchial secretions. In particular
(a) peripheral neutrophil chemotaxis to a standard
chemoattractant,
(b) peripheral neutrophil extracellular proteolysis ,
(c) the chemotactic activity of sol phase sputum,





Samples were collected from a subgroup of 24 patients
entered into the main study, who were selected simply because they
attended the laboratory for physiological assessments in the
morning.
The results reported here are limited to the effects of inhaled
therapy alone because of the possible interaction of oral and inhaled
drugs, and the small number of patients from whom samples were
available after oral prednisolone treatment.
12.1.2. Sample collection and processing.
Samples of blood and sputum were collected at the end of the
three week baseline period, on the final day of treatment with
placebo and at the end of beclomethasone therapy. Ten ml of venous
blood was collected into a lithium heparin tube via a 19G needle.
Sputum was collected in a sterile universal container by the patient
from rising on the day of assessment until attendance at the
laboratory 3-4 hours later.
Neutrophils were isolated from peripheral blood by the
method of Jepsen and Skottun(264). Each sample of venous blood
was diluted with an equal volume of 0.15 mmol/1 sodium chloride
solution and carefully layered onto the surface of 2 ml 54% 'Percoll'
(density 1.075g/l) (Pharmacia AB, Uppsala, Sweden) in 0.15 mmol/1
sodium chloride which had been layered onto 3 ml 78% percoll
(density 1.096g/l). The tubes were centrifuged at 200g for 25 minutes
at room temperature. The PMN layer ( at the interface of the two
solutions ) was collected and the cells (more than 96% PMN) were
washed three times in sterile hepes-buffered RPMI 1640 medium
(Flow Labs, Rickmansworth, Herts), counted, and resuspended at
appropriate numbers.
Sputum samples were centrifuged at 50,000g for 90 minutes,
the sol phase removed and stored at -40oC until assayed.
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12.1.3. Chemotaxis assay.
a. Peripheral PMN chemotactic activity.
The chemotactic activity of peripheral blood PMN was
measured by a modification of the technique of Falk et al(265), using
a multiple blind well assay. The lower chamber of each well was filled
with 270ul of 10'8 molar FMLP (N-formyl-L-methionyl-L-leucyl-L-
phenylalanine) dissolved in RPMI medium. The upper chamber was
filled with 380ul of hepes buffered RPMI 1640 containing bovine
serum albumin 2mg/ml, and 1.5 x 10 6 PMN. The chambers were
separated by two membranes, the upper was a polycarbonate
membrane of pore size 2.0 x 10~6m (Nucleopore Corp, Pleasanton,
USA) , the lower was a cellulose acetate membrane of pore size 0.45 x
10"6m (Millipore, Harrow, Middx). Lower control wells contained
medium without FMLP. The chambers were incubated at 37oC for 90
minutes, the Millipore cellulose acetate membranes were collected,
fixed in ethanol, stained with haematoxylin, dehydrated, and
mounted. Membranes were examined at x400 magnification, the
numbers of PMN seen in five random fields was counted, and the
average determined. Each assay was performed in triplicate and the
mean of the 3 membranes was used as a final result for analysis.
b. Sputum chemotactic activity.
Sol phase sputum diluted 1 in 5 with RPMI medium was used
as the chemoattractant in the lower well of the chemotaxis chamber.
Peripheral PMN from healthy control subjects were used as the cell
source, and all sputum samples from an individual assayed
simultaneously against one subjects cells to reduce variability.
12.1.4. Extracellular Degradation of Fibronectin by PMN.
Extracellular proteolytic activity of isolated PMN was
measured as digestion of radiolabeled fibronectin, by the method of
Campbell et al(266). Fibronectin purified from human plasma was
labelled with 1251 labelled sodium iodide (Amersham International,
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Buckingham) by the chloramine-T method. The radiolabeled
fibronectin was diluted with a solution of unlabeled fibronectin in
0.05 mol/1 carbonate/bicarbonate buffer (pH 9.6) to give 2000
cpm/mcg fibronectin. Fibronectin solution ( 0.2ml; 30 meg
fibronectin; 60,000 cpm) was dispensed into microtitre plate wells
('NUNC', Gibco, Paisley, Scotland), the plates were dried at 37oC,
and the wells were washed three times with phosphate-buffered
saline (pH 7.2). Neutrophils (3.0 x 10 5 cells in 0.2 ml RPMI 1640)
from the patients were applied to the microtitre wells and the plates
were incubated for 3 hours at 37oC in a humidified atmosphere of 5 %
carbon dioxide in air. All cell preparations were also assayed for
fibronectin digestion in the presence of 10 ~6molar FMLP. Blank
wells consisted of culture medium only. After incubation the fluid
from each well was collected and centrifuged and the supernatant
was assayed for 1251 with an LKB 'Multigamma' counter as a
measure of solubilised fibronectin. Fibronectin digestion by each cell
preparation was assayed six times and the mean expressed as meg
fibronectin digested in 3 hours by 3 x 10 5 cells, calculated from the
specific activity of the 1251-labelled fibronectin.
All reagents used for neutrophil studies were endotoxin free
(< 20 ng/1) as assessed by the Kabivitrum Coatest (Flow
Laboratories).
12.1.5. Sputum and serum albumin concentrations.
Albumin concentrations in serum and sol phase sputum were
measured in triplicate using standard radial immunodiffusion
techniques with anti-human albumin monospecific antisera
prepared by the Immunodiagnostic Research Laboratory,
University of Birmingham. The mean of the three measurements was
used for the final result for each sample.
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12.2. ANALYSIS.
To examine for a possible beclomethasone dose effect the
change in PMN chemotaxis after active treatment compared to
baseline and placebo was examined in the two dose groups by a
Mann Whitney U test. Changes with treatment for chemotaxis,
fibronectin digestion and sputum albumin concentration were
assessed by a Wilcoxon rank sum test for paired data. For changes
in lung function parameters paired Student t tests were used.
Correlations were assessed using Spearman's rank correlation
coefficient.
12.3. RESULTS.
The chemotactic response of the patients peripheral blood
neutrophils to a standard chemoattractant (FMLP) was measured at
baseline in all 24 patients, but samples were available in only 20
patients after all treatment phases. Of the remaining four patients,
one failed to attend subsequent appointments, one could not tolerate
pressurised inhalers due to coughing, one developed acute bronchitis
with purulent sputum, and the baseline biochemical screen revealed
unsuspected abnormal liver function due to metastatic liver disease
in a further patient who was withdrawn.
The demographic details, cigarette consumption and baseline
lung function of the study group are given in table 12.1. Fourteen of
the twenty patients fulfilled the MRC criteria for chronic bronchitis
as assessed by the questionnaire . However fifteen of the patients
produced regular sputum during the study period as assessed by
diary card scores (data not included). Nineteen patients were current
or ex- smokers. At the time of the study 10 patients were taking
inhaled beta 2 agonists alone, 2 inhaled Ipratropium bromide alone,
and 8 were receiving both drugs. No patient was taking an oral
theophylline preparation.
Fibronectin digestion by PMN was measured in 14 patients at
baseline, but we were unable to repeat these measurements in 4
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patients, three of whom were unable to attend the laboratory at the
appropriate time, and one who withdrew because of coughing due to
the placebo inhalers. Only 8 of 15 patients producing sputum at
enrollment were able to provide sputum samples for analysis at
follow up, although insufficient sample was available from one
further patient to measure sputum albumin concentration.
Before treatment there was no correlation between either
peripheral PMN chemotactic response, or extracellular fibronectin
digestion by PMN and FEV1, FVC, mean PEF, KCO, cigarette
consumption or total peripheral leucocyte count.
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Table 12.1. The baseline characteristics of the 20 patients,
as mean(SEM) unless indicated.
Male (female) 13(7)
Age (years) 66(1.2)
Current smokers (number) 6
Ex smokers 13
Cigarette consumption 43 (8)
as pack years
FEV1 (litres) 1.07 (0.11)
FEV1 (% predicted) 43 (4)
FVC (litres) 2.53 (0.11)
FVC (% predicted) 80 (3)
KCO (mmol min _1 kPa -11 _1) 1.22 (0.08)
KCO (% predicted) 68 (5)
Reversibility in FEV1 to
200mcg Salbutamol
- absolute change (ml) 148 (28.6)
- as % prebronchodilator 16.7(3.84)
- as % predicted FEV 1 6.0(1.2)
PD20 (umol) 0.75
as geometric mean (range) (0.07- >7.8)
Peripheral WCC (x 10 9 /l) 5.16 (0.33)
12.3.1. Lung function.
In the 20 patients there was no significant change in FEV1,
FVC and histamine responsiveness after inhaled beclomethasone.
However mean PEF showed a small but statistically significant
increase with active treatment in these patients (Table 12.2.).
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Table 12.2. Changes in lung function parameters with treatment








2.55 (0.14) 2.55 (0.12)
225 (19) 233 (20) *
Geometric mean PD20
(umol) 0.75 0.73 0.78
*
p < 0.05 for comparison of inhaled BDP with placebo and baseline by paired
Student t test.
12.3.2. Chemotaxis.
a. Peripheral blood PMN chemotaxis.
Nine patients received the lower dose of beclomethasone, and
11 the higher dose of 1500mcg b.d.. Table 3 shows the effect of
treatment on peripheral PMN chemotaxis in the two dose groups.
There was no detectable dose effect seen when the absolute change in
PMN chemotaxis from baseline after beclomethasone was compared
in the two groups (750mcg b.d. group median (range) change [cells
per high power field] -25.2 (-51.1 to 60.4), 1500mcg b.d. group -24.1
(-61.8 to 50.3) Mann Whitney U test z-value= -0.114;ns). Similarly
no dose effect was seen when PMN chemotaxis after placebo and
beclomethasone was compared (750mcg b.d. group change [cells
p.h.f.] 7.8 (-90.2 to 31.8), 1500mcg b.d. group -20.1 (-62.0 to 58.1);
z-value= -1.10:ns). The results for both doses were therefore
combined for the remainder of the analysis.
The chemotactic response of the patients peripheral PMN to
a standard chemoattractant showed a significant fall from baseline
after active treatment (median [range] cells per high power field;
baseline 67.6 [27.6 to 122.1], beclomethasone 48.1 [5.37 to 136.3];
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p<0.01). The average response on placebo therapy (58.8 [22.7 to
123.1]) was not significantly different from baseline or from that
seen on active treatment. The individual values are shown in figure



















































Figure 12.1. Patients peripheral neutrophil chemotactic activity
to a standard stimulus, at baseline, after placebo and BDP. Lines
indicate medians for each dose group.
b. Sputum chemotactic activity.
It was only possible to obtain adequate sputum samples at
each phase of the study from 8 patients. The 'chemotactic' activity of
sputum sol phase to PMN from a healthy control subject was
significantly lower after active treatment than at baseline or
following placebo (cells per high power field; beclomethasone 72.2
[46.1 to 102.2]; baseline 88.5 [65.6 to 124.9] z= -2.38, p<0.02;
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placebo 106.5 [34.6 to 170.6] z= -2.24, p<0.03). Individual results are
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Figure 12.2. Chemotactic activity of 'normal' control neutrophils
against patients sol phase sputum, at baseline, after placebo and
BDP.
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12.3.3. Extracellular digestion of fibronectin .
In the 10 patients where it was measured throughout the
study spontaneous and FMLP stimulated digestion of 1251-
labelled fibronectin decreased significantly after inhaled
beclomethasone compared to baseline and placebo, ( Spontaneous
digestion, meg fibronectin per 5 xlO 5 cells, median [range];
baseline 1.07 [0.4 to 4.23], placebo 1.20 [0.64 to 2.43],
beclomethasone 0.50 [0.33 to 1.68]; p<0.03 for both comparisons
with active treatment: FMLP stimulated digestion; baseline 3.07
[1.09 to 7.76], placebo 1.91 [0.71 to 4.56], beclomethasone 1.12 [0.50
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to 2.0]; p<0.02 for both comparisons to active treatment). Individual
results for FMLP stimulated fibronectin digestion are shown in
figure 12.3..
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Figure 12.3. FMLP stimulated fibronectin digestion by patients
peripheral blood neutrophils, at baseline, after placebo and after
BDP. Lines show medians for eachdose group.
12.3.4. Sputum to serum albumin concentrations.
There was insufficient sputum sol phase in one patient to
allow measurement of sputum albumin concentration. In the
remaining seven patients the sputum to serum albumin ratio was
significantly lower than baseline after inhaled BDP (median[range]
sputum/serum ratio x 10 ~2;baseline 0.57 [0.24 to 1.11], BDP 0.29
[0.20 to 0.48]; p<0.05 ). After placebo the sputum/serum ratio ( 0.30
[0.24 to 0.86] x lO"2 ) was not different to that at baseline or after
active treatment.
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The changes seen with inhaled corticosteroids were seen in
both current and ex smokers, and in patients with and without
reduced gas transfer (KCO less than 70% predicted value). There
was no relationship between changes in indices of PMN activity or
sputum albumin concentration and changes in the lung function
parameters in individual patients.
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12.4. DISCUSSION.
This part of the study has demonstrated that high doses of
inhaled corticosteroids in vivo reduce the activation of circulating
PMN, the chemotactic activity of lung secretions and bronchial
inflammation in patients with chronic airflow obstruction.
The results of this section of the thesis must be interpreted
with caution for a number of reasons. Firstly the subgroup of
patients studied were not selected on a random basis, and hence may
not be representative of the patients as a whole. However the timing
of patients visits to the laboratory for the physiological assessments
was arranged to suit the preferences of the individual patients, and it
is therefore unlikely that any bias in terms of peripheral neutrophil
function was introduced by this means of selection for the patients
for this study. Patients attending morning sessions were selected for
the study simply because of the time involved in the isolation of
neutrophils, and the setting up of the assays. In addition the
physiological characteristics of the 20 patients studied were similar
to the 105 patients of the main study, so it is likely the results are
applicable to the whole study group.
Because of logistical problems with technical staff and
patients, not all 20 patients in whom neutrophil chemotaxis was
measured had fibronectin digestion by neutrophils estimated. Indeed
only 10 patients had this parameter of PMN function measured at
baseline, after placebo and after inhaled beclomethasone. Again
although no intentional or obvious bias was introduced, as no overt
selection process was applied to pick this subgroup it is possible that
they are not representative of the whole study group.
Finally the effect of treatment with inhaled BDP on
decreasing sputum production means that the results of both the
chemotactic activity of sputum, and the sputum albumin levels
reflect the effect of inhaled beclomethasone on a subgroup of
patients with more severe bronchial inflammation. It is reasonable
to assume that in patients with lesser degrees of bronchial, and
bronchiolar inflammation, the anti-inflammatory effect of the
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inhaled drug 'switched' off sputum production. Bronchoalveolar
lavage would have produced information on all patients, but is an
invasive and potentially dangerous procedure. However the effect of
inhaled beclomethasone on reducing the numbers of patients
producing regular sputum is probably in itself an indication of a
potentially beneficial anti-inflammatory effect in the bronchial tree.
Neutrophils are thought to play a central role in the
development of chronic airflow obstruction and emphysema(139), and
in progression of airflow obstruction in smokers(159). Increased
numbers of neutrophils are found in bronchoalveolar lavage fluid in
smokers, and in patients with chronic airflow obstruction 147,
149,151). Furthermore PMN from peripheral blood of patients with
emphysema and chronic airflow obstruction also show increased
chemotaxis and proteolysis(154,156), and superoxide anion
generation 155), suggesting a possible mechanism for their proposed
role in the pathogenesis of this condition. Inflammation of the
bronchial tree also appears to be a cardinal feature of chronic
bronchitis and chronic airflow obstruction. This may be seen directly
at bronchoscopy(148), or measured indirectly by the increased
leakage of albumin into lung secretions(267).
Corticosteroids have been shown to diminish neutrophil
activation in a number of experiments. Degranulation of PMN is
decreased after incubation with dexamethasone in vitro(156), and the
chemotactic response of peripheral neutrophils is reduced after the
in vivo administration of dexamethasone(157). Furthermore oral
prednisolone reduces bronchial tree inflammation as assessed by
albumin leakage(268). It is possible that some of these effects on
neutrophil function and bronchial tree inflammation may partially
explain the beneficial effect of oral prednisolone on disease
progression in chronic airflow obstruction(57,58).
Our study has demonstrated that in the patients completing
the study, high doses of inhaled beclomethasone in vivo reduce the
activation of peripheral PMN. The results show a wide range of
response for the patients prior to therapy in keeping with previous
studies(154). There was no change in the chemotactic response at the
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end of placebo therapy, but the values at the end of treatment with
beclomethasone were significantly reduced compared to baseline
values. Comparison of results on treatment with results on placebo
therapy shows a reduction after active treatment, but the difference
failed to achieve statistical significance, indicating that the overall
effect was small and close to the natural intrapatient variability. The
raw data suggests that the higher dose of beclomethasone is more
effective (fig 12.1.), although this was not confirmed statistically.
However studies of another neutrophil function (extracellular
proteolysis) were clearer. Spontaneous degradation of fibronectin by
patients PMN at baseline showed increased levels similar to those
reported previously(154,156). There was no change during placebo
therapy but values on treatment with beclomethasone fell by about
50% to levels seen previously in healthy subjects.
On balance the results suggest that inhaled beclomethasone
therapy had a significant effect on circulating neutrophil function.
However the mechanism remains unknown. It may reflect a decrease
in the release of cytokines from the lung during therapy, or a direct
effect on the cells of low levels of beclomethasone that may be
absorbed into the systemic circulation. If a direct effect on
peripheral PMN of systemically absorbed beclomethasone is the
cause then such an effect would either be prolonged, or occur at low
levels of the drug in the systemic circulation, as all samples were
collected at least 12 hours after the last dose of inhaled therapy.
Measurement of beclomethasone levels in serum or body fluids is
technically difficult, but alternative, easier to measure inhaled
steroids are available, and could be used to assess if systemic
absorption of the inhaled drug is the cause of the effects seen. Other
workers have shown that corticosteroids do reduce the production of
inflammatory cytokines by lymphocytes(269), so that an effect on
cytokine induced activation of PMN in the lungs is a possible
mechanism of action of inhaled beclomethasone.
In addition to the above effects beclomethasone altered the
nature of lung secretions. Sputum has been shown to contain factors
with predominantly chemotactic activity although a small degree of
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chemokinetic activity is also present(270). The present study using
healthy control PMN confirmed this chemotactic activity. Again a
wide range of values were observed but this did not alter on placebo
therapy (Fig 12.2.). However despite the fact that few samples were
available for analysis, there was a significant reduction in
chemotactic activity after beclomethasone treatment. Again it is
uncertain whether this reflects a reduction in the presence of
chemotactic factors in the secretions or a direct effect of the steroid
that would still be present in lung secretions.
That inflammation in the lung is likely to have been reduced
by inhaled beclomethasone is supported by a reduction in
sputum/serum albumin ratio. The baseline results show the usual
wide range described previously in similar patients(271). Full data
was unfortunately only available on 7 patients, since 7 of the 15
patients failed to produce sputum during the active treatment phase
and one produced insufficient for this assay. The reduction in
secretions in these patients may reflect a general reduction in lung
inflammation or the release of secretagogues. Recent data has shown
that neutrophil proteinases (elastase and cathepsin G) are
exceptionally potent secretagogues(272). Hence a reduction in
neutrophil recruitment and subsequent degranulation may have
influenced secretion production. Whatever the mechanism the
results suggest a reduction in lung inflammation may have occurred.
Overall the results of this part of the thesis suggest that
inhaled beclomethasone treatment may alter several factors
implicated in the pathogenesis of destructive lung disease in a
beneficial direction. It is possible that these effects are additive and
if increased neutrophil recruitment and activation are responsible
for disease progression inhaled corticosteroid therapy may modify
this process advantageously. Such changes may underlie the effect of
inhaled beclomethasone on disease progression outlined in the
following chapter.
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13. OBSERVATIONS ON DECLINE IN FEV1 IN SEVERE
CHRONIC AIRFLOW OBSTRUCTION. RELATIONSHIP TO
SHORT TERM STEROID RESPONSE AND TREATMENT WITH
INHALED CORTICOSTEROIDS.
13.1. INTRODUCTION.
Chronic airflow obstruction is a slowly but relentlessly
progressive disease. The prognosis appears to be related in part to
the underlying cause of the airflow obstruction. The outcome of the
disease appears better in patients with asthma than in those in
which the airflow obstruction is primarily due to cigarette smoking,
when it is often associated with emphysema(36). The disease in non
asthmatic patients appears to be more aggressive, and in both
clinical and population based studies the prognosis has been shown
to be related to the initial degree of airflow obstruction(273,274,275).
Other variables appear to influence survival independently of the
degree of airflow obstruction such as carbon monoxide gas
transfer(274,276,277,278), age(181), cigarette consumption(279), and
bronchial hyperresponsiveness(108). Greater reversibility of the
airflow obstruction is, in some studies, a good prognostic
feature( 108,180,277) but not invariably so(280,281).
Patients with chronic airflow obstruction also show a more
rapid decline in FEV1 than that expected by age alone. Reported
values for the average rate of decline in FEV1 vary from 80 to 85ml
per year(108,282,283) to only 34ml per year, not dissimilar to the
normal deterioration with age(284). Most authors report rates of
decline of between 50 to 60ml per year in established mild disease,
but with a wide individual variation^ 80,276,277,285). It appears that
patients with the mildest and most severe impairment in airflow
obstruction show the lowest rates of decline in FEV 1(181). The
increased mortality of the condition is related to this accelerated
decline in FEV1(286), although in patients with more severe disease
the lower rate of decline in FEV1 probably explains the 'survivor'
effect noted by some authors(285,286).
Despite the variety of therapeutic agents available to treat
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patients with this disease, only long term oxygen therapy has been
shown to affect the outcome in a subgroup of severely affected
patients(55,56). Recently two uncontrolled retrospective analyses
from Dutch workers have suggested that moderate doses of oral
prednisolone may both reduce mortality and slow down the loss of
FEV1 in non atopic patients with chronic airflow obstruction(57,58).
Their patients were not selected by a short term trial of steroids, as
suggested by many(40,41). Indeed the long term significance of a
response in such short term trials has never been investigated. It is
assumed that responders to corticosteroids in such trials will benefit
over the long term by continued treatment with such drugs, and
conversely that non responders to short term treatment with
corticosteroids will not benefit. There is little if any evidence to
support either assumption.
13.2. AIM.
The aim of this part of the thesis was to describe the change
in lung function in a cohort of patients who completed a short term
steroid trial between 1983 to 1985 and relate decline in FEV1 to
various factors previously shown to influence rate of decline in FEV1.
The results of this short term 'steroid trial' study have been reported
previously(95).
Specifically decline in FEV1 has been related to
- atopy,
- reversibility of airflow obstruction,
- smoking,
- bronchial hyperresponsiveness,
- starting level of lung function,
- the response to treatment during the original trial,
- and to treatment with inhaled corticosteroids during




The original trial recruited patients over the period 1983-
1985. One hundred and twenty one patients with adult onset chronic
airflow obstruction completed the original trial. All had an FEV1 less
than 70% predicted and symptoms for at least five years. None had a
history of chronic childhood respiratory illness, or showed variability
in symptoms except in association with infection. Patients with a
clinical diagnosis of asthma, or a history of acute attacks of wheezing
or breathlessness, and those who gave a history of sudden
deterioration following specific allergen exposure were excluded. The
presence of airflow reversibility to a bronchodilator was not
deliberately used as an exclusion criteria. Full details of the trial are
given in Appendix VI.
13.3.2. Design.
The original 'steroid trial' was a randomised, double blind
placebo controlled crossover trial comparing 14 days therapy with
oral prednisolone 40mg o.d. to inhaled beclomethasone dipropionate
500 meg t.d.s.. (Fourteen patients did not receive the placebo phase
of this trial).
Follow up assessments were carried out approximately 12 and




| (t-12 to 48 mths)
First follow up assessment (n=107)
| (t-47 to 78 mtha)
Second follow up assessment (n=73)
Figure 13.1. Schematic representation of the design of the study.
13.3.3. Lung function measurements.
FEV1 reversibility to salbutamol was determined during the
run-in phase of the original trial. 200mqg and lOmg of salbutamol
were administered sequentially, and the response determined 20
minutes after each dose. The smaller dose was given by a metered
dose inhaler, the larger by nebulisation to dryness with an Inspiron
mini-neb nebuliser. At the follow up assessments FEV1 reversibility
was measured 20 minutes after the administration of 200mcg
salbutamol form a metered dose inhaler via a volumatic spacing
device. FEV1 reversibility is expressed as a percentage of the
predicted FEV1 in view of the independence of this index from the
starting level of FEV 1(160),
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ie reversibility
= post salbutamol FEV1 - pre salbutamol FEV1 x 100
predicted FEV1.
Bronchial responsiveness to inhaled histamine (PC20) was
measured by the method of Cockroft et al(161) if the FEV1 was above
0.6 litres during the run-in phase of the original trial, or greater
than 0.75 litres at the follow up visits.
At both follow-up assessments patients were asked to abstain
from inhaled bronchodilators for 4 hours and oral bronchodilators
for 12 hours before assessment. FEV1 and FVC were measured in a
sitting position on a dry wedge spirometer (Vitalograph). The best of
at least three attempts , with the top two readings within the lower of
10% or 100ml was used for further analysis.
13.3.4. Other baseline tests.
Serum IgE levels were measured in 97 patients by a PRIST
technique. Skin prick tests were performed with house dust,
Dermatophagoides pteronyssinus, Aspergillus Jumigatus, cat fur and
a control solution in 98 patients. A positive result was defined as a
weal 2mm greater than control in two or more tests.
Smoking status was determined by the replies to a modified
MRC respiratory questionnaire. Declared non smoking was
confirmed by measurement of the serum thiocyanate level, and/or
measurement of the concentration of carbon monoxide in the expired
breath using a portable analyser (Morgan Eco-check EC50).
Patients completed a modified MRC respiratory
questionnaire, at baseline prior to the original trial, and at each
follow up visit. This included questions relating to treatment since
the original trial. Answers to these were validated by cross checking
with the patients clinical notes.
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13.3.5. Treatment during the observation period.
During the period of follow-up the referring physicians were
advised to prescribe inhaled beclomethasone at a dose of 750 meg
b.d.., in addition to oral and inhaled bronchodilator treatments,
irrespective of response to corticosteroids during the acute trial. The
drug was not stopped for lack of response or any other systematic
reason during the follow-up period. At the first follow up assessment
50 patients were either not taking inhaled beclomethasone at the
time of the assessment or had taken it for less than 25 % of the follow
up period. All these patients were prescribed inhaled
beclomethasone at a dose of 750 meg b.d. at that time.
13.4. ANALYSIS.
13.4.1. Definition of steroid response in original trial.
Response to treatment in the original trial was assessed on
the results of FEV1 and FVC measurements on the last day of each
treatment phase, or on changes in daily mean peak expiratory flow
(PEF) over the final seven days of each treatment, measured five
times daily at home. An improvement of at least 20% in any one
measurement was classed as a full response to the treatment, and
patients not fulfilling these predetermined criteria were considered
non responders to corticosteroid treatment. For the purposes of this
analysis response refers to a response as defined to either oral
prednisolone or inhaled beclomethasone or both.
13.4.2. Calculation of decline in FEV1.
Decline in FEV1 was calculated from the values recorded at
the appropriate follow up study, and the initial FEV1. Because of the
difficulty in deciding which of the six FEV1 values recorded during
the original trial should be used for the starting FEV1, the decline in
FEV1 was expressed in three ways.
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The primary analyses were performed on the decline
calculated from the follow-up value and that recorded at the end of
the inhaled beclomethasone treatment phase of the original trial
(FEV1 decline).
ie; FEV1 decline = post BDP FEV1 - follow up FEV1
period of follow up (years)
In addition the decline in FEV1 was calculated by
determining the mean FEV1 over the six pre and post treatment
values in the original trial, subtracting that recorded at the follow up
assessments and dividing by the period of follow up (mean FEV1
decline).
ie; mean FEV1 decline= mean FEV1 - Follow up FEV1
period of follow up (years)
Finally the decline in post salbutamol FEV1 was calculated by
using the post salbutamol value recorded during the run-in phase of
the original trial, and that recorded after bronchodilator at the
follow up assessments (postbd FEV1 decline).
ie; postbd FEV1 decline =
baseline post salbutamol FEVl-f up post salbutamol FEV1
period of follow up (years)
A height correction was not used as suggested by others as in
this group of patients no correlation between decline in FEV 1 and
height, height squared or the cube of standing height was seen.
13.4.3. Statistical analysis.
Values for bronchial hyperresponsiveness were
logarithmically transformed before analysis. Changes in bronchial
hyperresponsiveness are expressed in terms of doubling doses of
inhaled histamine. Statistical analysis was by unpaired t test for all
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normally distributed data or by chi-squared test for categorical data
for comparisons between defined groups. Serum IgE levels were
logarithmically transformed before analysis.
Pearson correlation coefficients were determined and
stepwise multiple regression performed on all the patients with
complete data. Variables were rejected if the residual variance of the
regression did not change significantly (p<0.05) after addition of the
variable, assessed by an F-test.
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13.5. RESULTS.
13.5.1. Analysis of data from first follow up assessment.
The baseline characteristics of the original 121 patients are
given in table 13.1.. One hundred and seven of the original 121
patients were assessed at the first follow-up. Of the 14 patients not
seen, 7 had died and 7 refused to attend the laboratory or had moved
from the area.
Table 13.1. Characteristics of the 121 patients enrolled in the




62.4 (60.8 to 64.1)
FEV 1 post BDP (litres)
FEV1 post BDP (% predicted)
1.15 (1.06 to 1.24)
42.7 (39.5 to 46.0)
Mean FEV1 (litres)
Postbd FEV1 (litres)
1.14 (1.05 to 1.22)
1.39 (1.28 to 1.49)
Airflow reversibility
to 200mcg salbutamol
as % predicted FEV1 7.3 (6.2 to 8.5)
Serum IgE (ku/1)











(pack years) 38.5 (33.6 to 43.4)
FEV1 post BDP- FEV1 recorded after two weeks treatment with inhaled
beclomethasone during original trial.
Mean FEV1- mean of all FEV1 values recorded both pre and post
treatment in original trial.
Postbd FEV1- FEV1 recorded after lOmg salbutamol during run-in phase of
original trial.
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The period of follow-up ranged from 12 to 44 (mean 26)
months. The mean (SEM) FEV1 at the time of this assessment was
0.97 (0.04) litres, or 36.7 (1.5) as a percentage of the predicted value.
The mean (95 % CI) values for the three methods of
calculating decline in FEV1 over this short period were,
FEV1 decline- 78 (54 to 103) ml/yr,
mean FEV1 decline- 82 (57 to 106) ml/yr,
postbd FEV1 decline- 132 (100 to 165) ml/yr.
At the time of first follow-up 71 % of the patients were taking
regular inhaled bronchodilators, either beta 2 agonists and/or
ipratropium bromide, and 20% were taking oral theophylline in
addition. The remaining patients were taking inhaled
bronchodilators on a prn basis. Only 22% of the patients had taken
inhaled corticosteroids for over 80% of the first follow-up period. At
the time of this assessment 50 patients either were not taking
inhaled BDP or had only started taking the drug in the 8 weeks prior
to the assessment.
The differences between two groups of patients, created
according to the rate of FEV1 decline over the follow up period was
analysed (table 13.2.). One group was defined as showing an
improvement or a decline in FEV1 less than the median decline in
FEV1 (slow decliners), the other group showed a decline in FEV1
greater than the median (rapid decliners).
The only significant differences between these groups was the
higher starting FEV1 (when expressed as a percentage of the
predicted value) in the rapid decliners, and the longer percentage of
the follow up period for which BDP was prescribed in the slow
decliners.
Correlation showed statistically significant associations
between FEV 1 decline and the starting level of FEV 1, the percentage
of the follow up time for which BDP had been prescribed, and the
carbon monoxide gas transfer (KCO). Patients with a lower FEV1 at
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Table 13.2. Characteristics of the 'slow' and 'rapid' decline
groups defined, at time of the first follow up in the 107 patients
assessed (as mean and 95% CI for mean unless indicated).
Slow decliners Rapid decliners





FEV1 post BDP (litres) 1.02
(0.91 to 1.13)
















Smoking status [as number (%)]
Current 24 (44)
Ex smokers 27 (49)









Serum IgE (ku/1) 73 72
Number with positive
skin tests (%) 23 (42) 27 (52)
Number (%) of responders to steroids
in original trial 21 (38) 23 (44)






*p<0.05 by unpaired t test.
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the start of the observation period, those prescribed inhaled
beclomethasone for more of the follow up period and patients with
better preserved gas transfer tended to have a lower decline in FEV1
(table 13.3.). The same correlations were apparent when mean FEV1
decline was examined, but the KCO did not correlate with postbd
FEV1 decline.
In a stepwise multiple linear regression analysis with decline
in FEV1 as the dependent variable the following variables were used
as predictors,
-the appropriate starting FEV1 (in litres),
-reversibility to 10 mg salbutamol (as a percentage of the
predicted FEV1),
-age (in years),
-cigarette consumption (as pack years of smoking),
-the percentage of the follow up period for which inhaled
beclomethasone was prescribed (BDP treatment time),
-the volume corrected carbon monoxide gas transfer (KCO),
-the response to steroids in the original trial, (0= non
responders, 1 =responders),
-logio serum IgE level,
-the logarithm of the PC20 value.
For FEV1 decline the starting FEV1, KCO, the percentage of
the follow up period for which inhaled beclomethasone was
prescribed, and response to steroids in the original trial entered the
final equation (table 13.4.). For mean FEV1 decline response to
steroids did not contribute significantly to the equation, and for
postbd FEV1 decline the starting FEV1, KCO, and cigarette
consumption entered the final equation. For post bronchodilator
FEV1 decline the percentage of the follow up period for which BDP
was prescribed just failed to enter the regression equation ( partial r
= -0.22; p=0.062).
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Table 13.3. Correlation coefficients of the three measures of










Starting FEV1 (litres) $ 0 37*** 0.32** 0.58***




Post salbutamol FEV 1
(litres)
-0.07 -0.06 -
log10PC20 0.14 0.15 0.14
Percentage of follow
up period BDP prescribed
-0.22* -0.31** -0.23*
Log jo serum IgE -0.01 -0.08 -0.15
KCO (mmol/min/kPa/1) -0.27* -0.34** -0.14
* p<0.05, ** p<0.01, *** pcO.OOl
$ Starting FEV1, for FEV1 decline = FEV1 post BDP, for mean FEV1
decline = Mean FEV1, for postbd FEV1 decline = Postbd FEV1 (see table
1).
KCO = carbon monoxide gas transfer per unit alveolar volume
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Table 13.4. Parameter estimate b, the standard error of b, the
partial correlation coefficient and significance for the multiple
regression equations.
1. Dependent variable FEV1 decline (litres/yr)
b SE(b) partial r P
FEV 1 post BDP (1) 0.12 0.023 0.51 <0.0002
KCO (mmol/min/kPa/1) -0.09 0.025 -0.34 <0.001
BDP treatment time
(% follow up time) -0.10 0.035 -0.32 <0.01
Steroid response 0.06 0.02 -0.26 <0.025
Intercept 0.18 0.06
r squared = 0.35 residual SD = 0.11
2. Dependent variable mean FEV1 decline (litres/yr)
b SE (b) partial r P
KCO (mmol/min/kPa/1) -0.10 0.03 -0.41 <0.0003
Mean FEV 1(1) 0.11 0.03 0.44 <0.0002
BDP treatment time
(% follow up time) -0.09 0.03 -0.30 <0.01
r squared =0.34 residual SD = 0.12
3. Dependent variable postbd FEV1 decline (1/yr)
b SE (b) partial r P
Post salbutamol
FEV1 (1) 0.20 0.03 0.67 <0.0002
KCO (mmol/min/kPa/1) -0.14 0.04 -0.42 <0.0005
Cigarette
consumption (p.yrs) -0.001 -0.0005 -0.30 <0.02
r squared = 0.47 residual SD = 0.14
BDP treatment time is the percentage of the follow up time for which
inhaled beclomethasone was prescribed.
Steroid response entered as 0=non responder, 1 =responder.
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13.5.2. Analysis of data from the second follow up assessment.
Seventy three patients from the original 121 were assessed at
the second follow up. This occurred on average 62 (range 47 to 78)
months after completion of the original short term steroid trial.
Twenty five patients had died during the intervening period, the
remaining 22 could not be traced. Patients who had died during the
follow up period were more likely to be male, were older, and had
significantly lower FEV1 values, more gas trapping (as judged from
the residual volume measurement), and more impairment of gas
transfer (table 13.5.).
The decline in FEV1 over this longer period in the 73
surviving patients was (as mean (95 % CI) ;
FEV1 decline- 53 (39 to 66) ml/yr,
mean FEV1 decline- 53 (38 to 69) ml/yr,
postbd FEV1 decline- 68 (49 to 88) ml/yr.
Pre bronchodilator decline in FEV1 was similar in the 50
steroid non responders from the original trial, and the 23 steroid
responders (table 13.6.). Post salbutamol FEV1 decline (postbd
FEV1 decline) was significantly higher in the steroid non responders.
The two response groups showed very few differences in physiological
characteristics at recruitment to the original trial (table 13.6.).
To investigate the association between bronchial
hyperresponsiveness and decline in FEV1, patients were classified
into three groups on the basis of the results of the measurement of
bronchial hyperresponsiveness prior to the original trial. Patients
with a PC20 of less than 0.5mg/ml were considered to have severe
bronchial hyperresponsiveness, those with a PC20 between 0.5 to 4
mg/ml moderate bronchial hyperresponsiveness, and patients with a
PC20 in excess of 4 mg/ml 'normal' bronchial hyperresponsiveness.
There was no significant difference between the three groups in any
of the three measures of decline in FEV1 (table 13.7.). The
correlation between decline in FEV1 and the logarithm of the PC20
was poor, r=0.13;ns. However patients with a PC20 less than 0.5
mg/ml had a significantly lower starting FEV1 at the time of the
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Table 13.5. Characteristics of patients dying during the
observation period, and those alive at the time of the second
follow up assessment, (as mean and 95 % CI for mean unless
indicated).
Alive Deceased






FEV1 post BDP (litres) 1.22
(1.1 to 1.34)






















KCO (% predicted) 84
(77 to 90)
59









34 (46) 8 (32)
Responders to steroids
[number (%)] 23 (31) 11 (44)
TLC = total lung capacity, RV = residual volume,
KCO = carbon monoxide gas transfer coefficient.
* p< 0.05 for comparison between groups.
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Table 13.6. Characteristics and FEV1 decline over the observation
period in the two steroid response groups from the original trial
(as mean ((%% CI) unless stated).
Responders Non Responders
Number (female) 23 (6) 50 (14)
FEV1 post BDP (litres) 1.24
(1.05 to 1.44)












































* p< 0.05 for comparison between groups.
original trial, and decline measures showed a correlation with the
level of FEV1. When decline was compared in the PC20 groups
adjusting for the difference in the starting level of FEV1 by an
analysis of covariance, the patients with more severe bronchial
hyperresponsiveness showed a more rapid decline in post salbutamol
FEV1 (postbd FEV1 decline), but not in the other two measures of
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Table 13.7. Characteristics and decline in FEV1 in the three
bronchial responsiveness groups (as mean (95 % CI) unless
stated).
PC20 group severe moderate 'normal'







































Serum IgE level (ku/1)
(geometric mean) 78 97 52
Number with positive























* p<0.05 for difference between severe group and moderate and 'normal'
groups.
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FEV1 decline ( Mean (SEM) adjusted postbd FEV1 decline
PC20<0.5 mg/ml- 93 (12) ml/yr; 0.5<PC20<4 mg/ml- 44 (19);
PC20>4 mg/ml- 52 (19)).
When decline in FEV1 was compared in smoking groups
(smoking status at the time of the second follow up) no difference in
the measures of decline in FEV1 were seen (table 13.8.). Only ten of
the 73 patients had stopped smoking during the observation period,
and we did not find a significant difference in FEV1 decline between
these patients [mean(95%CI) FEV1 decline 33 (-2.6 (an increase) to
69) ml/yr], and continuing current smokers [56 (36 to 77) ml/yr] or
patients who stopped smoking cigarettes prior to the original steroid
trial [56 (33 to 79) ml/yr].
In a stepwise multiple regression analysis in the 58 patients
with complete data, the decline in FEV1 over the whole of the
observation period was entered as the dependent variable and the
following predictor variables used;
-age (in years),
-the appropriate starting FEV1 (in litres),
-reversibility to 10 mg salbutamol (as a percentage of the
predicted value),
-cigarette consumption (as pack years of smoking),
-the volume corrected carbon monoxide gas transfer (KCO),
-the response to steroids in the original trial,
-log10 serum IgE level,
-the logarithm of the PC20 value.
For FEV1 decline and mean FEV1 decline only the starting
level of FEV1 entered the regression equation. For post salbutamol
FEV1 decline (postbd FEV1 decline) in addition to the starting level
of FEV1, age, carbon monoxide gas transfer (KCO) and cigarette
consumption added significantly to the prediction of the decline in
this measure (Table 13.9.).
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Table 13.8. Characteristics and decline in FEV1 three smoking
groups (as mean (95% CI) unless indicated).
Smoking status Ex Current Never
Number (female) 44 (5) 22 (8) 7 (7) *
FEV1 post BDP
(litres)



































as geom mean (ku/1) 63 90 89
Number with positive

























For abbreviations see table 1, and text.
* p<0.05 for comparisons between never smokers, and both current and ex
smokers.
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Table 13.9. Parameter estimate b, the standard error of b, the
partial correlation coefficient and significance for the multiple
regression equations for measures of FEV1 decline over the whole
observation period.
1. Dependent variable FEV1 decline, (litres/yr)
b SE(b) partial r P
FEV1 post BDP 0.44 0.13 0.40 <0.002
Intercept -0.002 0.018
r squared = 0.16 residual SD = 0.05
2. Dependent variable mean FEV1 decline (litres/yr)
b SE(b) partial r P
Mean FEV1 0.06 0.02 0.4 <0.002
Intercept -0.68 0.50
r squared = 0.16 residual SD = 0.06
3. Dependent variable postbd FEV1 decline (1/yr)
b SE(b) partial r P
Post salbutamol
FEV1 0.09 0.01 0.66 <0.0001
KCO
(mmol/min/kPa/1) -0.08 0.02 -0.52 <0.0002
Age (years) -0.003 0.001 -0.36 <0.01
Cigarette consumption
(pack years) -0.0008 0.0003 -0.32 <0.02
Intercept 0.22 0.08
r squared = 0.58 residual SD = 0.06
Thirty two of the fifty patients who were prescribed regular
inhaled beclomethasone at the time of the first follow up assessment
were reassessed on this occasion. They were similar in most respects
to the other patients in terms of physiological characteristics at the
time of the original steroid trial. However this group had
significantly more steroid non responders than the 39 patients
taking inhaled beclomethasone regularly at the time of the first
230
follow up assessment (table 13.10.).
Table 13 .10. Characteristics of the 32 patients prescribed inhaled
beclomethasone for the latter part of the observation period only
(group I), compared to those prescribed inhaled beclomethasone
for the whole of the period (group II),(as mean (95% CI) unless
indicated).
Group I Group II





FEV1 post BDP (litres)






























15 (47) 19 (49)
Number of steroid responders
in original trial (%) 5(16) 16(41) *
FEV 1 decline over the






* p<0.02 for comparison.
231
Decline in FEV1 estimated by all three methods is shown for
the two groups in table 13.11.. In the 32 patients starting inhaled
BDP midway through the study period, all three measures of FEV1
decline fell significantly. In patients prescribed inhaled
beclomethasone throughout the study period decline in FEV1 as
measured by FEV1 decline and mean FEV1 decline did not change
significantly over the two observation periods, although the trend
was for a more rapid decline over the second period of observation.
Post salbutamol FEV1 decline was significantly less over the second
period of observation. For all three measures of decline in FEV1 the
rate of decline over the second observation period was not
significantly different between the two BDP treatment groups.
Table 13.11. Measures of decline in FEV1 over the first and
second period of observation in patients starting BDP midway
through the study period (Group I), and those receiving BDP for
the two periods of observation (Group II). As mean (95% CI).




86 (12 to 160)




127 (81 to 173)
101 (33 to 171)




167 (118 to 216)
154 (85 to 222)





35 (-8 to 78)
30 (-22 to 82)




31 (-17 to 78)
34 (-18 to 86)




131 (66 to 195)
93 (20 to 167)
38 (7 to 68)
t=2.58,p<0.01
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Bronchial hyperresponsiveness to inhaled histamine was
measured at the time of the original trial, and at the second follow
up assessment in 35 patients. There was a small but statistically
significant improvement in bronchial hyperresponsiveness of a mean
of 0.87 doubling concentrations of histamine (95% CI= 0.18 to 1.56).
This was despite a fall in FEV1 from a mean (95% CI) of 1.51 (1.33 to
1.69) to 1.22 (1.06 to 1.38). This was not apparent in the 37 patients
who were taking inhaled beclomethasone regularly at the time of the
first follow up, and who had P (20 values measured. These patients
showed a mean improvement over this shorter period of only 0.2
doubling concentrations (95 % CI- -0.47 to 0.9).
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13.6. DISCUSSION.
This retrospective observational study has revealed rates of
decline in FEV1 over the longer observation period of 50 to 70ml per
year depending upon the method used to calculate the decline. This
is similar to that reported in the literature for mild disease( 180,276,
277,286) but considerably less than the 80 to 85ml per year reported
for patients with disease of similar severity(283), or for patients with
'typical COPD' and an initial FEV1 greater than 45% of the
predicted value (87 ml per year)(274).
In our study decline in prebronchodilator FEV1 calculated
over the whole of the observation period was related to the initial
level of the FEV1 alone, with patients with a higher initial FEV1
showing a more rapid decline in FEV1. We found no effect on pre¬
bronchodilator decline in FEV1 of bronchial hyperresponsiveness, or
the short term response to a 'trial of steroids'. In the simple
comparative analysis post salbutamol FEV1 decline was higher in
those patients unresponsive to a 'trial of steroids', and, when
adjusted for the starting level of FEV1, in patients with severe
bronchial hyperresponsiveness. However neither of these factors
entered the multiple regression equation when this analysis was
performed. Smoking status appeared to have no effect on the rate of
decline in FEV1 in the comparative analysis, although in the
multiple regression analysis cigarette consumption was related to
post salbutamol decline in FEV1, calculated over the whole of the
observation period.
The results also suggest that treatment with inhaled
beclomethasone may have a beneficial effect on the progression of
the chronic airflow obstruction. At the time of the first follow up
assessment a relationship was detected between the percentage of the
follow up time for which inhaled beclomethasone had been
prescribed, and decline in FEV1. This effect persisted for both
measures of prebronchodilator FEV1 decline when possible
confounding factors were taken into account in the multiple
regression analysis. For post salbutamol FEV1 decline the effect of
treatment with inhaled beclomethasone on the prediction of this
measure of decline in FEV1 just failed to reach statistical
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significance. Although this data was uncontrolled the association is
certainly interesting.
In addition in the thirty two patients who were prescribed
regular inhaled beclomethasone after the initial follow up
assessment a dramatic fall in the decline in FEV1 was seen at the
second assessment. This was true for all three methods of calculating
FEV1 decline, and was not seen in those patients taking BDP
throughout the study period, who had a low rate of decline in FEV1
over the initial period of observation, and tended to show a slight
acceleration in rate of decline of prebronchodilator FEV1 over the
second observation period. Although these patients did not enter a
formal controlled trial, the first observation period can effectively be
considered as a control period without treatment.
Taken together these pieces of evidence suggest that inhaled
beclomethasone has a disease slowing effect. There are a number of
potential confounding factors which makes interpretation of these
results difficult however. The patients who died during the
observation period are likely to have had a rate of decline higher
than the average, and the 'loss' of these patients in the analysis may
bias the results. The fifteen patients seen at the first follow up
assessment who died during the latter half of the observation period
showed a more rapid decline in FEV1 during the first observation
period than those surviving, although the difference was not
statistically significant ( mean (95% CI) deceased 109 (69 to 150),
survivors 69 (37 to 101) ml/yr). However patients not taking inhaled
BDP at the time of the first follow up assessment who died during
the second observation period had a similar rate of decline in FEV1
over the first period of observation as those surviving (mean (95 %
CI) survivors 112 (64-160) ml/yr, deceased 104 (61-146) ml/yr).
Hence the comparison of decline in FEV1 before and after treatment
with inhaled beclomethasone is probably free of this potential bias.
Another potential problem in interpreting this data is the
relation between the level of FEV1 and decline in FEV1. Over the
period of observation the FEV1 will fall and hence the rate of decline
in FEV1 will also fall, and appear to be the result of treatment.
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However inspection of the actual levels of FEV1 at the time of the fist
and second observation periods shows no significant change, so that
although this is certainly a potential bias over a longer term, the
effect on the results seen is negligible.
Whether this results from a slowing of the rate of loss of
FEV1, or via a longer term response and improvement in FEV1
followed by the inevitable decline is not clear. The data from the
group prescribed BDP throughout would suggest that the latter is
the more plausible explanation. Postma et al suggest that oral
prednisolone may produce an improvement in FEV1 over 6 months
or longer in similar patients(57), and it is likely inhaled
corticosteroids will act in a comparable way. Only a prospective
study with more frequent estimations of FEV 1 will answer this
question.
The results of our analysis also question the usefulness of
short term 'steroid trials' in the management of this group of
patients(40,41). Implicit in the recommendation to assess steroid
responsiveness in all patients with symptomatic chronic airflow
obstruction is the assumption that unresponsive patients do not
benefit from treatment with steroids in the long term. There is no
published data to support this assumption.
Of the 32 patients starting regular inhaled BDP at the time of
the first assessment 27 were classed as non responders after the
initial 'steroid trial'. In this subgroup the FEV1 decline improved
from a mean (95%CI) of 102 (52 to 153)ml per year to 29 (-16 to
75)ml per year, a difference which just failed to reach statistical
p
significance but is noif the less marked, and suggests a beneficial
effect of inhaled beclomethasone on non responders to a short term
'trial of steroids'.
The method of calculation of decline in FEV1 may also lead to
problems of interpretation of the data. For instance in the analysis
of the first follow up data the multiple regression suggested a
detrimental effect of a positive steroid response on subsequent
decline in FEV1 (as FEV1 decline). This may be true but is likely to
be partly artifactual due to the method of calculation of FEV1
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decline adopted. By taking the improved level of FEV1 after 2 weeks
treatment with BDP as the starting level, we may bias the calculation
of decline in FEV1 because of the association between higher starting
FEV1 levels and an increased rate of decline in FEV1. The fact that
steroid response did not enter into the prediction equations for mean
FEV1 decline and post salbutamol FEV1 decline support this
interpretation, and indicate that acute steroid response does not
predict subsequent decline in FEV1.
The calculation of rate of decline in FEV1 was performed in a
variety of ways. It is difficult to know which of the values of FEV1
recorded during the original trial should be used to calculate the
decline in FEV1. We selected the FEV1 measured after the inhaled
beclomethasone phase of the original trial as patients were treated
with this drug during the follow up period. However using the mean
of the FEV1 values from the original trial gives similar results. In
addition using the best FEV1 from the original trial, or the run-in
pre treatment value does not alter significantly the conclusions of
this analysis (data not presented). The relatively high rates of
decline in FEV1 from the first follow up assessment reflect the
relationship between the period of follow up and decline in FEV1
previously described(283,287). Intuitively however such
methodological problems should apply equally to all patients and not
introduce bias.
Post salbutamol FEV1 decline was higher than that
calculated from prebronchodilator values. The reason for this is not
clear. This measure of decline also showed some differences from the
other two measures used. It was lower in patients showing an acute
response to corticosteroids, and after adjustment for starting level
was higher in patients showing more severe bronchial responsiveness
to inhaled histamine. It may be that the post salbutamol FEV1
reflects the reversible component of bronchial inflammation on a
baseline level of airway narrowing. With time fibrosis may ensue, and
both bronchodilators, and bronchoconstrictor agents may be less
effective. Hence post bronchodilator FEV1 may fall more quickly
than pre bronchodilator FEV1. Only more frequent estimations of
FEV1 and reversibility in a prospective study will answer this.
237
The association between a lower decline in FEV1 in patients
with the greatest impairment in FEV1 has been described
before(l80,279,286). The explanation is probably that patients with
severe disease only survive to produce data for an analysis of decline
in FEV1 if their individual FEV1 decline is less than that seen in the
group as a whole. Death during the follow up period was associated
with worse pulmonary function, a fact noted previously(274,280,286).
The Groningen group have published evidence to support the
Dutch hypothesis of a pivotal role of bronchial hyperresponsiveness
in the development and progression of chronic airflow
obstruction(39). In a group of well defined non allergic patients with
chronic airflow obstruction they showed an independent effect of
bronchial hyperresponsiveness on decline in FEV1(108). We have not
been able,confirm this in our heterogeneous patient group. A number
of possible explanations exist for this discrepancy, not least the
patient selection. The Dutch study included patients with less severe
disease (FEV1 >1.2 litres), and they selected a homogeneous group
with respect to the severity of airflow obstruction (FEV1/FVC
between 40-55%). Their patients were also considerably younger than
our group, and the most responsive patients showed a mean decline
in FEV1 of 127 ml/year. These factors alone may explain the
differing conclusions reached.
The association between the degree of airflow obstruction and
bronchial hyperresponsiveness in chronic airflow obstruction
suggests geometric factors are the primary determinant of response
to inhaled histamine. However the small improvement in bronchial
hyperresponsiveness seen in the study group over the observation
period despite a fall in FEV1, which would be expected to worsen
bronchial hyperresponsiveness, suggests that even in these patients
with severe chronic airflow obstruction factors outside geometry do
influence bronchial hyperresponsiveness. This improvement in PC20
values may reflect prolonged treatment with inhaled corticosteroids.
Our data showed no effect of reversibility of airflow
obstruction on decline in FEV1 (in the multiple regression analysis).
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There was no suggestion that better reversibility equated with an
accelerated decline in FEV1, but neither did our data support the
contention that a degree of reversibility is a good prognostic sign. It
was surprising that no effect of smoking status on decline in FEV1
was detected, although cigarette consumption did significantly
predict post salbutamol FEV1 decline. The number of patients
changing smoking habit during the observation period was probably
too small to produce a detectable effect, or alternatively the effect of
smoking cessation may take longer than the period of observation to
become apparent. Another possible explanation may be that the
effect of treatment with inhaled beclomethasone outweighs the
deleterious effect of smoking. Postma et al have published evidence
suggesting this is the case with oral prednisolone(57).
Our original patient group was intended to reflect the
population of a general chest clinic. Patients were only recruited if
the consultant chest physician thought the diagnosis was not, or was
unlikely to be asthma. The diagnosis can be difficult in elderly
patients who have smoked heavily, and have severe physiological
abnormalities, and the argument in these patients is largely
semantic. It is possible that we inadvertently included occult
'asthmatics' in the population studied. However the results of the
multiple regression analysis show that reversibility of airflow
obstruction, a feature of asthma, was not a predictor of decline in
FEV1. Hence it is likely that any bias introduced by their inadvertent
inclusions is not significant. The results as they stand can be applied
to the general chest clinic population with chronic airflow
obstruction.
The Tucson group have suggested that the airflow
obstruction is more benign in the patients with 'asthma'(36), in that
the rate of decline in FEV1 is nearly normal. It is possible this
reflects responsiveness to anti-asthma treatment, although no data
has been provided about treatment use in their study group. As
treatment with corticosteroids appears to be related to a diagnostic
label of asthma(288), it is possible that the difference in decline in
lung function between 'asthmatics' and 'typical COPD' patients in
Burrows population study is partly explained by treatment.
239
The data analysed for this part of the thesis were collected in
a controlled fashion, but not from a controlled therapeutic trial, and
hence must be interpreted with caution. Many confounding factors
could influence the results, but we believe the consistency of the
results when different methods of calculating FEV1 decline are used
does strengthen the conclusions. Bias in the prescription of inhaled
beclomethasone may be a confounding factor with the data from the
first follow up assessment. However the results of starting the 32
patients on inhaled beclomethasone at this time provides stronger, if
uncontrolled, evidence that inhaled corticosteroids can slow down
disease progression.
The final answer to question of the role of inhaled
corticosteroids in non asthmatic chronic airflow obstruction will
require a long term prospective randomised controlled study. One
such study is underway with another planned. At the moment
physicians in the West Midlands commonly prescribe inhaled
corticosteroids to patients who do not have asthma (DC Weir, PS
Burge; data presented at the British Thoracic Society summer
meeting, Birmingham 1990), so the results of this analysis will at
least reassure those who do that their current practice is not without
some justification. It would also appear ethical to enter such patients
into a long term trial without first performing an acute steroid trial.
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14. DISCUSSION AND CONCLUSIONS.
The rationale for the main part of this thesis was to
determine whether the same short term effect as that seen after
treatment with oral prednisolone 40mg per day, could be achieved
after treatment with high dose inhaled corticosteroids, without the
systemic side effects seen after oral prednisolone. If so high dose
inhaled therapy could be substituted for oral prednisolone in 'steroid
trials', and subsequent treatment in 'responders'. Two high doses of
inhaled beclomethasone were used, and their efficacy compared. In
addition in an attempt to determine the mechanism or mechanisms
by which corticosteroids produced their beneficial effect, changes in
bronchial hyperresponsiveness with treatment were documented, and
a subsidiary study on a subgroup of patients measured the effect of
inhaled therapy on peripheral neutrophil function. Finally an
uncontrolled retrospective study investigated the relevance of short
term steroid response, and the effect of inhaled steroid therapy on
disease progression in chronic airflow obstruction.
The results showed that inhaled beclomethasone at both
doses used was more effective than placebo in producing
improvement in physiological measures, and in some subjective
parameters. There was no significant difference between the doses
used in terms of the primary end points selected, although a greater
effect of the higher dose on post bronchodilator FEV1 was seen. In
addition the subjective changes seen tended to be more pronounced
in the higher, 3000 meg per day, dose group. Both doses were shown
to be as effective as oral prednisolone, both in a 'group' analysis, and
a 'categorical analysis'. Tests of adrenal suppression showed,
perhaps not surprisingly, that the lower dose of inhaled
beclomethasone was the safest therapy, and the data from local oro¬
pharyngeal side effects, and global respiratory muscle strength
supported 750 meg b.d. of BDP as the dose of choice, in terms of the
balance between efficacy and side effects.
The results of the measurement of bronchial
hyperresponsiveness showed no effect of treatment, unless a small
subgroup of patients, with more severe bronchial
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hyperresponsiveness were analysed separately, and in this subgroup
the results may be explained by regression towards the mean.
Peripheral neutrophil function, and the inflammatory nature of lung
secretions were both reduced by treatment with inhaled
beclomethasone, with a trend towards a greater effect of the higher
dose used.
Although these results are of interest, perhaps the most
considering this, and the implications of the results of this part of
the thesis, I would first like to discuss some of the points already
raised in the appropriate chapters which may affect the validity of
the results obtained.
Firstly by design the trial was a sequential nature, with the
investigator therefore aware of which treatment phase was placebo,
which inhaled BDP alone, and which oral prednisolone. It was felt
that the results of our previous analysis concerning the time course
of action of steroids in chronic airflow obstruction, meant that to
perform a double blind cross over study a minimum six week
washout period after each treatment period was required to avoid
any carry over effects. This would lengthen the study period to over
seven months, which we felt was too long. The increased dropout of
patients entered outweighed any benefit gained by increasing the
scientific purity of the study, for the results of the study would have
been less applicable to the general clinic population. In addition as
the investigator was blind to the BDP and prednisolone dosage
groups, the only part of the trial in which bias could have been
introduced was in the comparison of placebo with active treatment. I
believe by applying rigid criteria to the tests of lung function, and
using validated instruments for assessing subjective change any bias
unintentionally introduced has been minimised, and is not
significant.
Another controversial area in such studies as this one is the
patient selection. This has been discussed fairly extensively in
chapter 4. The splitting of the elderly patients studied into
asthmatics and non asthmatics is largely a semantic exercise. The
interesting data comes 1 the retrospective study. Before
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entry criteria excluded patients whom the referring physician
believed had asthma on clinical grounds. In the absence of a
diagnostic test for asthma, such a criteria'is justified. Hence patients
in whom the benefits of corticosteroids were proven were excluded,
and the population recruited were therefore patients in whom a 'trial
of steroids' is recommended. As such the results of the study should
be applicable to the many such patients who present to chest
physicians.
The subanalyses carried out tend to support my contention
that the split into asthma and non asthma in this patient population
does not achieve anything. Arguments against the contention that a
substantial number of 'missed' asthmatics have been included in the
study population are numerous. The patients were elderly, ex or
current smokers (except one individual), and had developed
symptoms in later life. They had a prevalence of atopy as measured
by skin test reactivity similar to normals of the same age. Serum IgE
levels appeared to be high, but levels were similar in patients
categorised as 'asthmatic' or 'non asthmatic' on the basis of
questionnaire answers, and the high levels may simply reflect the
cigarette smoking of the group. Reversibility of FEV1 to beta 2
agonists was similar in the 'asthmatic' and 'non asthmatic' patients,
and less than 10% showed an improvement in FEV1 of over 15% of
the predicted FEV1 following salbutamol. Variability in PEF was
similar to that described in the normal population recently(184).
Finally the lack of any difference in terms of 'asthmatic' features
between responders and non responders to inhaled beclomethasone
suggests the majority of patients studied had non asthmatic disease.
Indeed the implicit assumption in many past studies that
steroid responders are simply missed asthmatics is not supported by
the results of my studies. The discriminant function derived from our
initial study did include some features many would associate with
asthma. However when the function was applied prospectively to this
study population, prediction of response to BDP was no better than
by chance, suggesting 'asthmatic' features are not important in
determining response in this group of patients. Perhaps the basis for
steroid responsiveness in these patients lies in the degree and type of
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microscopic emphysema present in each individual, as recently
described by Cosio's group(289). Only studies incorporating
bronchial wall histology, and more complex, and invasive
physiological tests could answer this.
Another possible point of contention is the classification of
individual patients into responders and non responders to
treatment. On a group analysis the active drugs do have a small, but
statistically significant effect on physiological measures when
compared to placebo, but the validity of arbitrarily categorising
patients into response groups may be questionable. Historically the
majority of trials studying oral steroid therapy in chronic airflow
obstruction have used this approach, and usually with similar cut off
points to those used in this study. I have used three variables to
classify treatment response, as our previous study did, and although
this undoubtedly increases the response rate to treatment, and
explains the higher rate seen in this and our previous study
compared to others, it increases the risk of attributing clinical
significance to changes which are little more than normal variation.
Although the correlation between changes in single physiological and
subjective measures was poor, patients classed as physiological
responders did show greater and statistically significant changes in
most subjective measures, and hence the classification system
adopted appears to be reasonable, in that it distinguishes between
both objective and subjective response. It would also appear to be a
reasonable aim of treatment to optimise physiological function
alone, as FEV1 is closely related to death from chronic airflow
obstruction.
However when the dataH^ examined more closely the change
in each of the three variables after treatment shows a unimodal
distribution, and not the bimodal distribution one would expect if
responders and non responders to treatment were truly biologically
different. This observation, the difficulty in predicting a response to
treatment, which implies a heterogeneity of the population with
respect to steroid response, and the contention by the Groningen
group that steroid effects in patients with chronic airflow obstruction
may take up to 9 months to be effective, all cast doubt on the validity
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of short term steroid trials to determine steroid responsiveness. The
Dutch workers did not determine short term steroid responsiveness
prior to their study. Only if a short term steroid response equates
with a longer term response, and hence better prognosis, and vice
versa, that non responsive patients do not show a longer term
response to treatment would the continuation of short term steroid
trials be justified.
The data from our retrospective study would support this
contention, and suggest that the concept of short term steroid
response may be fallacious. Although this data was collected outside
a controlled clinical trial, the change in decline in FEV1 in the
patients starting treatment half way through the follow up period is
strong evidence for a significant treatment effect in all patients, both
short term steroid responders and non responders. Indeed the
majority of those patients starting treatment at this point in the
observation period were short term steroid non responders. It is
possible we are seeing a longer term, say 6 to 9 month, steroid
response, followed by the expected accelerated decline in lung
function, but only a long term prospective study with more frequent
measurements of FEV1 to demonstrate the pattern of change in
FEV1 will clarify this point. We are currently performing such a
study in our centre, and organising a multi-centre study to
investigate this point more fully. Another European wide study,
under the auspices of the European Respiratory Society, Euroscop, is
already underway, and more data on this problem should be
forthcoming in the near future form the Groningen group. In the not
too distant future the role of inhaled corticosteroid therapy in this
patient population should therefore be more clearly defined.
Interestingly the effect of treatment on peripheral neutrophil
function in this study, could possibly underlie such a disease
retarding effect of inhaled corticosteroids. Further studies will be
needed to confirm these findings, and clarify the mode of action of
inhaled corticosteroids. Studies need to address whether inhaled
corticosteroids reduce local pulmonary production of cytokines, and
secretagogues, and indirectly reduce neutrophil activation, or
whether the action is by a direct effect on the cells following
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absorption of the drug into the systemic circulation. It would be
appropriate to use a fluorinated corticosteroid in such a study, as
these show less systemic absorption, and can be measured in body
fluids.
At the moment inhaled corticosteroids do improve lung
function and symptoms over the short term in this group of patients.
This 'group' effect, and the data from the retrospective study,
strongly suggest the concept of short term steroid trials is
redundant, and argue for the more liberal prescription of such
treatment to patients with chronic airflow obstruction. A
recommendation that appears to be normal practice for a high
percentage of UK respiratory physicians already.
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APPENDIX I. BASELINE RESPIRATORY SYMPTOM
QUESTIONNAIRE.
Steroid Trial Initial Questionnaire
Please use the actual wording of each question. Put l=yes or
2 = no, or other codes as indicated in the ooxes. When in doubt
record as no.
I am going to ask you some questions about your chest, please
answer yes or no whenever possible.
COUGH
1. Do you usually cough first thing in the morning in
the winter?
2. Do you usually cough during the day - or at night -
in the winter?
3. Do you cough like this on most days for as much as 3
months of the year?
PHLEGM
4. Do you usually bring up any phlegm from your chest
first thing in the morning in the winter?
5. Do you usually bring up any phlegm from your chest
during the day - or at night - in the winter?
6. Do you bring your phlegm like this on most for as
much as 3 months of the year?
BREATHLESSNESS
7. At your best are you troubled by shortness of breath
when hurrying on level ground or walking up a hill ?
If yes:-
8. At your best do you get short of breath walking with
other people of your own age on level ground ?
If yes:-
i
9. At your best do you have to stop for breath when
walking at your own pace on level ground ?
If yes:-
10. At your best are you breathless when washing or
dressing ?
11. At your worst are you troubled by shortness of breath
when hurrying on level ground or walking up a hill ?
If yes:-
12. At your worst do you get short of breath walking with
other people of your own age on level ground ?
If yes:-
13. At your worst do you have to stop for breath when
walking at your own pace on level ground ?
If yes:-
14. At your worst are you breathless when washing or
dressing ?
WHEEZING.
15. Does your chest ever sound wheezing or whistling ?
If yes:-
16. Have you ever had attacks of shortness of breath with
wheezing ?
17. Is/was your breathing absolutely normal between
attacks ?
18. Do you wheeze on most days or nights ?
19. Are you worse in any one season or another ?
20. If so which season is worse - Spring= 1, Summer=2
Autumn=3,Winter=4.
21. Do you wheeze during or after exertion ?
II
22. If so for how long ?
23. When you get up in the morning how does your chest
usually feel ? Is it Free
Tight
or Very Tight ?
24. If tight or very tight, how long does it usually take
to become free ? (hours)
25. Are you ever woken at night with chest tightness,






26. Do you wake from sleep with cough ?
27. Do any of the following affect your chest ? (If so
indicate in which way).
Shortness Wheeze Cough None
of breath
(a) Going fqrm a warm to
a cold robih.
(b) Going into a room where
people are or where
smoking.
(c) Traffic fumes.
(d) Chemicals such as hair
spray, perfume or bleach.
Have you ever had:
28. An injury or operation affecting your chest ?




33. Pulmonary tuberculosis ?
in
34. Bronchial asthma ?
35. Hay fever ?
36. Eczema ?
SMOKING.
37. Do you smoke ?
If no:-
38. Have you ever smoked as much as one cigarette a day
(or one cigar a week, or an ounce of tobacco a month)
for as long as a year ?
If NO to 37 and 38 omit remaining questions on smoking.
39. How old were you when you started smoking regularly ?
40. When did you last give up smoking ?
41. Do (did) you inhale the smoke ?




43 Do (did) you smoke manufactured cigarettes ?
If yes:-
44. How many do (did) you usually smoke on weekdays ?
45. How many per day at weekends ?
46. Do (did) You smoke plain=1 or filter tip—2 cigarettes ?
47. Do (did) you smoke hand rolled cigarettes ?
48. How much tobacco do (did) you usually smoke per week in this
way ?
49. Do (did) you smoke a pipe ?
If yes:-
IV
50. How much pipe tobacco do (did) you smoke per week ?
51. Do (did) you smoke small cigars ?
If yes:-
52. How many of these do (did) you smoke per week ?
53. Do you smoke other cigars ?
If yes:-
54. How many of these do you usually smoke per week ?
v
APPENDIX II. QUALITY OFLIFE QUESTIONNAIRE.
CHRONIC RESPIRATORY INDEX QUESTIONNAIRE
First Administration, 7 Point Scale
INTERVIEWER FORM
This questionnaire is designed to find out how you have been feeling
during the last 2 weeks. You will be asked about how short of breath
you have been, how tired you have been feeling and how your mood
has been.
1. I would like you to think of the activities that you have done
during the last 2 weeks that have made you feel snort of breath.
These should be activities which you do frequently and which are
important in your day-to-day life. Please list as many activities
as you can that you have done during the last 2 weeks that have
made you feel short of breath.
{CIRCLE THE NUMBER ON THE ANSWER SHEET LIT
ADJACENT TO EACH ACTIVITY MENTIONED. IF AN
ACTIVITY MENTIONED IS NOT ON THE LIST, WRITE IT IN,
IN THE RESPONDENT'S OWN WORDS, IN THE SPACE
PROVIDED]
Can you think of any other activities you have done during the
last 2 weeks that have made you feel short of breath?
[RECORD ADDITIONAL ITEMS]
2. I will now read a list of activities which make some people
with lung problems feel short of breath. I will pause after each
item long enough for you to tell me if you have felt short of breath
doing that activity during the last 2 weeks. If you haven't done
the activity during the last 2 weeks, just answer 'NO'. The
activities are:
[READ ITEMS, OMITTING THOSE WHICH RESPONDENT HAS
VOLUNTEERED SPONTANEOUSLY. PAUSE AFTER EACH
ITEM TO GIVE RESPONDENT A CHANCE TO INDICATE
WHETHER HE/SHE HAS BEEN SHORT OF BREATH WHILE
PERFORMING THAT ACTIVITY DURING THE LAST WEEK.
CIRCLE THE NUMBER ADJACENT TO APPROPRIATE ITEMS
ON ANSWER SHEET]
1. BEING ANGRY OR UPSET
2. HAVING A BATH OR SHOWER
3. BENDING
VI
4. CARRYING, SUCH AS CARRYING GROCERIES
5. DRESSING
6. EATING
7. GOING FOR A WALK
8. DOING YOUR HOUSEWORK
9. HURRYING
10. MAKING A BED
11. MOPPING OR SCRUBBING THE FLOOR
12. MOVING FURNITURE
13. PLAYING WITH CHILDREN OR GRANDCHILDREN
14. PLAYING SPORTS
15. REACHING OVER YOUR HEAD
16. RUNNING, SUCH AS FOR BUS
17. SHOPPING
18. WHILE TRYING TO SLEEP
19. TALKING
20. VACUUMING
21. WALKING AROUND YOUR OWN HOME
22. WALKING UPHILL
73 WAT KING TIP8TATRS
24] WALKING WITH OTHERS ON LEVEL GROUND
25. PREPARING MEALS
a) Of the items which you have listed, which is the most
important to you in your day-to-day life? I will read through the
items, and when I am finished, I would like you to tell me which is
the most important.
[READ THROUGH ALL ITEMS SPONTANEOUSLY
VOLUNTEERED AND THOSE FROM THE LIST WHICH
PATIENT MENTIONED]
Which of these items is most important to you in your day-to-day
life?
[LIST ITEM ON RESPONSE SHEET]
(b) Of the remaining items, which is the most important to you n
your day-to-day life? I will read through the items, and when I
am finished, I would like you to tell me which is the most
important.
[READ THROUGH REMAINING ITEMS]
Which of these items is most important to you in your day-to-day
[LIST ITEM ON RESPONSE SHEET]
VII
(c) of the remaining items, which is the most important to you in
your day-to-day life?
[LIST ITEM ON RESPONSE SHEET]
(d) of the remaining items, which is the most important to you in
your day-to-day life?
[LIST ITEM ON RESPONSE SHEET]
(e) of the remaining items, which is the most important to you in
your day-to-day life?
[LIST ITEM ON RESPONSE SHEET]
[FOR ALL SUBSEQUENT QUESTIONS, ENSURE
RESPONDENT HAS APPROPRIATE RESPONSE CARD IN
FRONT OF THEM BEFORE STARTING QUESTION]
I would now like you to describe how much shortness of breath
you have experienced during the last 2 weeks while doing the five
most important activities you have selected.
a) Please indicate how much shortness of breath you have had
during the last 2 weeks while [INTERVIEWER: INSERT
ACTIVITY LIST IN 3a] by choosing one of the following options
from the card in front of you: [GREEN CARD]
1 EXTREMELY SHORT OF BREATH
2 VERY SHORT OF BREATH
3 QUITE A BIT SHORT OF BREATH
4 MODERATE SHORTNESS OF BREATH
5 SOME SHORTNESS OF BREATH
6 A LITTLE SHORTNESS OF BREATH
7 NOT AT ALL SHORT OF BREATH
b) Please indicate how much shortness if breath you have had
during the last 2 weeks while [INTERVIEWER: INSERT
ACTIVITY LIST IN 3b] by choosing one of the following options
from the card in from of you: [GREEN CARD]
1 EXTREMELY SHORT OF BREATH
2 VERY SHORT OF BREATH
3 QUITE A BIT SHORT OF BREATH
4 MODERATE SHORTNESS OF BREATH
5 SOME SHORTNESS OF BREATH
6 A LITTLE SHORTNESS OF BREATH
7 NOT AT ALL SHORT OF BREATH
VIII
c) Please indicate how much shortness of breath you have had
during the last 2 weeks while [INTERVIEWER: INSERT
ACTIVITY LIST IN 3cl by choosing one of the following options
from the card in front of you: [GREEN CARD]
1 EXTREMELY SHORT OF BREATH
2 VERY SHORT OF BREATH
3 QUITE A BIT SHORT OF BREATH
4 MODERATE SHORTNESS OF BREATH
5 SOME SHORTNESS OF BREATH
6 A LITTLE SHORTNESS OF BREATH
7 NOT AT ALL SHORT OF BREATH
d) Please indicate how much shortness of breath you have had
during the last 2 weeks while [INTERVIEWER: INSERT
ACTIVITY LISTED IN 3d] by choosing one of the following
options from the card in from of you: [GREEN CARD]
1 EXTREMELY SHORT OF BREATH
2 VERY SHORT OF BREATH
3 QUITE A BIT SHORT OF BREATH
4 MODERATE SHORTNESS OF BREATH
5 SOME SHORTNESS OF BREATH
6 A LITTLE SHORTNESS OF BREATH
7. NOT AT ALL SHORT OF BREATH
e) Please indicate how much shortness of breath you have had
during the last 2 weeks while [INTERVIEWER; INSERT
ACTIVITY LISTED IN 3e] by choosing one of the following
options from the card in front of you: [GREEN CARD]
1 EXTREMELY SHORT OF BREATH
2 VERY SHORT OF BREATH
3 QUITE A BIT SHORT OF BREATH
4 MODERATE SHORTNESS OF BREATH
5 SOME SHORTNESS OF BREATH
6 A LITTLE SHORTNESS OF BREATH
7. NOT AT ALL SHORT OF BREATH
5. In general how much of the time during the last 2 weeks have
you felt frustrated or impatient? Please indicate how often
during the last 2 weeks you have felt frustrated or impatient by
choosing one of the following options from the card in front of
you: (BLUE CARD)
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
IX
6. How often during the past 2 weeks did you have a feeling of
fear or panic when you had difficulty getting your breath? Please
indicate how often you had a feeling of fear or panic when you
had difficulty getting your breath by choosing one of the
following options from the card in front of you: (BLUE CARD)
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
7. What about fatigue? How tired have you felt over the last 2
weeks? Please indicate how tired you have felt over the last 2
weeks by choosing one of the following options from the card in
front of you: (ORANGE CARD)
1 EXTREMELY TIRED
2 VERY TIRED
3 QUITE A BIT OF TIREDNESS
4 MODERATELY TIRED
5 SOMEWHAT TIRED
6 A LITTLE TIRED
7 NOT AT ALL TIRED
8. How often during the last 2 weeks have you felt embarrassed
by your coughing or heavy breathing? Please indicate how muchof the time you felt embarrassed by your coughing or heavy
breathing by choosing one of the following options from the card
in front of you: (BLUE CARD)
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
X
9. In the last 2 weeks, how much of the time did you feel very
confident and sure that you could deal with your illness? Please
indicate how much of the time you felt very confident and sure
that you could deal with your illness by choosing one of the
following options from the card in front of you. (YELLOW
CARD)
1 NONE OF THE TIME
2 A LITTLE OF THE TIME
3 SOME OF THE TIME
4 A GOOD BIT OF THE TIME
5 MOST OF THE TIME
6 ALMOST ALL OF THE TIME
7 ALL OF THE TIME
10. How much energy have you had in the last 2 weeks? Please
indicate how much energy you have had by choosing one of the
following options from the card in front of you: (PINK CARD)
1 NO ENERGY
2 A LITTLE ENERGY
3 SOME ENERGY
4 MODERATELY ENERGETIC
5 QUITE A BIT OF ENERGY
6 VERY ENERGETIC
7 FULL OF ENERGY
11. In general, how much of the time did you feel upset, worried,
or depressed during the last 2 weeks? Please indicate how much
of the time you felt upset, worried or depressed during the past 2weeks by choosing one of the following options from the card in
front of you: (BLUE CARD)
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
XI
12. How often during the last 2 weeks did you feel you had
complete control of your breathing problems? Please indicate
how often you felt you had complete control of your breathing
problems by choosing one of the following options from the card
in front of you: (YELLOW CARD)
1 NONE OF THE TIME
2 A LITTLE OF THE TIME
3 SOME OF THE TIME
4 A GOOD BIT OF THE TIME
5 MOST OF THE TIME
6 ALMOST ALL OF THE TIME
7 ALL OF THE TIME
13. How much of the time during the last 2 weeks did you feel
relaxed and free of tension? Please indicate how much of the
time you felt relaxed and free of tension by choosing one of the
following options from the card in front of you: (YELLOW
CARD)
1 NONE OF THE TIME
2 A LITTLE OF THE TIME
3 SOME OF THE TIME
4 A GOOD BIT OF THE TIME
5 MOST OF THE TIME
6 ALMOST ALL OF THE TIME
7 ALL OF THE TIME
14. How often during the last 2 weeks have you felt low in
energy? Please indicate how often during the last 2 weeks you
have felt low in energy by choosing one of the following options
from the card in front of you: (BLUE CARD)
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
XII
15. In general, how often during the last 2 weeks have you felt
discouraged or down in the dumps? Please indicate how often
during the last 2 weeks you have felt discouraged or down in the
dumps by choosing one of the following options from the card in
front of you: (BLUE CARD)
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
16. How often during the last 2 weeks have you felt worn out or
sluggish? Please indicate how much of the time you felt worn out
or sluggish by choosing one of the following options from the card
in front of you: (BLUE CARD)
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
17. How happy, satisfied, or pleased have you been with your
personal life during tht '
following options fron
1 VERY DISSATISFIED, UNHAPPY MOST OF THE
TIME
2 GENERALLY DISSATISFIED, UNHAPPY
3 SOMEWHAT DISSATISFIED, UNHAPPY
4 GENERALLY SATISFIED, HAPPY
5 HAPPY MOST OF THE TIME
6 VERY HAPPY MOST OF THE TIME




18. How often during the last 2 weeks did you feel upset or
scared when you had difficulty getting your breath? Please
indicate how often during the past 2 weeks you felt upset or
scared when you had difficulty getting your breath by choosing
one of the following options from the card in front of you: (BLUE
CARD)
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
19. In general, how often during the last 2 weeks have you felt
restless, tense, or uptight? Please indicate how often you have
felt restless, tense or uptight by choosing one of the following
options from the card in front of you: (BLUE CARD).
1 ALL OF THE TIME
2 MOST OF THE TIME
3 A GOOD BIT OF THE TIME
4 SOME OF THE TIME
5 A LITTLE OF THE TIME
6 HARDLY ANY OF THE TIME
7 NONE OF THE TIME
XIV


































































































































































































































































































































APPENDIX V. DETAILS OFPATIENTS WITHDRAWN.
Details of patients withdrawn during the three treatment phases.
Patient Number. Treatment. Reason for withdrawal.
12 Placebo Cough and wheeze
after trial inhalers.
35 Placebo Pneumonia.
46 Placebo Failed to attend.
47 Placebo Infective exacerbation
requiring oral steroids
43 Placebo Infective exacerbation
requiring oral steroids
48 Placebo Abnormal liver functio
undiagnosed metastatic
hepatic disease.
86 Placebo Infective exacerbation
requiring oral steroids




8 BDP 750mcg b.d.
+ prednisolone
Pneumothorax.
37 BDP 1500mcg b.d.
+ prednisolone
Diabetes mellitus.




73 BDP 750mcg b.d.
+ placebo
Did not attend, severe
depression.
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Abstract
One hundred and twenty seven adults
considered on clinical grounds to have
non-asthmatic chronic airflow obstruc¬
tion entered a randomised, double blind,
placebo controlled, crossover trial
comparing the physiological response to
inhaled beclomethasone dipropionate 500
/;g thrice daily with oral prednisolone 40
mg a day, both given for two weeks. One
hundred and seven patients completed
the study. Response was assessed as
change in FEV, and FVC measured on the
last treatment day, and as change inmean
peak expiratory flow (PEF) over the final
seven days of treatment from home PEF
recordings performed five times daily. A
full response to treatment was defined as
an increase in FEV or FVC, or an increase
in mean daily PEF over the final seven
days of treatment, of at least 20% from
baseline values. An improvement in one
measurement ofat least 15%, or of 10% in
any two measurements, was defined as a
partial treatment response. Response to
placebo showed a significant order effect,
suggesting a carry over effect of active
treatment of at least three weeks. Res¬
ponse to active treatment was therefore
related to initial baseline values, and
compared with placebo by considering
responses in the first treatment phase
only. A full response to oral prednisolone
(16/38) was significantly more common
than to placebo (3/35). The number of full
responses to inhaled beclomethasone (8/
34) did not differ significantly from the
number responding to oral prednisolone
or placebo in the first treatment phase,
though full and partial responses to
inhaled beclomethasone (12/34) were
significantly more common than those to
placebo (4/35). When all three treatment
phases were considered 44/107 patients
showed a full response to one or both
forms of corticosteroid treatment, a
response to prednisolone (39) occurring
more frequently than to inhaled beclo¬
methasone (26). Only 21 of the 44 respon-
ders showed a response to both forms of
treatment. Inhaled beclomethasone dip¬
ropionate 500 /<g thrice daily was inferior
to oral prednisolone 40 mg per day, but
better than placebo, in producing im¬
provement in physiological measure¬
ments in patients thought to have non-
asthmatic chronic airflow obstruction. It
was, however, an effective alternative in
over half of those showing a response to
prednisolone.
Oral corticosteroids improve symptoms and
lung function in some patients with severe
chronic airflow obstruction related to cigarette
smoking.1 Published trials have in general used
doses of oral medication which in the long term
would have serious systemic side effects.2-4 The
efficacy of inhaled corticosteroids in asthma is
well established but only two previous studies
have looked at the effect of this form of
treatment in patients with chronic airflow
obstruction, both with small numbers of
patients.56 The study of Harding and
Freedman identified a response to 400 /(g/day
of inhaled betamethasone valerate in only three
of six patients who showed a response to oral
prednisolone. All responders to the inhaled
drug were inpatients and the authors suggest
that this may have improved compliance and
delivery of the drug to the airways. In the
recent study of Wardman et al with 22 out¬
patients, however, all with good inhaler tech¬
nique, the five responders to oral prednisolone
improved to the same degree after two weeks'
treatment with inhaled beclomethasone
dipropionate 1500 /tg per day. The different
results may reflect different doses and delivery
of the drug to the airways, but the role of
inhaled corticosteroids in patients with severe
chronic airflow obstruction is still unclear.
The aim of this study was to compare the
response to oral prednisolone 40 mg/day with
that to inhaled beclomethasone dipropionate
500 /(g thrice daily in outpatients with non-
asthmatic chronic airflow obstruction.
Methods
SUBJECTS
Outpatients with adult onset chronic airflow
obstruction of at least five years' duration and
an FEV, below 70°0 predicted were recruited
to the trial. Patients were excluded if they had a
clinical diagnosis of asthma, respiratory
symptoms in childhood, variability in
symptoms except in association with
infections, acute attacks of wheezing and
Corticosteroid trials in non-asthmatic chronic airflow obstruction
breathlessness, or deterioration after exposure
to specific allergens. A lack of a "fixed"
element in the airflow obstruction after
inhalation of bronchodilator also favoured
asthma as the diagnosis. The presence of some
reversibility of airflow obstruction in response
to inhaled bronchodilators was deliberately not
chosen as an exclusion criterion so that its effect
on steroid response could be assessed. No
patient had received oral or inhaled cortico¬
steroids in the preceding six months. All
patients gave informed consent.
measurements
Spirometric indices were determined on two
occasions during the baseline phase before any
treatment was given, and on the final day of
each treatment period. Patients were asked to
refrain from inhaled bronchodilators for six
hours before the measurements, and visits were
performed at the same time of day. FEV, and
FVC were measured on a dry bellows
spirometer (Vitalograph), the mean of three
technically satisfactory attempts within 10% or
100 ml (whichever was the smaller) being used
for subsequent analysis. Baseline FEV, and
FVC were taken as the highest mean
measurements recorded on the two baseline
visits before any treatment.
Lung volumes and single breath carbon
monoxide gas transfer (Tlco) were determined
once during the baseline period and at the end
of each treatment phase. A closed circuit
helium dilution technique was used to measure
lung volume subdivisions, rebreathing being
continued until the concentration of helium
was stable or for a maximum of 20 minutes.
Single breath Tlco was taken as the mean of
two satisfactory manoeuvres within 15% of
each other.
Airflow reversibility in response to sal-
butamol and ipratropium bromide was deter¬
mined during the baseline period. Two doses of
salbutamol (200 pg and 10 mg) were adminis¬
tered sequentially, and the response was deter¬
mined 20 minutes after each dose. On a sub¬
sequent day 72 and 500 fig of ipratropium
bromide were given and the spirometric res¬
ponse was assessed 25 minutes after each dose.
The smaller dose of each drug was given by a
metered dose inhaler and the larger dose by an
Inspiron mini-Neb nebuliser, the drug being
nebulised to dryness. Bronchial responsiveness
to inhaled histamine was determined by the
method of Cockroft et al,1 on the second
baseline visit if the FEV, was above 0 6 1.
After the second baseline visit patients were
asked to measure peak expiratory flow rate
(with a mini Wright's peak flow meter) four
hourly during waking hours at home, and
record the best of at least three attempts with
the best two within 201/min. All baseline values
were obtained during the two weeks before the
first treatment phase and mean daily PEF was
calculated over the final seven days of this
period. Diurnal variation in PEF was calcu¬
lated from the same readings as mean daily
maximum PEF (mean daily maximum PEF
minus mean daily minimum PEF divided by
mean daily PEF).
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Serum IgE concentrations weremeasured by
a PRIST technique and skinprick tests
performed with house dust, Dermatophagoides
pteronyssinus, Aspergillus fumigatus, cat fur,
and a control solution, a positive result being
defined as a weal 2 mm greater than that
obtained with the control solution in two or
more tests.
Inhaler technique was checked at each visit
and corrected as necessary. All patients
continued their usual bronchodilator treatment
unchanged during the trial, and were instruc¬
ted to maintain a constant timing between
doses and PEF readings.
design
The trial was a randomised, double blind,
double dummy, crossover study designed to
compare inhaled beclomethasone dipropionate
500 pg thrice daily, oral prednisolone 40
mg/day, and placebo. Each treatment was given
for two weeks followed by a two week washout
period before the next treatment period. The
first treatment period was preceded by a four
week baseline period. Patients attended the
laboratory on days 1 and 14 of the baseline
period for initial investigations, and on the last
day of each treatment period for subsequent
assessments.
analysis
A full response to treatment was defined as an
improvement in absolute values of FEV, or
FVC on the final treatment day, or mean PEF
over the last seven days of treatment, of at
least 20"(i when compared with baseline. An
improvement of at least 15% in any one
measure or at least 10% in any two measures
was defined as a partial treatment response.
Baseline data were compared by means of a
paired or unpaired Student's t test for normally
distributed data or a Wilcoxon signed rank or
rank sum test for data not normally distributed.
Treatment order effect was assessed by a logit
regression on proportions, the GLIM statis¬
tical package being used.8 Active treatment
response rates were compared by McNemar's
test, and the responses to the treatments given
during the first phase by a /2 test.
All predicted values are derived from pub¬
lished equations.9
Results
Of the 127 patients who entered the study, 107
completed the protocol. Eleven patients
defaulted at subsequent visits: six had an
infective exacerbation of their disease, one died
of an unrelated cause during the run in period,
and two had complications during the oral
prednisolone phase (exacerbation of chronic
duodenal ulceration in one, left ventricular
failure in the other). The mean age (63 years)
and the FEV, and FVC (39% and 70% predic¬
ted) of those withdrawn were similar to the
mean values in patients who completed the
study. The baseline lung function characteris¬
tics of the study group are given in table 1 and
details of smoking and atopy in table 2.
There was a significant order effect in the
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Table 1 Baseline lung function characteristics of the
study group (mean (SD) values unless otherwise
indicated)
Table 3 Number offull responders (partial responders
in parentheses) to each treatment according to the phase
in which it was administered
(25F) Number 107 (25F)
Age: years 62-9 (9-0)
FEV,: litres 1-19(0-47)
°(, predicted 44-2 (16-7)
Forced vital capacity: °() predicted 79-2 (19-0)
Peak flow (PEF): predicted 52-4 (17-9)
Total lung capacity: predicted 121-5 (19-4)
Residual volume: predicted 173-6 (52-0)
Transfer coefficient: °u predicted 77-8 (31-7)
Diurnal variation in PEF: mean 19-8 (9-9)
PQo (mg/ml): geometric mean (range) 0-81 (0-03-16 0)
FEV.v: indices of reversibility of airflow obstruction
As °0 initial FEV,, in response to:
10 mg salbutamol 18-0(15-9)
200 fig saibutamol 11-4(11-2)
500 fig ipratropium bromide 201 (17-0)
72 fig ipratropium bromide 13-1 (11-7)
Phase 1 Phase 2 Phase 3
• - t~o *r f -- -
As °(, (predicted minus initial) FEV,, in response
10 mg salbutamol 15-5- V. ---&
200 fig salbutamol
500 fig ipratropium bromide






PC,0—provocative concentration of histamine causing a 20°,,
fall in FEV,.





Mean (SD) cigarette consumption
(cigarette years) 761 (547)
Number with chronic bronchitis* 77
Serum IgE (kU/1): geometric mean (range) 74 (3-4500)
Number with positive skin test responses 46
*Medical Research Council definition.
response to placebo, in that the placebo res¬
ponse rate was greater when placebo had been
preceded by active treatment {j\ = 5-06,
p < 0-05: table 3); this was not seen with the
response to prednisolone or to beclomethasone
dipropionate (xf = 0-75 and Xi = 0-02).
Because of this order effect, response to treat¬
ment was defined with respect to initial
baseline values before any trial treatment had
been given, and the two active treatments were
compared with placebo by a parallel group
analysis of the first treatment phase data.
ANALYSIS OF DATA AS A PARALLEL GROUP STUDY
USING THE FIRST TREATMENT PHASE ONLY
On entry into the study patients randomised to
receive placebo, beclomethasone, or predn¬
isolone for the initial treatment phase, did not
differ in terms of baseline physiological charac¬
teristics (table 4). The number of patients
showing a full response to prednisolone (16/38)
Table 4 Baseline characteristics of the groups according to the treatment received in
the first phase (mean (SD) unless otherwise indicated)
Placebo Beclomethasone Prednisolone
Number 35 (7F) 34(1 IF) 38 (7F)
Age: years 64-2(8-1) 60-8(10-1) 63-7(8-5)
FEV,: litres 1-15(0-48) 1-21 (0-53) 1-20 (0-43)
°o predicted 42-8(14-2) 45 1 (18-2) 44-7(17-7)
Reversibility of airflow obstruction
(as °0 baseline) in response to:
10 mg salbutamol 16-3(18-3) 20-2(16-3) 17-7(13-3)
500 fig ipratropium bromide 20-0(18-5) 22-6(19-5) 18-0(12-9)
Cigarette consumption:
Cigarette years 712 (522) 620 (486) 896 (566)
Number of:
Current smokers 11 10 7
Ex-smokers 19 20 28
Lifelong non-smokers 5 4 3
Placebo 3 (1) 35 7(1), 31 12 (0)/4I*
Beclomethasone 8(4) 34 10 (4)/41 8 (2)/32
Prednisolone 16 (l)/38 12 (l)/35 11 (3)/34
**p < 0-05 for treatment order effect.
was significantly greater than the number
showing a similar response to placebo (3/35,
x] = 10-64; p < 0-005). A full response
occurred more frequently with beclo¬
methasone (8/34) than with placebo, though
this was not significant (Xi = 2-22; NS). When
partial responses are included in the analysis
the response rate for both inhaled beclo¬
methasone (12/34) and oral prednisolone (17/
38) was significantly greater than that for
placebo (4/35: Xi =5 51, p < 0-02; and
XJ = 9-86, p < 0 002 respectively). There was
no significant difference in the response to
either active drug in this analysis either for full
responders (x? = 2-79, p < 0-1) or when full
and partial responders were considered
(X? = 0-67).
ANALYSIS OF DATA FROM ALL THREE TREATMENT
PHASES IN THE CROSSOVER STUDY
When all three treatment phases were
considered to allow within subject comparison
of response, 21 patients showed a full response
to both prednisolone and beclomethasone. A
further 18 patients responded to prednisolone
only and five to beclomethasone only. Six of the
18 prednisolone only responders showed a
partial response to beclomethasone and one of
the five beclomethasone only responders
showed a partial response to oral prednisolone.
In total, 44/107 (41%) patients showed a full
response to prednisolone or beclomethasone
and a further six a partial response. The
response rate was significantly greater
with prednisolone than beclomethasone












There are no significant differences between groups.
Figure 1 Percentage change in FEV, from baseline
values in individual patients after treatment with
prednisolone and beclomethasone (BDP). Slope of least
squares regression line =0-72 (SE 0 06).
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Figure 2 Percentage
change in mean daily peak
expiratory flow (PEF)





Slope of least squares
regression line = 0 46
(SE 0 05).
Figure 3 Percentage







Slope of least squares


















% change in FVC with prednisolone
The responses of individual patients to oral
prednisolone and inhaled beclomethasone are
shown in figures 1-3 for FEV,, FVC, and PEF.
The slope of the least squares regression line
for each plot is significantly different from the
line of identity, indicating a greater effect of
prednisolone on each measurement.
A full response to an active treatment
occurred on 65 occasions. The measurements
in which a response was seen on these occasions
are shown in the Venn diagram (fig 4). A full
response was seen in all three measurements on
only seven occasions and in two of the
measurements on a further 17 occasions; in
most cases (41) a full response was seen in only
one measurement.
In the 44 patients who had a full response to
prednisolone or beclomethasone the change in
the measurement showing the greatest
response was expressed as a percentage of the
patient's predicted value, a measure
independent of baseline FEV, (fig 5). The
responders remained distinct from the non-
responders.
The mean reversibility in FEV, in response
to 10 mg inhaled salbutamol was 18%, expres¬
sed as a percentage of the prebronchodilator
value (table 1). If expressed in terms of
potential reversibility—that is, as a percentage
of the predicted minus the prebronchodilator
value—the mean improvement was 15-5%.
Only 13 patients showed an increase in this
measurement of over 50%, indicating that
most of the patients had relatively fixed airflow
obstruction. Response to prednisolone or
beclomethasone or both in the 13 "reversible"
patients (4/13) was similar to that seen in the
"irreversible" patients (40/94; Xi = 0-64 NS).
Cigarette consumption in the patients varied
from zero to 2520 cigarette years, with a mean
of 761 cigarette years (table 2). Twelve patients
claimed to be life long non-smokers. Eighty one
patients admitted to a cigarette consumption in
excess of 400 cigarette years. Full and partial
responses to prednisolone or beclomethasone
or both were similar in this group of heavier
smokers (39/81) and in the remaining patients
(11/26; zf = 0-57; NS).
Figure 4 Venn diagram
showing the measurements
in which response occurred






The finding of a significant order effect with
placebo treatment complicated the analysis of
the data from this trial. The analysis of the data
on the first treatment phase removes the
confounding influence of the order effect and
shows that both active treatments are superior
to placebo in producing a physiological
response in these patients. In this analysis oral
prednisolone produced a response in more
subjects than inhaled beclomethasone, though
the difference was not significant. Previous
studies have not always commented on an order
effect, though some have used a single blind
design that would avoid this problem.36 Two
smaller studies with a crossover design found
no treatment order effect,1011 possibly because
of the smaller numbers of patients.
Although in our study the order effect was
seen only with placebo it might have occurred
to some extent with active treatment. The lack








































































Figure 5 Change from baseline after treatment in the measurement that showed the
greatest percentage change. The change is expressed as a percentage of the predicted
value for the patient for that measurement. The horizontal lines represent the mean
response of all the patients who showed a positive change.
of any detectable order effect for the response
to prednisolone and beclomethasone suggests
that the action of the second active treatment is
more powerful than the carry over effect of the
initial treatment. We feel justified therefore in
using data from all three treatment phases to
further compare individual responses to predn¬
isolone and beclomethasone. When this was
done prednisolone was superior to beclometh¬
asone in producing a response, though over half
of the patients showing a response to predn¬
isolone also responded to inhaled beclometh¬
asone. The reason why five patients responded
to inhaled beclomethasone only is not clear.
Our study may be criticised for the response
criteria adopted. Response was expressed in
terms of percentage change from the baseline
value, a criterion used in previous trials.6101113
The validity of such a definition is questionable
when the absolute value of the variable studied
is low. In these circumstances small changes
that are within the error ofmeasurement of the
variable may assume undue significance. Only
4% of our responders, however, showed a
change in FEV, or FVC that was within the
95confidence limits for short term
variability in FEV, and FVC published
recently.14 Previous studies of longer term
variability in spirometric indices in similar
patients suggest that our criteria are reason¬
able.15 16 Expressing change as a percentage of a
measure independent of the baseline—that is,
the predicted value—did not suggest that any
responders had been misclassified (fig 5). One
partial responder and two non-responders may
have been wrongly classified.
Symptomatic change was not determined
formally in all patients. Visual analogue scales
for five symptoms and six minute walking
distances were, however, determined in the
first 83 patients recruited to the trial.17 Six
minute walking distances improved signifi¬
cantly with both active treatments in the
steroid responsive patients, whereas no effect
was seen with treatment in the non-responders.
Visual analogue scores showed a wide variation
and, although they improved in all response
groups with treatment, the changes were not
significant.
A further possible criticism of our results is
that because of the "soft" entry criteria we
inadvertently included patients with missed
asthma in the study population. The criteria
were chosen to reflect clinical practice and only
where the physician was unsure of the benefit
of steroid treatment—that is, where asthma was
not present—was a patient entered. Those who
had had respiratory disease in childhood were
excluded, which eliminated many patients with
asthma. Not all patients were current smokers
or ex-smokers, although most had smoked
heavily. Many patients showed a degree of
reversibility in response to inhaled broncho-
dilators that was within the "asthmatic" range
of20°o or more of the prebronchodilator FEV,.
This, however, is a misleading measure of
reversibility in patients with a low pre¬
bronchodilator FEV,. A better indication of
reversibility is obtained by considering the
reversibility as a percentage of the predicted
FEV, minus the prebronchodilator value (table
1). Most ofour patients had largely irreversible
airflow obstruction. Response to one or both
corticosteroid treatments was not related to
past cigarette consumption or to reversibility in
response to inhaled salbutamol, suggesting
that our patients were predominantly non-
asthmatic. The degree of response to cortico¬
steroids shown in figure 5 shows a unimodal
distribution, again suggesting that the patients
came from a single disease group. Hence we
believe that most of the patients were not
asthmatic, and that our findings are relevant to
patients diagnosed as having chronic airflow
obstruction in clinical practice.
The trial of Wardman et al6 showed that
1500 pg beclomethasone/day was comparable
to oral prednisolone 30 mg in patients similar to
ours, in terms both of the number showing a
response and of the degree of improvement
seen in the measure of lung function. Like
Harding and Freedman,5 we have not found
this to be the case. The likeliest explanation for
this is differences in selection of patients and
perhaps in deposition of aerosol in the lung. We
attempted to optimise inhaler technique in our
group by checking and correcting technique at
each visit, but possibly improved delivery of
the drug to the airways by means of a spacing
device would have produced more responders
to beclomethasone. Our results would suggest,
however, that inhaled beclomethasone 500 pg
thrice daily should be considered an effective
treatment in over half of patients with non-
asthmatic airflow obstruction who show a
response to oral prednisolone 40 mg daily.
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